var title_f10_59_11184="Estrogen and progestin types and doses in hormonal contraceptive";
var content_f10_59_11184=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F69223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F69223&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected hormonal contraceptives",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        US trade name (manufacturer)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Progestin (mg)*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Estrogen (mcg)",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Monophasic combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zovia 1/50E 28 (Watson)",
"       </td>",
"       <td>",
"        Ethynodiol diacetate (1)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ogestrel 0.5/50 28 (Watson)",
"       </td>",
"       <td>",
"        Norgestrel",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (0.5)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kelnor 28 (Barr)",
"       </td>",
"       <td rowspan=\"2\">",
"        Ethynodiol diacetate (1)",
"       </td>",
"       <td rowspan=\"2\">",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zovia 1/35E 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alyacen 1/35 28 (Glenmark)",
"       </td>",
"       <td rowspan=\"6\">",
"        Norethindrone (1)",
"       </td>",
"       <td rowspan=\"6\">",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dasetta 1/35 28 (Northstar)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necon 1/35 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Norinyl 1+35 28 (Watson)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortrel 1/35 28 (Barr)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho-Novum 1/35 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brevicon 28 (Watson)",
"       </td>",
"       <td rowspan=\"4\">",
"        Norethindrone (0.5)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Modicon 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necon 0.5/35 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortrel 0.5/35 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Balziva 28 (Barr)",
"       </td>",
"       <td rowspan=\"6\">",
"        Norethindrone (0.4)",
"       </td>",
"       <td rowspan=\"6\">",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Femcon Fe 28 chewable (Warner Chilcott)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ovcon 35 28 (Warner Chilcott)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Wymza Fe 28 chewable (Warner Chilcott)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zenchent Fe 28 chewable (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zeosa 28 chewable (Teva)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        MonoNessa 28 (Watson)",
"       </td>",
"       <td rowspan=\"4\">",
"        Norgestimate (0.25)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho-Cyclen 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Previfem 28 (Vintage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sprintec 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Cyestra-35 (Paladin)",
"         <sup>",
"          &yen;",
"         </sup>",
"         , Diane-35 (Bayer)",
"         <sup>",
"          &yen;",
"         </sup>",
"         , Novo-Cyproterone/Ethinyl estradiol (Novopharm)",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        Note: these products are not available in US; Canadian trade names shown",
"       </td>",
"       <td>",
"        Cyproterone (2)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Apri 28 (Barr)",
"       </td>",
"       <td rowspan=\"5\">",
"        Desogestrel (0.15)",
"       </td>",
"       <td rowspan=\"5\">",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Desogen 28 (Organon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho-Cept 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reclipsen 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Solia 28 (Prasco)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ocella 28 (Barr)",
"       </td>",
"       <td rowspan=\"5\">",
"        Drospirenone (3)",
"       </td>",
"       <td rowspan=\"5\">",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Safyral 28 (Bayer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Syeda 28 (Sandoz)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yasmin 28 (Bayer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Zarah 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Altavera 28 (Sandoz)",
"       </td>",
"       <td rowspan=\"5\">",
"        Levonorgestrel (0.15)",
"       </td>",
"       <td rowspan=\"5\">",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levora 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Marlissa 28 (Glenmark)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nordette 28 (Duramed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Portia 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loestrin Fe 1.5/30 28 (Warner Chilcott)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Norethindrone acetate (1.5)",
"       </td>",
"       <td rowspan=\"3\">",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microgestin Fe 1.5/30 28 (Watson)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Junel Fe 1.5/30 28 (Barr)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cryselle 28 (Duramed)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Norgestrel",
"        <sup>",
"         &Delta;",
"        </sup>",
"        (0.3)",
"       </td>",
"       <td rowspan=\"3\">",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lo/Ovral 28 (Akrimax)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Low-Ogestrel 28 (Watson)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Beyaz 28 (Bayer)",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"       <td rowspan=\"5\">",
"        Drospirenone (3)",
"       </td>",
"       <td rowspan=\"5\">",
"        Ethinyl estradiol (20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gianvi 28 (Teva)",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loryna 28 (Sandoz)",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vestura 28 (Watson)",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Yaz (Bayer)",
"        <sup>",
"         &yen;������",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aviane 28 (Duramed)",
"       </td>",
"       <td rowspan=\"6\">",
"        Levonorgestrel (0.1)",
"       </td>",
"       <td rowspan=\"6\">",
"        Ethinyl estradiol (20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Falmina 28 (NorthStar)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lessina 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lutera 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Orsythia (Qualitest) 28",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sronyx 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loestrin Fe 1/20 28 (Warner Chilcott)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Norethindrone acetate (1)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Microgestin Fe 1/20 28 (Watson)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Junel Fe 1/20 28 (Barr)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loestrin 24 Fe (Warner Chilcott)**",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necon 1/50 28 (Watson)",
"       </td>",
"       <td rowspan=\"2\">",
"        Norethindrone (1)",
"       </td>",
"       <td rowspan=\"2\">",
"        Mestranol (50)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Norinyl 1+50 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Multiphasic combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alyacen 7/7/7 28 (Glenmark)",
"       </td>",
"       <td rowspan=\"6\">",
"        Norethindrone (0.5,0.75,1)",
"       </td>",
"       <td rowspan=\"6\">",
"        Ethinyl estradiol (35,35,35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclafem 7/7/7 28 (Qualitest)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dasetta 7/7/7 28 (Northstar)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Necon 7/7/7 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nortrel 7/7/7 28 (Barr)",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho-Novum 7/7/7 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aranelle 28 (Barr)",
"       </td>",
"       <td rowspan=\"2\">",
"        Norethindrone (0.5,1,0.5)",
"       </td>",
"       <td rowspan=\"2\">",
"        Ethinyl estradiol (35,35,35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leena 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tri-Norinyl 28 (Watson)",
"       </td>",
"       <td>",
"        Norethindrone (0.5,1,0.5)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (35,35,35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho Tri-Cyclen 28 (Ortho McNeil Janssen)",
"        <sup>",
"         &loz;&yen;",
"        </sup>",
"       </td>",
"       <td rowspan=\"4\">",
"        Norgestimate (0.18,0.215,0.25)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (35,35,35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        TriNessa 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tri-Previfem 28 (Vintage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tri-Sprintec 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Caziant 28 (Watson)",
"       </td>",
"       <td rowspan=\"4\">",
"        Desogestrel (0.1,0.125,0.15)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (25,25,25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cesia 28 (Prasco)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclessa 28 (Organon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Velivet (Duramed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho Tri-Cyclen Lo 28 (Ortho McNeil Janssen)",
"       </td>",
"       <td>",
"        Norgestimate (0.18,0.215,0.25)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (25,25,25)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrostep Fe 28 (Warner Chilcott)",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        Norethindrone acetate (1,1,1)",
"       </td>",
"       <td rowspan=\"3\">",
"        Ethinyl estradiol (20,30,35)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tilia Fe 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tri-Legest Fe",
"        <em>",
"         28",
"        </em>",
"        (Barr)",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azurette 28 (Watson)",
"       </td>",
"       <td rowspan=\"4\">",
"        Desogestrel (0.15,0,0)",
"       </td>",
"       <td rowspan=\"4\">",
"        Ethinyl estradiol (20,0,10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Kariva 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mircette 28 (Duramed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Viorele 28 (Glenmark)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myzilra 28 (Qualitest)",
"       </td>",
"       <td rowspan=\"3\">",
"        Levonorgestrel (0.05,0.075,0.125)",
"       </td>",
"       <td rowspan=\"3\">",
"        Ethinyl estradiol (30,40,30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trivora 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enpresse-28 (Duramed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lo Loestrin Fe (Warner Chilcott)",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Norethindrone acetate (1,0)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (10,10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Natazia (Bayer)",
"       </td>",
"       <td>",
"        Dienogest (0,2,3,0)",
"       </td>",
"       <td>",
"        Estradiol valerate (3,2,2,1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Extended combinations",
"        <sup>",
"         &Delta;&Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amethia 91 (Watson), Camrese 91 (Teva), Seasonique 91 (Teva)",
"       </td>",
"       <td>",
"        Levonorgestrel (0.15)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (30,10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Introvale 91, Jolessa 91 (Barr), Quasense 91 (Watson)",
"       </td>",
"       <td>",
"        Levonorgestrel (0.15)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (30)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amethia Lo 91 (Watson), LoSeasonique 91(Teva)",
"       </td>",
"       <td>",
"        Levonorgestrel (0.1)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (20,10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Non-cyclic combinations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Amethyst 28, Lybrel 28 (Wyeth)",
"       </td>",
"       <td>",
"        Levonogestrel (0.09)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (20)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Progestin-only",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Camila 28 (Barr)",
"       </td>",
"       <td rowspan=\"7\">",
"        Norethindrone (0.35)",
"       </td>",
"       <td rowspan=\"7\">",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Errin 28 (Barr)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Heather (Glenmark)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Jolivette 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micronor 28 (Ortho McNeil Janssen)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nora-BE (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nor-QD 28 (Watson)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Other delivery methods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depo-Provera (Pfizer) intramuscular",
"       </td>",
"       <td>",
"        Medroxyprogesterone acetate (150 mg/mL)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Depo-SubQ Provera 104 (Pfizer) subcutaneous",
"       </td>",
"       <td>",
"        Medroxyprogesterone acetate (104 mg/0.65 mL)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mirena (Bayer) intrauterine device",
"       </td>",
"       <td>",
"        Levonorgestrel (0.02 mg/day)",
"        <sup>",
"         &loz;&loz;",
"        </sup>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ortho Evra (Ortho McNeil Janssen) transdermal",
"       </td>",
"       <td>",
"        Norelgestromin (0.15 mg/day)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (20 mcg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        NuvaRing (Organon) vaginal ring",
"       </td>",
"       <td>",
"        Etonogestrel (0.12 mg/day)",
"       </td>",
"       <td>",
"        Ethinyl estradiol (15 mcg/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Implanon (Organon) subdermal implant",
"        </p>",
"        Nexplanon (Organon) subdermal implant",
"        <sup>",
"         &sect;&sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Etonogestrel (68)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: Products with same or similar trade names available outside US may contain different active ingredient(s) or component strengths. Consult local product information before use.",
"    <div class=\"footnotes\">",
"     Fe: contains iron.",
"     <br/>",
"     * Different progestins are not equivalent on a milligram basis.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Ethinyl estradiol and mestranol are not equivalent on a milligram basis; the results of some studies indicate that 30-35 mcg of ethinyl estradiol is equivalent to 50 mcg of mestranol.",
"     <br/>",
"     &Delta; The progestin norgestrel contains two isomers; only levonorgestrel is bioactive. The amount of norgestrel in each tablet is twice the amount of levonorgestrel.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Also available in a 21-day regimen.",
"     <br/>",
"     &sect; Also available in a 21-day regimen that does not contain iron.",
"     <br/>",
"     &yen; Also approved for acne.",
"     <br/>",
"     &Dagger; Taken as active pills for 24 days and placebo for 4 days.",
"     <br/>",
"     &dagger; Also contains 451 mcg of levomefolate calcium per tablet. Beyaz is taken for 24 days followed by 4 days of levomefolate calcium alone.",
"     <br/>",
"     ** Loestrin 24 Fe is taken as active pills for 24 days followed by 4 days of iron tablets alone.",
"     <br/>",
"     <span class=\"double_bullet\">",
"      &bull;&bull;",
"     </span>",
"     Lo Loestrin Fe is taken as active pills for 26 days (24 days of the combination and 2 days of ethinyl estradiol only) followed by 2 days of iron tablets alone.",
"     <br/>",
"     &Delta;&Delta; Seasonale, Introvale, and Quasense are taken on a 91 day cycle: 84 days of active pills and 7 days of placebo. Seasonique and LoSeasonique are taken on a 91 day cycle, but instead of placebo, 10 mcg of ethinyl estradiol is taken for 7 days.",
"     <br/>",
"     <span class=\"double_lozenge\">",
"      &loz;&loz;",
"     </span>",
"     Decreases to 0.01 mg/day by 5 years. Do not leave same system in place for &gt;5 years.",
"     <br/>",
"     &sect;&sect; Also contains radiopaque (barium sulfate 15 mg).",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with special permission from: Treatment Guidelines from The Medical Letter 2010; 8:90.",
"     <a href=\"file://www.medicalletter.org\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      www.medicalletter.org",
"     </a>",
"     . With additional data from: Lexicomp online Copyright &copy; 1978-2013 by Lexicomp, Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11184=[""].join("\n");
var outline_f10_59_11184=null;
var title_f10_59_11185="Pustular psoriasis - plaques";
var content_f10_59_11185=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pustular psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Numerous small pustules are present on erythematous plaques.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Callen, MD, FACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11185=[""].join("\n");
var outline_f10_59_11185=null;
var title_f10_59_11186="Patient information: Mouth sores from cancer treatment (The Basics)";
var content_f10_59_11186=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?17/27/17842\">",
"         Patient information: Hair loss from cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?1/40/1667\">",
"         Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/36/579\">",
"         Patient information: Managing pain when you have cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/53/6994\">",
"         Patient information: Mouth sores (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/57/19346\">",
"         Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/32/40450\">",
"         Patient information: Radiation therapy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/4/29762\">",
"         Patient information: When your cancer treatment makes you tired (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Mouth sores from cancer treatment (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H261742112\">",
"      <span class=\"h1\">",
"       Why might people get mouth sores from cancer treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mouth sores are a common side effect of a cancer treatment called chemotherapy. Chemotherapy is the term doctors use to describe a group of medicines that kill cancer cells.",
"     </p>",
"     <p>",
"      Not everyone who is treated with chemotherapy will get mouth sores. It depends on the chemotherapy medicines and doses you get. When mouth sores happen, they usually start shortly after the chemotherapy starts. They are often worst about 1 week after the chemotherapy starts.",
"     </p>",
"     <p>",
"      Another cancer treatment, called radiation therapy, can also cause mouth sores. Mouth sores happen only when people are treated with radiation to their head or neck. Mouth sores usually happen within the first 2 to 3 weeks of radiation therapy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742127\">",
"      <span class=\"h1\">",
"       What are the symptoms of mouth sores from cancer treatment?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Mouth sores usually start as red areas or a burning feeling in the mouth. The sores can then become raised white patches and, later on, open sores that are often painful. Mouth sores can also cause a sore throat.",
"     </p>",
"     <p>",
"      A person&rsquo;s symptoms can be mild or severe. Some people have mouth and throat sores that are very painful. This can cause trouble swallowing and make it too painful to eat or drink.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742142\">",
"      <span class=\"h1\">",
"       Can mouth sores be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help prevent mouth sores, see your dentist before you start cancer treatment. He or she can check your teeth and do any dental work you need.",
"     </p>",
"     <p>",
"      In some cases, people can lower their chance of getting mouth sores if they chew ice chips right before their chemotherapy.",
"     </p>",
"     <p>",
"      Doctors are studying other ways to prevent mouth sores. Your doctor might recommend a medicine or procedure before your cancer treatment starts.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742157\">",
"      <span class=\"h1\">",
"       What can I do on my own to manage my mouth sores?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To help reduce symptoms and help your mouth sores heal, you can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Change your diet &ndash; Try to avoid spicy, salty, or dry foods, or foods with sharp edges (like chips) that could cut your mouth. You should also avoid caffeine and alcohol.",
"       </li>",
"       <li>",
"        Keep your mouth clean &ndash; Rinse out your mouth with water each time after you eat.",
"       </li>",
"       <li>",
"        Keep your dentures clean &ndash; Remove and clean your dentures often.",
"       </li>",
"       <li>",
"        Use a soft toothbrush or foam swab (if they don&rsquo;t hurt you) to clean your teeth",
"       </li>",
"       <li>",
"        See your dentist for regular follow-ups",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742172\">",
"      <span class=\"h1\">",
"       What other treatments can help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor can prescribe other treatments to help with your symptoms. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A special mouth rinse or mouthwash &ndash; These have medicines in them that can numb and coat the sores.",
"       </li>",
"       <li>",
"        Strong pain medicines",
"       </li>",
"       <li>",
"        Medicines to treat an infected mouth sore &ndash; Sometimes, mouth sores get infected.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you can&rsquo;t eat or drink because of your mouth sores, you might need to get fluids or nutrition that goes into your vein through a thin tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742187\">",
"      <span class=\"h1\">",
"       When will my mouth sores get better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In most cases, mouth sores get better within 2 weeks after the cancer treatment ends.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742202\">",
"      <span class=\"h1\">",
"       When should I call my doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse if your pain is so severe that you are having trouble eating or drinking.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H261742217\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=see_link\">",
"       Patient information: Radiation therapy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=see_link\">",
"       Patient information: Managing pain when you have cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=see_link\">",
"       Patient information: When your cancer treatment makes you tired (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=see_link\">",
"       Patient information: Hair loss from cancer treatment (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=see_link\">",
"       Patient information: Mouth sores (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?10/59/11186?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 87048 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11186=[""].join("\n");
var outline_f10_59_11186=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742112\">",
"      Why might people get mouth sores from cancer treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742127\">",
"      What are the symptoms of mouth sores from cancer treatment?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742142\">",
"      Can mouth sores be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742157\">",
"      What can I do on my own to manage my mouth sores?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742172\">",
"      What other treatments can help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742187\">",
"      When will my mouth sores get better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742202\">",
"      When should I call my doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H261742217\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/27/17842?source=related_link\">",
"      Patient information: Hair loss from cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/36/579?source=related_link\">",
"      Patient information: Managing pain when you have cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/53/6994?source=related_link\">",
"      Patient information: Mouth sores (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/32/40450?source=related_link\">",
"      Patient information: Radiation therapy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/4/29762?source=related_link\">",
"      Patient information: When your cancer treatment makes you tired (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_59_11187="Paravertebral mass MRI I";
var content_f10_59_11187=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69331%7EPULM%2F76000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69331%7EPULM%2F76000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive neuroblastoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 214px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section through the mass shows chest wall invasion (black arrow) and extension into the spinal canal (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Invasive neuroblastoma on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1-weighted section through the mass shows both chest wall invasion (large arrow) and extension into the spinal canal (small arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11187=[""].join("\n");
var outline_f10_59_11187=null;
var title_f10_59_11188="Audiogram presbycusis";
var content_f10_59_11188=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80255&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 627px\">",
"   <div class=\"ttl\">",
"    Audiograms of an individual with normal hearing and individuals with presbycusis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 607px; height: 787px; background-image: url(data:image/gif;base64,R0lGODlhXwITA/cAAP////8gIHdISLdWjzhL19dwcAAAAAAJL38AAYgoiENo/58BA48BBszW///u7r8LOn84l//e3q8CCgAem1cAAC8BAwoOSoiIiERERLu7uyIiIt3d3WZmZjMzM5mZmREREe7u7szMzHd3d1VVVaqqqv8AAAAz/4CAgEBAQMDAwP/AwPDw8BAQEDBZ//Dz//8QEODg4CAgIKCz/6CgoGBgYP/w8P/Q0P9gYNDQ0JCQkP/g4DAwMFBQUP+goLCwsBBA//9AQP+wsP+AgHBwcNDZ/2CA//8wMP+QkP9wcLDA/z8AAP9QUAADDy8pz+Dm/+8DDwApzwAv7w8v75Cm/xFB/78AAJ8TX1Bz/+7x//8zMwATX68PTwAWb8DN/wAZfwAs3++ToF8fn+8TIO8AAM8JL98AAP/MzICZ/59Dj/9ERA8AAM8AACBN/zBJ7t/f3+9TYO8yP2Awr88ZQBAwr++jsE8irKCj75+fn+/j758yf+9DUP+qqm8wMK8gYHCN/7+/vxA53z8/P++zwB8fHzA534ig/+/T4J9Tn28AAO/v70BTnx8s3/+/v58jcDBDj2Bzv88DD28TX19fX/+fn69gn7CzwKBgYA8PD5CZv49QUN82UP9vb78gIN3k/2Bw7+9jcEBDUGaF/3eS/59jr/9VVaBzv98mP79AQB8AAI82j89ZfxAjcP+vrzNc//+IiFBAQJmt/18/v58QEM+Jr8+Zv88pT885X5+T36+Av48gIJ8gIDAyP6+AgHBzgP+ZmaCDz+9wcI92z8/Pz6Cw7yBJ7sCt3y8vL79wcO9QUI8Wb9/AwP9/f7+MvyAQEI9Wr89QUN+AgIBwcODj718wMICDj2BjcO/D0B8pz3BgYN8QEH8ZfyApT7+AgFBw77/M/++Djz8fn+4jMG9vb98GH4CJ74+W749Dj++goM+pz39/f9+mwIAjcM+goMCwsN+goK9wcODW75+AgP8/P4CT35CToM+AgM+QkI8PT38gII8wMN8WMA8pz59AQO8wMAAmv2BmgCH5BAAAAAAALAAAAABfAhMDAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu3rt27ePPq3cu3r9+/gAMLHky4sOHDiBNHNKC4sePHMBlDnky58kfJljNr3uwQM+fPoDl7Dk26tOPRplOrFox6tevXeFvDnk3brezauHOTva27t2+tvH8LHw41OPHjyI0aT868Oc/lzqNLlwl9uvXrKKtj387do/bu4MNT//wu3mQGAxpAAOCAobxEEQY8EA3RwYCBDvJ/knc/8rwGDuu1x59DIHyAgYBCdSCCQBcAqN+AM53ngQEZsLeeffEBgIEG9m1owAcbAHCBfRqEwJ0HIBoQ4gb12ZcBACPY14F6NXWAIIMkhnAeCQB04CB1EMp03gYbWjgQBx1o2N6EL2pwQQgfmCjCCNxhsCAGF8CYJAAUXjBjj1nWFAIHHYYApZRUkvDBCDfGtF+QHg0ZQocifkCihlmeJxCWE2KowXYbYIgeABrkRyGZGP54E5J93nkhjTO9CSdHQ16IQaA8ivAnlgDoieeZ4HkpUIEkjEDlnBl4CalN+AnEHqgDkf+gwYE1STqpRpUG2h4GJG6ap2ScjmifotM5eeQIIXDI4Ysx2pcfTfDJGKKwBnBwXggg/EeTrbd2C9OcIQbGrbc4nSDoueimq+667Lbr7rvwxivvvPSie8JD59kXJkPm1ivvvR316++6AHdG7sEQjovwwr0pzPDDtDkM8cSrSUzxxaRZjPHGm2nM8ceUeQzyyI2JTPLJhpmM8srisuxyaiq/LHNsM9fcsc04VxZzzjyvtXPPQJv1c9BEhzX0yRQSxGnRZR09MXzPDpT0QEszPZbTDxdIa0FT77mv1UaDfRCKga7YYtLNGpBlfP9lwGGG0RoQAor6it0U1gxbiSeMAnb/qUGInBpAJQAfyKcmlzzuuaDdTuGNcKB+EmpohQ4G/iLkGG5wAYccgJBBfRiYyLhSjh8sKgCkmgoAqpuDkO3aLxIe9UCFDzQCsaMXVTq5xrqKLIf1ZQBCfR8YO7XbJBYoIwi8oid67kftDv30Q0kPPQoDZ6/99tx37/334IcvPrsFN2Q99ej3dH767OO0fvvwRxr//F+9T//9KtmP//4l6c///yDxHwAHuBEBEvCAFjEgAhe4GAY6sHoPjOCDJEhBnSiwghi8IAYpqMENRrCDHnQgCLvFqzZNpGuTucCNPOWaEW4nX+iJXUHUtKqKoLB59wmXXXD4tYOokCAsrBj0/yolgi0V5IcZuSGACtTDuWAAQNdSCBIFEkTVuBA7lVIdi4aFOQ8Iq0Rc8sB/sLShLVYLAGZUIhqjhCL1nA4uTxRI4cj4txYtaHN2mpGezAigzcmoRYkL2RAxdCkYAWgDUfohqKbEpcFhoAMhut0aQ8AmgdwQQ60qlOTkEscJEQmSMDrVB1KVntfpSZKIDMHmNhCoLBlJkLkbEtkIJSgvLklQf5ra0t7mLE1ySYYactCIQKBCWTkRQ/LZZX4wYMs9WYsxvIwPEpM2xclc8TpEnJEkB6LIKBFEl2HapkBUhyqlCfMDrvtAB5rYljhSLZyn6lJ7EOmBUypqmi+qJmSuaf+dSikpjZoTELUABE6BADRZ97kkifIjAnQ6UVFLM+MdMUSlPZ4toJbMpwlPE8KLVK2jJwQpRUhggBoCQGDjS2n4ykcdlbr0pfVi6UJgStOa2vSmNpWpSHfK05769KdADapQh0rUohr1qEhNqlKXytSmOvWpUI2qVKdK1apa9apYzapWt8rVrnr1q1GtIljrdy5gGgSFABBjRZb20biAYFAL0ZM+JYJWp9CHROx0yIgG17sKzvUgaFUrRdpKFy+NMq4OqytTECnMwU3kAh+oXV8piMRmzeiugkOUigYiWBzdx0TUGhMyG+WBYMnIRAnNEFqcxIFDJk2tyLOPiNqTATv/1c6P9wFkp97mAc1qLkdh1FZR3mhQTIIAs1T64vNE5CR0GktYHVguAn+oKjARN7B/EsicTPSquiJpb5+SW4C4lKXNoeU8nkNnoF6k1g/8araEy1IbV9nK8dbucElbJJUEh5QGIQRTb9QvQVr3AQ44abvjdeAPNVutDcSoVdjlbHbd1tk63YmtFxCs236Z1uyahcEeWG+Hy9YpxqiQxFzCKIdPfC4RN2pQig2KeQkSAhyG+MEeeLGHmSsifWl4x9NtT3WPmMtACqSzCGZTOdFogExtanFYSnJ7XgtksZCKQUnK0Ibi22P4urdOxOybRmX3TR7BKqNIQeTgLnC7JL31/1mbO/OAs8uhJ4m3kpMdYGWRSS35IEqHL74AdEGLoRr3Kq3OMu1nOVzhsaBoIIFSpYz+1Kf6wLe2H5IPPi/9tj/9eaAcRsrnZHQBTHPIi8js8bDmfGS1qTq6hMrrWGdt1BTg9NaC0ulPUIpre/WE173OKa2HTexiG/vYyE62spfN7GY7+9nQjra0p03talv72tjOtra3ze1ue/sxhOXmRv/67e6gy6xcMyu1QGkQLIkVvgOR665gR5cX4w4i5HYK5gywOIPk+6f/lpq6s6ugg4SbQeO+UYzZ0ui2kPhzjh3wRoO65/sct0W3yxw3//S63ToLT3pqVB81kEfPmXjemv9to4iMqJYKQ5aVhcOcHtHzoWbdcVctOmTOZzuioqB4TiAQOeY4wEeKC/lL67yuuhMlR8N9AOSemRAxS+kkee9tapr05VrsDYAirpMgmDpPk24JX1oNCZWJ1AC6gYLiUCM6zOM8pDcB3h4GEx3HbmeQp5O0bxW5mzEeuCgSn2h1yyHcmG1puAa2ZGhneYpThc9S2aLZTKP8vKSBzxwSKQ9U6n6JyIgDfY8AVLt36kkDCyIpRukZ+dCjTp2yLkujRbAhV7o5Po9/7w85VTZxwtvnm/0cgFAPANWfzvedF1DaUP3xP2/coFXvNNRVzaHf2qeiJ9+b8xtqUrTYu3Vzqqf/nU6d+xKXXfIqAmjAebLvMH1RRVBq8EXLDd6DADvYNdV1Te6Pf/2LhP/4F4Dn4n8oQ1LdR38ImIAKuIAM2IAO+IAQGIESOIEUWIEWeIEYyBaIgnrZ0mQ9liR2MjgPpmodQiOaJUz8RhAkgHGzgzJp42pzsiUxQgJzgiG3dS6rQlLnwl1Mp2qZ4mp2giH9Nip2giB24kYpGIToEU4U5So9KCwmUoM0eC4reC4jQC2fdR4OFSP3dhzwIXmhMyF/syyEYx9mIiM9tiAxkiW8Ul4GIGQpSITZ5V8vM4Ma0mQxOE54eB+r8yFpqBBv9XR74mojAoeD8oVleIDUEi5H+IeN/9iGAoGId+iGhkglzTKFLBeJrvaHe3UhI+AfB0gcMWIlkMIrduIgtmUqefSHMRICgeJh1Tci/TYnHyACz9KKK2OHX5iHMLKHSXIeSSKLgOiHTAaLKjIinIOIjXgQ9VEfi9OIwtiIBSKIiPiKAxGLHxIf2YiJBiGJwiiMHWgnLZgcCCUta4QeNGInwjIiwSgooUNSjjWDwngkgpIluOiCHlgfZyiDe2hcJMiHZ6MegSgQ8Gg7TTYiXvKGQCgoRjYnJQJX0JiEJSVHE4mIBamHJCCLwDODNYghNOKNguJYfTJxzAECtLeJZLIvR6gBD9mOC+KQ1igQ2DiERwYfgugyaf+jSbzIkZ/1IdMShwgxkMV4jceoNjCUJctYEAzmgRG5INJYPJqIfsb4WyIwIh7Ak5nYdZsoi+xIEBwiXc1xhU7IUJuYiNrFh8LoH5PYY3DYb6ViIoj0J/d4MnZIEMWjHvWxAXnYlfMYlMS4loXYY1kSLUg5kQZhJ4S2K0lDJvLxiJsoiZAYmH2Jld24lSnIKz+ij9bBZvbxZVFJO4a5l+4oOifoWZ25AZrSIZEkXvhoZMXXIhpgZnzYI9WChYZJEELphKsmmDK5kELITbOpPKzEQxS5UHp4fbp5Rn+IkR1pH4kDkguiPPmhmRlYndZ5ndiZndq5ndzZnd75neAZnuL/+RaM1CODs077lktNmJ53iJwh0XDaBZs9VI8uAZ+rI59cgyGxN54rcTjTiDpy03ZhVGKuuFlUI3euyRHwyVgMEnEDaoAtsaAF1qBcYzi3yZ8w8VYhUCrRdTgCmiGyAgICGkcIRl4dAZ/EdVaadpMrgaJZ+U0riqE0cYVVWaNUwp4hWaCR0zyeaaIKaozSRCyIQlAysnYn0Vm8RYf0eEaYZKQyuhJs1qEj0AE88qH5MaUj2jkF955VxmMJER9QkqAogaJdKjUeEKZPlZSEASVPpzzqYaXjdCkG6kxrZCj7KRESumYOCqJz16JdqmYUCqPF16fzEy2xI4kIAVm7GRFq/5oQ4PiXcbEmAtEBW4KjmKSjF+YgYuejGxFoQNQiXyeozKVDKeGp8Qaq85kfq3Q/b9OF/vaG4ySmC9GoiQqUT8oZJNUBkYWEFxCIvAIp1YebzRObWokBIYg6pniEyihe1IJDJRVZyEoiP2is/DUnDnqrfbGGayiYb+WRowKpvUgC2YJOy0pJC2mSCylpjjWP0DqD44quhXmG14qtetF37dir4FqGpNqI9UECiKiPmqms6VqXywmt/Npk/8qa9AoYnUhLqaI2uQmcylcqTfauCWtoPCKwTik3DdtjqPh07kpy8Eqb8rqwfsEhz1mbEJuvFnZGzCMjP5gl+rgBwHOENP/7hohJgiIwPPbxny97HzFLstaKFQJYtEZ7tEibtEq7tARosk77tFAbtRnxs1/CYIOonCvBS7Q1fqLTPK7KErQXb1yLRi2yTIvaEpilqWNrRmaLtS9BswJianBZtlf7tSZhRhigHnJLth/XnnZbYuHyShhDJK5jLK01ZyL6AbJKElrHZUXEXIm7uPkDq3I0mEmiOgbYOogkuSXhAS8pXl/2uJhbUpqruBkKOpXbdZebJqSbHpv7Eo9LT467usXXupGLWIFLkhTzdRvILFB2pyDxNpAEdOY3Ar9LE0hEvHpiur9kvF4jExqqvIzBvBTivPXXEj5iIdJLOIlTvcdbn4X/UiBnqLfT270ZYL0HF28Gyh77No4Lk6Ic8HRs9bciMTyfKBlDMr/IG7f4qyJTEx/6GxN64ylD8r+lFSbu1BK0YiEE7L+xA8AITL8iwSLxi31U5MCWdMB0qhAwRCdYForkgiQ1dErf2xIqtL3oC7wnkbwTubzmm8Kn6yDbS73nW8Ir0Xeh08Llm1Ew7BLoKwIz/MI2fBD+ZCQi/BEy0AXNQcEEAWsWUrqcCxIZkLfDg5SWC7mvOxNTFLq0m7muy7wtUVtRw8WhVLtTd7sxYSRkPLpnnMUtMaWoU3BrzLptDMYIUcR1p7sPIQMyUBBE8AMt0Bw61ouL5rcsgbd6O7aG/xwpGre3bFu3MGF3nbK2dLvIaRy3lNy3XgsTiDzJzsO3qrXJuOsqGNDBKowQLWACfSwQf/wDRPAQPoIQ6TtgWRlu+eKkUusXLpDKfewCbODKDxF4V5tD16sQbRVuX7d+uawXu2wCU5DKSQARxBpMr8eGKox473QQh6XMy5wXzazKEBEoNBJHqYQnLvYnsZUfGqo0bug8S+m2yiVzJichTLG09nzP+JzP+rzP6dK0B1EEJgDO+OJhONQqWHLOZHY4MglMUeZNjERNbSJgxUUC53HKW+FCO5PRI6HRIsHRIeHROeEHJlAEvDzQB4ojzHMB59x34aJ27DzIEF0QOtZ4uP/HTyuB0Rud0x2t0x/N0wHk0zchAyZwBQDQzKvMEOK8wZCV0gO6ZaU3EOv8TnJGTZl4Zt/1Zu+2G+oD1N7B1R0B0pfh1RzRQULdAi4gEEbtENOMQ5qkaB2AztJXfECmaEz6IvF3T4liajXtM1u9037d03/904Ed1oNdE2xg1gSxyz/gEMKMEbN8GDhd2F8t1gVE2RoB1l2dEy7gBAax2bAswY76oiXT14Bd2oJt2oSN2pmt2ugT2aw91padRLGNEZg92fHj2qed26mt26vN27b92k2R1Qzxb1W0cHeB27ud3L2t3L/t27At2UrRwBRB3KNh3HaB3Mud3c3N3M8N3Jf/PdtFId2PpbvFjcvXTdpEYdNnFT3sDRWdBowfglpiZC28pZVmuDnAox7Nk7cWhSEZgFx7gd1Bod5c0966ExUN/CJxxF8J/XQeqHcbUCBeVErrdEpilqJ5IeBAQeDfZODpjeD96yoEdTkt5keds3m9JUzPtEm/5GD34b5asbch9RweDkHKUeOPtTw0gV7mtx4j3nTaXHmF0jqmxBjk1DUzBhZkPOM7weFSg+MDDuUQgWBbCr31oXaScbjH02nKY3Eo3p78zRgIFTx9Fhbby+QWJOUTdOA3bhGnw80v1L+k+hAavuYf3uZsXhFIlORBcubfxM+AHuiCPuhIG9oI1y1L/w4RNaACSqACNdDkar4TKrAEL1ACL7AEKnDneU4RVE6TECLjDqEDS1ACpE7qS6ADOSEZLnAGZ73d2t3dG1EDo37pCEDpJbAEj+7qug7r3I1vOn4yNlDpN8DoKnADlm4DM+ECRdDqkgHQ0bzrlY3WvV4RQFACSPDojFEDSFACRvDq0V7U0y7b1KMDL/ACyM4lAhHsL4DqMZEEJoDYjAHQRRDuFOEEPWAEpW4EzPADz87rGCEEJXAETy4QR1ACQgDtFsHZliQQXcDv3v7dRc3qo2Ps547u6V4CNzATZe0CBjAFI+3cFuHuVhAAQoAAQlALUiAFePDwExEAAdDhA+HyCP9PEe6+yozRyq3u7xih7MwuEM6OEyrQAz2Q6daB8TAvEMZOE2XNBe/u3RNRA3DQBOBsAE7wAz9ABkaQ69+eETYQ8EcPAAXP7hDPEWlN9Vb/yiw/Ee4O7wAg7zchBJVe6i9w8NGhAiUQBF8fBCVA9DLxCAENBZWQAoI/+IOPAxehMQAPBrzMBKlMBD1g8DMfEXbP9xYvEJOv8zu/+I0P8hax8R3/8TZR7UDQAzZgAz0g+nW/919/+SyxAikwAyeAAjFgAAcQBSYABUzgLzGAArzf+75PA+ZyAsI//MLvA4R//CmwAgnxAkBQ1Kn8BQINBC8Q+RBh93g/8AKh95RP2yD/AQZSvwgm0Ag9wPmd/+5MH8g2se0ZXxDGjgQOEcv4dnTjnRddP/7YDwCPX/Ek4fo5ABBDULAwUNDADh7/ovzwYgJQpRQRJUacccLiRYw8UGzk2JGgQZAhRY4EWaFEro27opiYYzFdgRLsAMykWdPmTZwGcO7kWbNGCSQ1dc50gaREjZ5JcypViiPixVf9SkCSYqJOmRJV1JAkyaLj144GwIKlgdHsWYy80Jgw0eSNDaZx5SbVUWLJziUldCj10GEmBoMjkl7A8PcCT8I4E9PMMHTuY8iRJU+m+QKI0JpAXlBWCiPFCRooQqLgccIHDqItTBAxIMNECxecdzq2OdF2/wofaC1aKsFn4wQTK7UUVFJCiUGOFyXOpS0bgGZ4NId2+dHnsnPpSldEzA16YwySa0qcmhPchCNgJdbo1h167Fex7zl+5DqSQQkyVZs8AYoduxC9dqpLCKU0IOEvDgDY4IMDESsMABI0gGyxmRrz70IMM5wJwCCymymIEgj0D4fcNBqtrBRgwMkF1WTQQQkdXIMtw+Y4U6GEDqcwoQgmWlyhnhK4scg98EbyijSLcogINQ/9U2ELE2SYSScifpDiCRUw1MmzFHKwiKOuNirthBkiUhHAI3TkscUjQtQywxtK0EQKhkwgRI8SbtBQMiCM6MmI63jawAAQEAQgBANCAP/ggoI0UJTRgh4EIdGaMCBMg8Qy0MCgRTXYtAMQNjVAQsZE9QAADgw61VIMSN3zVf9qCOCFDgEYSpA4wkFqshQq4mEHkLwaQskVmHItjxdKUPaFPEyYgkYM85TRVhajjJMnLivyDoUiRfLKgDGVTIHJyehowgQ7ajDACSvJ6IFX3CwSiFuSYthoCIt8iIipAICY1oBqZQAigDcv7KGEN1RjTcY3SngXVrmACBQniZPSlCbADPjgsBA+UFSEERDNYNEHAdBgZIw72IBkAD4QAQALL9BgAxA+8MBCm2yG8IOaOPALA5UhFto5a8J4wgghlBACjnOTmGu7iug1yF4yUyj/FjIb5CgBiCOUOAII/OAamrIbHngtNp2q3UJPybId8rswkTxBXHJ5EqQNE6x44txaat3J7RM0GogkMZM0kzMbShjgbFsBqHaAEsSGGAXJAhCjxcZlFIPgsZNagvOdArirp4sRBKGDlz0ASQMPSKXw5EoPI3nQlWN+kHWcaRoUpA0u+KBRACztfHjIkmhLDGVLqCPKpLbLQSD6DiqtTOdkpXXKD18IYFfi59JBjjoMwR4AQ+qQY689AScy7nCXdFy1RdAFwKnPTpgX2JHsRaEs0yK6es8b0eIKsWmc465AixJkCWIzMEAKIFOXtUipgK5JRYC6d5M2KfAmNzpCUgZV/6jgJWhBHuiYomaCKEWNQFKUwpjsErOxRelkMbgjVM5ONZNBHUgEEhLeBX3YExnhQQmeMIEfbuIZ74ymNKfRkFH85hgQBeWHcenBC14gBBUYQAVCSNbDfKg+uI2ECSuZAEl2sBHDjWuKN/JbAT+UQKGJhgeQuZEKiNAkItRxijSpwQuMwD0+GuEFgNyJgQwFMwNkAFIGSFCqDNCBB0XIJj1MjOpGJcPbeeB0o6qJpoCXMU8FT3Z7JOVMZAScIsyvRKIByf5OkKKhWQYzNNFMKZViA7Alb2uSs+VN6OelE5RnJY6omtV6eZOfsG18M4kTITMEA4OoaC56bBIAqEnKg/8ZAX0z0YERHMaUvlCmh0yR2THNKRvXmMAf+CuIsIjVvcR50Y0AOBgvz1kTHfQAAUHY5j13oqYeMc+fNlnCC7bpGB28YHSwooFBhvCYn0hxmQAwijN/eLAX3EAIQrhBF+XSgQRF5gJ+UQqkPoCygaZUKcYzARR2UbX//fCa85ypSudpU5r8K2A4Tdwfx1cDb9ozQyugDwsgoxnuOaaPEyulDfKSvCUIFadTHWiV2MAFxtnyRvKkzcE0iNMa2bQLjEubapxmU4weQQcG0MERPAqxHIRkBo+5ERB2NZQa5OWrVOVrX21ZpR8sLKulzNMsmVmCvoZVpUQY4PhccIU74lT/BQHQZQkCsNc9gUezB4GMUYzQIZ0EwZsi8qtScvcYCuHktLZCaWnNyaLAZm6we4yT5ByTOGVOVbFU3a1NbXAEBBxBqhrCAQ0cqJMU8KBuVEyWepYlT9faBGerlUtqb7LaREb3nMaT4FBcc1ZSJvQFYhuKDazYT+f0Nr0QU69s2suZ91ImvpNR7Hx34oBJbEIem5iEA7S7k+natybWlW5zsvvfYzqhSQrupXnzFAQlBCFO44UWrAQMmQs/JsPMYW+Hl4JgiInqZI/UmKIM0DoOePLEABCBQUIgs08VKmMYAIGFNtABg2QgBDg2gGBAXMoND00HcdLlDdCLnSDHJclM/1myUpqclCf3JMo8qe+PYRXgkWEgQT2eic5IwDMDNKhTNLOZzEBwugtYSIVTUiRJrQxkldZABUpQgUWR7OFXTXk2eN6Tnj98Ez+/mTFDwRkHtjyy3Rmkd5viAAhm6AFDz+QCKdYJ69i8gRE88oaC9mGgNeRpw/aZz58edYXzvGdOY6gxhSr0obu86ZqUOZNmDlWadTICwYiMJuVM9QVBXbBTW7jUwBa1sI19k0D0+kKbHPFMIn1gFWugZgUB1aODF6ka6yQEn0rkImGt7LH9+kLivqmpix1sdJ9b3eBmd7s7R+47H3vd5ia1vOudbnfnW9/09ie5/T3scQPcP//ed//BDe5esAo83vjmN7HvPe+hIcrHB6e4hkRQsgz8zlGSgfd67d3wgH/c4SAf+E0y/YFC4diE/pG4XEjgmIyPauUVp3mkaAJDEbhZwwnXbsdFzlef1yTTXFY5hlrOlIzd/DA5p3nTJf0gRLE6wzZQwnCPGXSIA/2/WJ9JpjfVF0q1uCBL77HLWoyB33Hg5Ck0CAY2cHSm4CzqiHR60xcT4JXFpQZcTN4V7Qznnm9d8MTL9Jc9lShGvQwwJBC7AUTQ4sP8bgOqC2nXDXABuJuW0JvPe90Pvpi5U5crFcBKFRChBERUoQRlqEB9XP962Mde9rOnfe1tf3vc5173u+d970P/InTEu7jwLHY85Gdi/N+B4OWCkZlBRJB5iw0l9BdeQUwBUH3P+5VCONd5T/p4vQIGQR+DvCfXSa7bwQ8v04ri8Ysdf23GX/748k/+8hHFs8RDn3SO4T5kTrCD/1mBHTiB2si+lOIdmNG4meuJOFEHD3GNtSm/9HMt8xs5oVm/QymIjykInJM/4os8Qlk+ABg6HHs+LkM6VUlAmYsM0qAJjaCJFAAW8NgBHzDAVHsBKOkuADCeFtCDzTinCgy56ArCkrNB2RBAGgAAGgDAmZgBFpirJnxCnmgMaUOVkvEnAqO5GwEDzDEAq3KBegLCCSwtIlw4I6QMohqIq4Gm5cIB/wOQpusalUa6wnvKwoqro4A5gB+IrZqaorZagipYArWiwDH0qzIEtxMwAAKciRxIwpuggRwAsBNLJA4ojJjTmUFrDA+AFEcBgYzhGaApCBHisZeBsUc6s0+MoRXEIYPggBsriJehuK16HxP4gijABNTwKlsCEMuqAsp6AnIgICHMuiJkOAscxofTNzdMRCaxCJxwRtUygA1olUpsmcPwAJQbNI7xGBYbgVXDmFxLFFw7lJOSGTK7mRoix4+ZOJYZwVw7qYorLABwArYoo4JYgBJIDouQCOuDmE8IAz2AC52wgTgwAUo4P48zRmRESIT7OXDDASl0QtSYAcq5CRSAwv84fLtIoZ0p6TycsSTgaTEY6qETs7Tg2cRMIr6NAUlO2rWUPMmKqy0AuIJaNIFHmAEBKAFO2Ah2EokzQgF8KSY4lI0ggJIZ0YkiMIFYwJFjLEZiNMNkZEj4UrgLWoEYWEQAOIEYqD4prAkn7McKkUZUMYDCgCHfASG6U8ebQJRpPIyXw7RwVKSXzMASUgySGkddozjxIiI/CKhbsCJC2o54+ZKN4IojaZ99iQsjCAA7OBsDUBNZ8ZOFbEqolEr5osqGVMgfAg2bKIv5YQEa0BcfoAEWWK5OEstBscTfwcSw3LVWbAxRvLaxUxBSbEcais1FqjxyZKRXfD+as4EEMIH/OIAwczGBRrC6nvglixCcbhEJjghKfTGmuggKGcGqFpgJoziyy3TIyqTMhHzK74zKlFqBeeGICxqnM8QQ4yEAXXoCvAGvC+GS7rgfkigO36ABR2ALQCCgPtxOzezOyQxQpxRPAbUpq4xE4kHP9PQPFygCF5AzOquBBhVG4pGI3eiNgTiAlYACJrCXTCgBewBLjsPMqeTO8LRM+iLRgUoBFhjKBf2xQ8SJAZnHPWwIKACFHUCAEkCFgnAlJhpRE81M8BRSAh1QFPUnfHlRQYtRnFhMPFCY1ngNPAgAI/iM0IieM6oauSC4/zxR7yTSI40MJlVSAxxTmwiCJyAE5tEJ/9cghCdoo+vrlROQmnYCSiVx0WrCkHxCgB7QTgA10i8t0S4F07qzwyubLwV1NzO1iVIwgTzYC53QgWYJBqYgkcBhJeQoix/1NFyqLCBAzhQNUkEd0lEtUjLNEOriiURtt0W1iVlQlgDwRWWZhbb5DOgBiSwtExGFDIzCIi3ioieALp4bwkK0MirUmKFLnVYMHr/4shcrjFaJlE35gMkbikiLVrKc1s6jTVi0wplgHRFrDBxzlEEZmdYByW9jt1a1CR0QAiCoAiAQAj+NDKiZ0+YUllfCU6ZIKFNAn6EoBinog3ntt2LVul5rjJHRgMJQnZpQnZQbAXhMDAxY2OzCFP+GRZUEmVgAUJ2EHSV3JMcMqEaTQcewTKERKNeN5SGPzbd1/TNYsdTQUCLTME2cuIEcxB7AeoLcGlZCDLyDHQrhsRCwK4iVGZRYlNjDwBlLudhrTVqg9ViTxABIy6QAk7SZya7WESWDcwwGk8Du8YznGZypQQGYugmE6UJ2CaxrMVhi9dlUU1qnNZmXeUsA6IBMGxmkTUtLaYwNuLGMjVutpQm87DYJyTh0lLqZAClbWRUeisV261rvMgH4vDpbklMU6El8TQF3wJGACag7AhHMOsCC5S1lg1u640RpxADm85i8NV3A+ADFDdqnrYnefJkN+BSbYTbYfKSVgZQOkBD/S0pXQeMu7OFBCrUlCK2zc4JZTLVPHugFKKhJCerPgWpZDnPbU+2cVOWrHYtNFdy4uNgpL/wBNjje8CKy5DGylPIMXjgJ8BgjlgDKE4AJUDUn693S0Y0LT6Q2VlPA7I3D//KAl0Eha2Sx7kuKPNzDyGqwZLkBCJOwEqAwlZIlACAA81iFgqiCMTgIsr1T0cVeMuSMaTwzTClgpvvfXpuUEJi+x6iWL4itYxIv8poJ8zIolQKQHgCoFoGGEniGOe1JsZgeY7Kl+1Wy/H2MDsC8GtpeFEYwDHgZvJOLvTMFtgiDADiFaKgamh0emVwm3ArUuQAqK3gNalENK/ApmnAK//uhUwPwCk11IFQb1FINUwxT0ZLyiyjuJUiJxgwx1HY7nZBiYZvgCjUQj+X5grxRj63wvdwrgQUgCSbAR0aeZIOwgLaABAZAAAaAhHOxAEr+ZFAOZVEeZUpOCp8pFEG2pUlprarFkLydDCb2J8ONtaU74J0AqhIIgyIKqEMoASNohy7xDiBuYzTqn12NjK2C3JmgDkqAI0DlDMaiA29SFiOgA8iCjHo1EVxVRA+uMBc4A/Ml1AL10nFWCr+lZQM+JkQpsNZ0ZTqUjFi+J0eKzZgDX6UAEAjYkTI2gV4mrdoI5tBozoKwlzHxH2QuAVwQKCrZQ0Fw5j996Fr1EkxFDv8hPmaemNDxScrJJedn7miI5ovV+d4F7J4ZCxXvNZlGEdcSU0V73thlFVlLWyRoPQzfNTFRcaS75F8R680EIQxG2dYfw0ETUADsUZsfjAvBXE42HmgkEZekSBwuXNO0JQJd9GiOvjM1Foh79VE4TgrjbZykTCU63jlR9U9Oo7UkXi0sC6G6BBmccFiYJqHsQloCrkb544CZKdeRSjlb6zoRYl3Y4TSodlDHKgIwiJwjfIo5FVtcdSWnngnL6FyFeY6j/ug5PsZ4uVKQsBd8UaObkBEXeEx9NtWrLm1xBrFIWxRKY+e0NDSWdJWN5TFpjOusZZmlJZWLmesHoUSQWG3/lFYVP9aumaIN6nUOz+iOjYiegtgBWSiBY6AHQJBeAIgiMA5VOY5TX5loDp4bWKpOMiZVsybt00YwWsMUtV5ia+WAurwJDZhbaSwnwyXgNbMU+S4M3WazvR60QhkB3Qzu6GKjUAPdr5VTgXiFMhgDCoDfljgH7fk7IL1u64YMsP3hkBCAdWCLJviE+n1w8I5w8daukl4t3U1vVWSkAWsUabzdR9IZnJ5pVewAE8Pb3R6ZoTsxZuvN935nK5PHiVpbUrIBygIHE6iKSFi9aciBLebwDw9vzlDj5s6PtuAPiSrny6ZyJm9iLH+MLnajL0ZeZzABozkXc8CGImEBHsgB/30lawhXcueIkzmpk2uQAB636vE27SrPcjynCyuaYQCo4YElHhl5EUPAHBjIAR74iBiggRlIcyezYzbnjINJmNWIUijAR37ASDu/civ38Dzv9KRQAStCAhWoABVAAiuC0ykaq6OkRfjEAUNH9NC0aOIpYpywnC4EANcABDEoAwO4SlkHvLb1dGF/6lxKnk89JsYioKF4rAWujTk1iB0YAh/4dUcPrxKIoPGhoBKIB/yhgSQn4iMednHXARVABBX4c1ISsM9gpwHs6u6hdZuoowV2jDyCoxRoKLHAdPsNd3EXd3gvN6T2gSFgJ7J196H5d5oY7pq4Jhg4AYLwdTEE4f9+n/hQq94jHM0yP/Nvp/NjiqhQq6ibmIFuN/g9Qngqo3iUH2SelQ0YmAEayHg0X/NSQqomWSqeuPfl1vcfMvk4TnmU/3dQK/RDH2hFZ/RHT6kbWYK7mom8cuidWAGtbOMTMPqD5/cfYgusz3oTmHjGs0Kg3nebgjdXH/pej/VMPybPAq3p9qYpTwqKLAjj2nmr96Gtx4m6ZwrFxYlVvYmRuolVhc3WUikVghQd7yWgH57PwNRon/bIsAF9Eq6+qiJlUb0I7qDHKK6c97W5v6C7t4nO74lwkk3eDVylUNBVTeJ2tCnUSRVGQcuIVykudXZ2f6W46FRd0gNwHmumqIH/HkCCKkCCHnDw5ol6Fpj6itd9/C1rut+Jz+cJQwohAKiZw9j7m5Ck2MGJiC38c1LdDuiAl3N9sId9qlwBgSd42t8JOggDMRACGzAAGxACXcYF5Ddi7Hh7cIHj2F9yTj+m5gcIAABMCCxo0OAGAyAEYuAAYMOHEAAwXEiYAYAHDQAyaDBgwINAEAYkFqQI4IJHDSE4eGxpwGFBlAZUJvTYAUQGAzlBHuzp8ydQgx48iuCgMSjSpEqRGljq9OnTplChSlW6wgeNGB5Z8MiBw6COPiZauADQtIiJOCVsTGXaNupboDhosDAQY0bVuG71Js3L96ffv4INEvRZGCnHki07/4CkaBGjxg8gSXwoqOFiyQshIgIQMcLsxQsYDm6W6LlgQhI5LwyGeoH1BZ6tZ5ulbVtgYNq5k8KYkXVrVxhLStwa68LAFBNFdJRYovu2wd18V+TQamAIDOi1tW/XLp2708MHxQNNzBAmShCOdUKu2XKDwMsGKQ5tqZG96IP1U4bA0NJDTuD1dIEIBRoowmA5eTTaRh/MRNJU3wnolIR/VYgUDDnwUJcaJXAywzxjcTGWQDeU8Bx3F8blQ0s8pHCbinHF+NaMPoHgoAEdwJeBgyrxRV5BQPqU0EITofeBeqx9NFFksoU00nyacVYQfh2QNiUAHFgpEoA1/tWBSy0VOf8YRCQA8AFrIljZlpcT9tQmXIPh8E4JFHikhQnGCRRECSrMBieF4BkAA112zbDCn4IqOlgHCKLZ2ZpxCTnQUhqYOZF9jcFmk0YcpSQQCUdldlJLDrG32UsGyfQSjzN9FKCbAmVAAq21XtpaCAZskOtCsEYYq16ALiVsTyr0+ccJ20QxljQCGetna8T2tSh1WrGA3WDS7uXdYCBo4AGvGxE76aQ9eRCpXiYBuy4AJGyQAXytdcQarDnFSxW7bC46mA0lHAGAEz/84IUJUFCzwhFrJZrivgL5gIJHKPhgYcMwCsbSaPXqqleeHXtcbk8dwBTXBejmCx6qRZn8l7fgKiT/7pthyjwzzTXbfDPOOeu8M887j1EFE1CYcIABeELBRBVj9Lw00007/TTUUUs9dc1KjcBBuL6evDXXbY3wAQYikPDyXxywBhFrj6pJY9fDVvyXEE+0YYIMtclgwj5P6PJVtG+j6NMKM1hLQ3a/Mnx4XB58BkAHn6m9ctuRS25QowUONaZeGXm0eKs+6js5UNoGJXpBNaBhwii4CTSKCRA0cx2igpEOmN8HpcBDxBPHyS3ib4UAZo479ggh6ElpPTpmPakbYfI+LX8Sg2+N0Pj0kE8+O+/FI1WDLSUEgAQCSARQgi01wIA7Czlo7xP2ccEwRF0x5BD7tOsHav/Wx4fe/7y6z0fVvPJYE5PotQUi/8FfdxDYPjf1wAgleKARemCQFOzAADt4kQJBF7jB8W10CFTKAj9oPBWxZ1QTESDzgvK8/OhlAwQCoPZC+DcR0u4nOagL4fAnQ73cLmIz8CAAXHCGstAwOkVsS0468oEREAUjpcIIji4QoBBooCLAc8gGgFdCJ3rEAxi4IvRQsgEm5ggEv9ucWYAHklZJ5oSkWlBnWkI8pWSgQDAs3g77dkT2BWUFNDAAC05gvzzqBQYniN8JYueCIhBRKmhJwh5VF0mn5OQiGhjNUISikLAVJCdUvMjVHhKRETBoi26cSMZ0dQH5lGwhHXgNugwAm8iwxv8DSKJIrkIzGgPc6in7kWUGRUjI2hkEBxCLAQZBN0y+zKCCBqABDpKgp7MoZ5IJtGZQYGWSAJ3rPRkAEwZCkJMPIAgAHfnPt3DDPwGaJCEuZBBLSjXGHIGEPRlxJ242QJ+j5GeVL8FcUjrAGBJ0oDI6pOEys4eUGdQFBYWTXEL5koI/GgAFijAOcqppzYiuS5v0aooGEDS2e12tko8KZUFG8Jlczqec7VQlg1o5oPtcJCNngs0tNQMlUhqkjU4ZQTnHBlBlIhSbVHLKCk7gkURCdI+GrAueWjCiFhiVo8DyKMxk0hF98meKH+BAFt9DxRyZsj5ePBtMU/qfVdWzpp3/clAbTRLPDmDgRjYZ6k8IZJQCfS2YH7TqDJUCg2P+sG2A/Usz8aQnbB7WqI71iRZdgtemCvOxbfKBVlDQwZM19i+YWBYUqpHMSHb2sabdiK1q5dfVWqx3UDnkM+n3JmJmCzoBG1jBmICC0dbWtaf9rZsuQKsDlXOQRfVtYKFyPkCqj4/IXRhtXNACE6BDCb/IbUV5y5c8lha42KxcmCYbue6CkLay+wsFLahd7pq3LdI1gRUeWAIrmIAYvYhfYSn2XO/ylzbw2kBqWWvc/fb2Lzc0AA8eek3bsJc2doAvEI6ghCMAgb7lSKpW7qJfhfa3w7c5l0Q4edDKEvi8g/Ej/yAFKUkOM5g2NQiAHIIgySDI4QU1EIjg7DI/GbXXwz5uCwYWl54R/7XHwaKNMe0ysQazmC8mglZ3jHUDg+Q4kLK9X5N/rOW3NApUZFsfeeuXZT3ShqEVZTJ0sPcCIBixIEB4QU8eluIriznNRdSBDrZ8Mg6giaDWo2yRS7xh2iR1qXQms51bYywJHrUgPVBYT1IAsWcqeFuJFiEQ2KxndhmwiwIGs5F5rB0YbCW/yT11XJ7VZmf1CSiS9kgO69zaD6rgBS+AslNE5prRlKwtLDwiCF4Y6GFfutgwwmxFN1tgY/Nl0asGwKNx7RNCwVrZsxV05ALQgx4EACrnYkhLFv8HFBb6T1UEHKBB9Kc9d8Hr0zEMNdsOB1saHFrUY35LCabc6BKdSLAU3W3o4H2yIxhBIEb4l1MsdR5R9nJADArVVH4NM/ylTEuz2cAlZTW8eBN7o7FabvoQTUMTsWXF/dL3Ut7XUO1OSHT+0fiD/lKDWzvLxksh0sJzJRGt7rwlDBIJ8SiCgSpm7JxNWWVHbnJOUW3knCCJ55KEznTofC1sQu0WOAXyOI67+4gcTe8FTXxEHdi65FKxga1vDJWk1mUHpm75xTyi9TT92Sk3cE5BloByxIjKPwZ4VGk6MwKW/lo+JdER9M6EoACtcgM36lJP2kgZg1j8i/fiTuVEcDn/RnGAA6PJGpzCbGmPs+vACd7uJNGe7yAoIQgmekHJ28J2Q8VKWmpCCQBA32ybl47mxus7B0DQ5V9+i5/RMzxDBCgafDKeQd86nns84kIcaaTcVKeeQAeDgdF4fuL2+lzHJ3lYFAeyLTXogRAksIweqP3OJpJvvvOM2AwfSkDEanwmNXb5qQQA4QY5QrclBc4ZiSiBC5boHADwFAAAXZQIRH48Cu6x0PN9mdbJRmp0RvWhEHh02pL8RfQZQDi9jP5QDQmWoAmeIAqmoMxQwBjAXwmMgZ2ooAmqgRLUoBrIIA7mDFAYnUfoXlwIgab1BBAIgVIoHAGKSwasikPM1cNN/5265Ed9dETimZMHCN9MpNvSYcpMZGCsuJAI3BFfdN9NQQrXERljtY2ZOZRSCEEJGIGMNUUQOJD/eZ12NNOcMdtbZNIYrs1bMIcL/qH8BcW3xYX15dXUidCspFbDlQ2DdM4cYVnXFRF5FZoBMBVQGIsRqJ1U1IADSRuJacerXUuliR1f6KEjto2u+VrdxYRHfAAY4k9kiYkZzqL4Tc5gAdLbGcSbtV9VzFwQSuKEvBqlQdemFeNSEMj2FcgXReL1WFbxpEBmWVsNlAASPBsSlED7HdeEzAWsjWIZGiM4BkWXtYtBDVj4oZrItdhUzJtsqdq+AYA7LtusGRu1Zdeghf/jT6gb+4BhIfbFK56SA54bVGCAZJAAE4mXYWkjHhLjPD4FtYUcq+FaXsQjKTakOh4EoazckeFjNpHQOiUfjfzjCgnkU6CKR4wMqH3iQqYjOioF2L0Ic8xhVbhAwgRiRV7kSs4eCuSi23BkeXhkAwIkVYikBkpcARGIk6TkOTIkTlrkVJgeDARAADhBo3XBD/RBALIkU7YkAMyehuGLhyXR35ERguyHQ9iSR0hRU1CRFZ3kQ2hR8uyHF4GRaIgRGd3EGRnAZ5DVkrCRprwRCMZRD3qY6AHRvd0kVy7FCgwBIOXDFtCN6hDBD0jBEzCaVl6mPP5EIlQH7UEif1WSOWH/Ul5cjoiJyyclIBaNUil9JCqJiwux0k0wDixFxyyNoS0lCeHt0iLyV2EGHLZt5GE+RZIxQBNApgEEjBSQwd5lZmKinlPkWAxY4uh5F1Zxkxa9CziJ09+VEw9mBE+YUv+g1TsJBNS9xDwxBmi0x8aYhT7FhvGdREcEH2EqpFNupX3GheAQpwkcggTMjXLWJ2YiZk/8AZVZi3TWUIdVJ0iJ1HqipkmxBkoJhErlHni6lHiykEwdxCqlp01BYE4hoAJWoGscCDMC2koy533GxQpQQwUIzSKYQCl4IooG6D36hBsYQCLYDsQEkjdKkhAR0W8p6Bttld+phFeB1XWOFZg0/49ZvdR4SuhaHZA9vdXf/SUT2lUZPYUIhBctKuWJCiiNvgUMgMKydMNv2tuXAoA4GEA6+IQwxtoiNZJAPJJP1mlBeYBqdem7nek3NudboMWyKIK1zSihgmlBXIIBDIKrURThSBNZ1AZaFEGd1qnF0ac5pqlzBudbJEcRMMF0acEQ1BtwYuqo+sQdtMQdBEU98sAjYBSnTmqdDgWJ6ikeOeMk3Q1VGcB7aQEL8GSJgocxtEQg8AZFRdVUwWqdbqlk0SpROVZvKkUXTFMQTZcFJBsdbs0fhIkbWMUhKVYbACmyhiOA2cqvJqSzThIRXIGcBtEVEAFshaqlAoskhIkkLP9FDSDDA0iBCTSBGNxANoYrwDajSpJeVfUEyPlqs+ZLIhhAIJzqHQTCJSCkQKDdOEgBbjXBE8BewOqZcJEAcZVr1zwrWBasm0YjyNqGG2zrdgiDygLFzD1BcRKBAdwNxvLexvoYeC3rpTJrvO7Rd7DjznKW3cGscQIAzT7Bct7sZ27AuOZp0HopwZ6hqqJPc9WquSrFCzQCZG7H3SQAnCkt2AZF9NHLxoHfyUJtLSYFNKqX1YbsUiwaEewbEUQbVBhdxpTtbzHRbmoZCHhAgWjGzTXoHq6iby7ltZKsUhwYvQms2yoFRU5kqz1FOhXE1k1FrizGI74FQdmE1/CSUuT/ypqASebSkAjgSLhJ7EOEG4X2Suj1bJiWalPGbh/9EUTKmuym6DsGhbO9I91Krk3sigi2CeiSirjpRU4gHoFMhd5+bo6IEIEQV3FhygiQAAiYUemWY1JshlrKiuB65tPibo36KZouxUvarvj26bVh7d7lxQ187VQI3wjon+U2L0qwRl5iAHyACRnZr9/hL+V1YEEoKzBtKUHqJXm2Ii+NzWcw0aYQheka5EioR0qYCQE7yEoZ8ITEokeMCQbAkPChbmb4YHTkIAmXsAmfMAqnsArzTG3ozAKUgBLMjBKUwALQjFKIhgiXpEugpwYgyfEyjk6MkzkhyVCgpOiqigEg/4h/eCwwOUgIoMQCJ7ABMzAUF8TwJuBI6K23IMmWps1I5ErxckciBlhBTBbqJu9mXETlGo7hFmr4gm+mTgX5VW36kur4ImhSzJzvSUWt2exSZEBdCV/a0F1bXHFHDK9IKIToikREhAm6MJGTLO+WFggwiW4XYzGtTLEsLa9AXDEToYor8dIlH/HJsNv+5R6tgHAnnVM5naLZ8uwbv+4dn6+bVlDY1TGAuvGCBYXq3UAPtN7rxZ5ThBUI9gre6vCWbFUP40TzLvLfDfEpiwvyigBKKLEoV/JIVDOmZLKVUDEGU+hRfLIWL/Mof/E3T0jFmUx5omS+iCwu364so288A/+F4l4ZmuVy7ubx+8mXv0rO5aYESNxv/kbwM/eH6hrE5javYKoNNofY34GJmfiHBoBJAycxFvPSJ0twjlBwQ4MxsFSd2HzZUEz0B3RE9LKLOx/EPcOzLsPuW8zxs+FzLMe0UzCCTYftpmXe5gkEH77SCBwisKQ0TdMyG9uxPLdFeiHTihn1K+MxToPt9KhU9rFi5yXx1QntwLK0oW71TL8FVK50cwr1U0cOBzqJFXoECQwZVrcxV8exTLv1idEuWMOxWI9123ihBxMISagyU691X4/sX++ObSSZUge29zqXXSstQhYJgext7bkuMJ4rd5jZ6Wm1m9R1Yp+MCITUI27/thYC09ZgNmYbptRyx2KmmGXDXWbf7AXgyPOoiUg0SkFxjWjbKuKCB2Gz3CyzC4GuttJC8JehBEeYyU63M2Qfd1ZPdl1Udlf7tnOTScl8Shn3iEAptF/DMlsnt2kzZvk193N/d1xs6RIlZe4Znedc9/cebmkDS27DNXhDRyoG0A2vjPUpyD8WjwcI17tE86zct2pnN4Cf7WxQdo+W19Z0k0VrtP+aVgMoACzk4Zr4XfAIpQppIIULxCtNoQilc0+EQCpfrYC37Xqzy2lXoqiS9roosEHo7RU/FhYogAm0QiFMhRE2xAI+Sj8eBMQF5UG4ooZ/EEhf9QE/EW0jd4Bj/zduH5PuCPa6SHSVnsnLOAgHA5N/nJHeouUzF08nhIIJUIEoDDPZ2DhEhFhFTGnTedoCQsmo8Fx5uiUrPoh73EQlAXAGG0hxj3RBmXSRa/c8F/VbuzQcA0COqeFh36eUQwSSZLmUF8TY6EhgatHYfEA0Tw4W5MmM01HfLYamPEaHTkY5It8JBd5p4Me5ibq4pcZqsEtUV49B9PQF/PSeH/lRtzWg9zlgIwUlHiiKw/NWATEoQznmdMTykjLUhXHkbHmXf/kfA58DblKZu9UHxguo04dL0NSPcxF/SDjkcZrpOglKVHVI83Vqg/if77atM/m4F8QtxsCS7zo6djFEaP+E3v4wEl+hrxuEXU16vrx4jF86mBeJjZ9ETplFYzTJQTBgCGNJevaaQQQeeW7JqxwWXh88pKu1cfN5S5t7xs+6d8dZZhX4UucyGYXTAvbv/tmVAB3xPz/K5DT4g7dFjWeKG8lEB3RKFraLE1a0qVwEqqCkEnZOxGtPsInAXsd6iKM7Ud96unP8T+S6qM51W9wI9m7ZIPJFjhvV834sUICAY/fEN8ldg8RcU6Nt0iN9oGs8rf/Eurf7qoHrufuENtMGV7GHK3NNfL8Fw/eXBlOgjvP9TyQESq6x0pP92TN9rW/82EMFshE6VUqSVUJS2QPLRI+J4L+3dowxuXaSQG3/PpiAsAgQUA6bvYiXu+GjfcebPrcu1TBsbVNI5g+4fdqXMpJYcfBaftuMjcyAcAEHj/z6eXojvu9Hfk9qaspBzAcITd0cp8DE7dLnS2u3Ygb0ftfoY1IY5UEcjyk91pbWisUHxQikPNbUvkqvMPmXv/mfP/p7RNCYgBasP9Gk/wmOG4Nsduh3lFRQP1JYf7r5RfYDBACBAwkWNHgQYUKFCwlm6DDQIUOBFzqAANBBBIAPFwCIeCjRoAGQI0mSFFmy5EmUI1WulNjS5UKYMRPOpClwxQkmUEx8MSHjpkKbQQkOHRniQ4iODzcuJRozw8moLi9gUDi1aIanWxNmIPEV/yyJrSMMGMBgMcMHAxqUrjTKNehbuHMFyqUL1+7doMoQSDERR4gOvYMB5F14oWwHpWnXtiWcUENZDVE7GEha2IMGDhkiG/DQsayBEBc0RK4IAEPZs1M3VC6bIYTrEY9jug5d1iJtt7pvGuaN0vdvk8KfCikRxkQUE1ZKCCFONPhzmlijasXAofBsjZ9JfCgsdqKGDSA+eCANAkSHC1NHWC2cgaJ0khdEYMAgov5H+TL3s+wf97/eAizphhKSMaEIJlpYroQbBhzuQbioO4kD7AzQaoPbDNiANAM4AKEqgTTwoMKJNhNpxLoy2ICsDj6L0CCMBOoOxoKik+5GGHOMcP9H+YIowQoTWijMhQWZC6JG/pIkKiq0KLRQq+0OKi9EAEY8DwQN1hNphNlCuHAg0pYcCIPySCArtyR7/G3NANv8703hjHhASBcKA6BIE7bIZoYxD4pzyfTWwqpEMAHgTDLyEgPRvRRTMwuEqUIw7ULEynpxTKRCww4hEDDgSD5ACRMVRz9fMrUgHUpQ5Qo778RTAVVKQAUFGFCt69ZcdT2IQxEwRUitFJ8jVS9iiTNWOGT1UqEEFYoiiNlMDGAhh1uV3RXb/+DLaFhrs7Xx22d1ZdbZgVoiF4cdDKjV1GvDfZcq/OTFr6A0BbL3WG/hdZc2fuFSFQlxBUKiBMEAOGH/2mrH9BfehiWy7bY0STBAYopD1bfYUTUejF9ijQigBnMHqiEAIwhK14AdcHCpY4ddls+rsL4iaOIObLbZ4lJRbZnjjTPumasfHcRVoAKRLCgHFgw4YTegX35aOEEtcwyAiTXMududfb6L55+93qpAIGy40wYgGkQIBhRSXhnCr6F+m7ARPuBAhNJoNiAsxPBlE2Out6ara7/nMq6EAKoIoITmFkp66bYFhxtyvWSsGusNuBXI8v0YBtDpxz0H/O+tdDhiiSqWOMLghdI2IIYUQAo88tjHcvFMDQgCwVcAKLpc53ZDx+t3rmCf60bGh1iBoeFlXz4mTcsCVSAPLoyq/yze89W6c9CzJz74rXJcgQfWXReq+5c74HSkEONDqUpde41yII9Aq9D2i7F3m/vtgddf+Jh8UPp4NSlfjcxAij2MxAMfeZQBtJOQKn3Kge4pSPsOtbm5yK8yXsHa9XzHP+8NkHP4259LwCc+hCgvSb5IQwnSEIGRaAA81wHABj4AHoRUiQT1m48EK2gq+siLINLjgGV0t8Fk9U17IuyfB5+CQpL8zwA8QB64mDggVyAuDWYgSYZyI8MvKcVSbCmiau4lGoJ8CgNasgqiyqK70higIp3R4aE685khXgo1VZnjXUSgIXu5JiMY0E/WOqjED1YxhJ/L301WMIRp+YCKhv8c0B4Sd8CScIZMZWkKUpQighF8SSvtm8wZO7AB3VnlAxmZCmnGUx6sEKQ8VfPOQDjwEEGa8jEdMNPMbicCjuDOhoT0kwUViS1iJjEoKYhBFKfYL1RdkYVaHAkmBXKd9GREeqEZUf1ECb88TgQDGTLlKhvlgVdiTkMcUstavkmbWiLEcvOil0TuWBbsMEaMTStkuI65SH5ypZGP1E2bsimZQwWLajdRIQtdKBEuVhM7NPQAJwfyRQC0p4xUg+ApNcIRxHDUSuY0YizRKZa6tXMw9BnivO52tb0pJEufaYr89DnMhvVzhP+EizLXZSsQjmQE2JnpIIlSQEtKBIYQFUj/dSzlIQDcsQPuyWFBNhqibEYGpCMS1BzZaLtH2W2jg4FYaNIEgq8ksCwNBImYvuQkliExWzhd4ruQlZOE/VQiUdlAW3u4nwTSJKwMEdOuYgbDyEBvIDk0SzAdWsO+6rWmC7vpZPelF5Sxq5grkdGEcCmf81GFqDfUpDd11R5L8RAEZGkKSjjgHr6esy5Xk+1saVtb294Wt7nV7W5521vf/ha4wRXucIlbXOPqdiEe+IBFXitX5sEFI0PUW2ITc7PQJgSUAxnqW++nU7pSdjCX9elcY5Il6G33uQ3DwAhsNrGKuRQk620IQrm7z285t4ngJQzCGkdeqmggTfhMKMx2/0RBg8DWULnKpgg4sEf0PBg9moOrMfV7X96sTmWHhNyEqMLDA8Mkwbm6gEd/dWD0CVOyiBSQimnixPxmj3FMg07sOLwSAxcEwaS9FQk2sCJeUQQ39rOvP5FZZCIfOadGxjDbWhw7OVJmapjRDBs/08eyjOaNp3nUakTSmtDARjam0hSDieoBsmjyxBy0KYtj4uIZs7m+mTVeMyMLtQlZx0LaiSWN8BYm8ZDHPABOz5Yu6p5KXTdJcruPe6lrmRFowHpqTrEk30zpRBo5yUgWCAzC17o201gqT3rPDNPZoQ9VaUQl0t2JQqoiFsGxxDXCCH6k994LxCbSR+wupv2raf8NZ/bXvB4IFAMIHFC79alQEghJC0KlcmJJS+zxUoIHOyb2dslmt2twaEbQWRQvyc2X9vWLLb1iS5fQ0ymJ3VYJpWw6JmqdFUH1Z7YcKZFMCo6VCk2sYUTDfR/EzGQV8prL3WQ41znTCe81QqBIAzonL70Rd8n7FMKh0/SO4MAmt8YrzXFxK/wgJWQBJF8ncZOnD9GIJYjKeYNf/xzc2DBXt8wdJ2yCoGAgPJXiqU7ec4VMN0af7KURBzrhhR892OPuuM2XfpAZGGB8AAjoyCHuc6sbpDt0m2f01DJruRkg187ctdI/jvSNM73sSTeI2nhQEJ0/PJJXl7uVBT4Q3Ln/RgNCx/ikvdt3C+8HBqEZL04cSS2DHMEIiSuBEY4g96tvQGadeqmuh0zhyl5ePjQIzRAOkgJ1YbYGiQ+AEBAgBMQZIWSO7/kPt64mo+vK5WnPFX5XoLSysCAhCKNW6EvQ+Fd9QxtwSL3qI073IIP79bOvcFz3kwMN9QkhKNPFE2LhqpMUQU/OIX7EdekBsGSc73//Luafs8xBGOD8O1jICcZwjzrdCftFAMILth/xdyb/QbE3t9+ZLx0c0MB1RCIFeIDJDsIGSgAftKBODGAKEAQAeqAExqb+ZEelwA6Iwg/5yE/8+O/bEIJccmAVhIQLhEQgyAVGLkA71GOa1sIi/1rLhzwsl2Rr8twE/8bO8savPwyDWZAEBhTBBN4PAH6kXP4Dd55HIPoolfJqLbDDBf3kxggjZiKPKLwMUg6qMeIMA2+QA3dF/3zjbACACJSjBVylQFDizBTDCvMJJUJAtVhOBNSCA7ztw6QnA1yQMZitgqLCPCQjBDxFk1DDNSIKkNzINNDjUbwjjBwjQ+yJCsOOK3oMc3TMJeRHojrKKRCuRsJt/9BuE8muE0FOYBiiQGzACX7gB7ygTg5waEaiO0zps9ALJSoD0QSiMtTqwzYgjVywKZQrwAyAIyjKk5qETKaNDb3kA+Djz1wpZ4BRraqkSwAAKSSRK2iK0YIiM/88gDxCoLmwMAML7tNo7uW8kRtBUWRAQgdeAA4WhAgMQAaEBA5eIHVAIkM44lO2cSXY0DLcEA7lEMc25EvMQpzqorOwoqDYCQnpEVQ8Q1gwwDzKCTQ2oiDnaN6qid+2ogM04ANsJjJmcIvO5wNmg7MwUUfw6hvFUSTPzhMNTklAAgyawATQQAUMQAXQwASaAAxWAttKKSRdAgRCA1SQMC8ga4hQyaOWCyJOgqIK4ktwkSMmhkWmDT4cUiC+6DIMYn2eMbvuoic1xBFLYgS45T7ssSiOiyzL0izPEi3TUi3Xki2RSyR0SwEjQfESJxJMgAtoy4E+giLE8q1QkBY5Iij/N4TU1kgt8PCVmupE7Ak1fHKGBnHeqMepEJMgNCUOB3EwQORDIuwp2AsArskSaSrmKs/smo4cZY80R9M0iWYkiAAAIoAVloEVXMgbbOwDTOmdYHEcX0U6AutlSIAjUYIKzyINB6zkbBA1P/E4VdLjkFPtQmI/HgUNBQw58Ys3HaYnGcv1jLM5txMlS5M5u/M49Y8uos7tJjAorlM7eYQkc5M7T7M9U/M7y9E857NT+kw0RxIci9MkQ3M5lZMTxZM+c0UE+DETazA+4dM/U7Ik+3NBBShAbQwGHwO2FKI6J05mCHRAAJR88pPn9nPmPLTmPFFDH3QhJjQhKnQljA+P/7LzPpVPA/svB+czKiLjI6sHAAoKOwRJlkbDKtJINWh0A6RHIErER80CSAmiEZ+qnJ4s39giQ7TiGv/tJuoDPwTpIrsR/GB0C2GPBs2zOqzEKoR0IGrtIuQmlHo0TMFES8SUSNNUK7SEILDyGJtwRCZEKbrkSW/Uq1jOJe5jRsqD6Lq0RQ00S7Vw4LYPKyBoKtCqLEwpQ7glRBT1JD6FTXOUIxIVsRaSRMqpxlgJTDIDpW6iTLyPLMi0QNOTULOQCwPkD2R0Ui8VRTLCKcsUTCIVVqtpSzagNSy1rwILKyvFdtJCpJDtszwDNbyqK0nCauyp2vBzUFEVWp+VRAcDU/97KIw2RL4uIClstVfp0TI+S1JxFUkHcQNMozzYLTRKaYyuNJsqsiRCgNakFU6Wz1C1dFrvdamIifWSNUajtVBX9UXxlURNlI/8SFWddUtdFAeJIwS+Siz8ECAFVu667/sOVj0DFmAXVjgiIwQyxDvIggS+ZBYl9rnuz1/7FUTDkUHZEzzfkznJ4lOcSi0sYmYzyVtjg4HwRrn+MHIs5SAIliaeEEakh6UsNv/W8yTds2WXVmnd8x/XAhuJSCOwpmYyxCpsY2JqU3Z60ptqjCu4FSquRUV/U8JOlmWbFkEbVEHPNu0wUpY2pGZrdiAiA2Qvwoyeitsi50v6MV/nQmj/L+laIC8s/hVhOTFBvfNwk1NtQe4DtDYyXo0EKGOCDMpuqUZRMDRb6q0z0IdJK+MyEjGINkVJReQzmqpHPSoxlGIt7CkxBOIMs0QyqBA7qgIxMNeBvkKeCPdiU1Y/VzZp05ZtmZMEXKMDHnbL5FBRQKUylOJpV8thsEQ9YOvOUIMDmBHgKIZOJ6pWT9eiXNAXn0o8npQiLCJ6TyKoZmhbR0mz8MNgsdRogfd3D1R+E9dl6RclyGOWSpZTLoDVGiLUhpQDIjKIbGMDshdUOYpS6weTtldF6slDsKIzLuVvGWJFBLdigyJJhzN455VDq453O9R3+dNwJQIx+NUMVQMt/+hLPqCN0PwX2SokKQsC0iiHQ4K1PCwKo+rRjDCKgd9jfI/SIs43TCJ0PkbWJZ6xXMUCN0OURUP4Q52YiRV3gxc3Qs4DNTJiiYmj3mALXQF4jJwqTCRjQ8oVjmIJqk53XVX3TFXkovZtq6hwQyaYhAOVJjpAO76SL6O4cNc2fu0XbeeXiutXPurGIvbSYoCWZAkj6y4wKNgolXbyid8XkKeYkvs4kJkWfomDCjMSkhOZN8YWLjYijwujLUvZlE8ZlVNZlVeZlSWiS0bZkx/DgnlpK8qEZjkCNCPZfe2Vl+vVl20MTLI4lmkDwp5iEdFQgy25bDW2lzM2YUEiMoRFOv+HmTfwre6aWJJ1N1V3+ZepOVvkJiPtJptR9pnNFpub2Zux5XyK94C5+VSZuZsVtpzTGVWi6yvpWFC12ZzfeZ71mZ5NpcGsxojJeZzdmUsx9qD/+V3MKoGI82j3eY/jeZvPuUYa4AdNgApiMc3IhE+tMrQqlHqkMUnGzGQpmp83EKXRWZ79BAswuiT+ajETw5RQ1CB4s0JVUI4fRNFEoBpNOqKlWJmDWoT5eKgR95IjpKUzmiSSino7sylouiCm6oz49BhBqp7lxVR9enehWGVHuJKLGqjBWpD7I6m3KGdkiIaU4lPyFFSpLKOmeozYwoEVM4wbYxHhyN708Deujb3/BnqZ/dmPM1mXjfqrBzusDbtGynqadGiBXCSP2Np29ix/1RdXrbeHK+oyPGkgMiRyv1c4/G1FDXqrvVqoERuTJ7m09fi0A0SxQYKamrqIPOUCIPuuG1VEvIlSb8N2Ljt6dLth9w2RB4PiAJugidq0/ziwUVusV/uoH6S1Heqs93e5IMhY00hKbuduK7sq2Xh9MNsx3qknRYpER/SEkHa5kbu5lfu4BVu1kdqllzqGtIneUBeOglWOZmSPIEgywYQyV25T8Mkzgnsu4il3C/pQjbu92burEXzBCTu1ieO5JQKmRbWjG2ZZI8bA947Be5e0z1vBOXzDQZil35skPito//36W+IpNRhZqx/6gz2Yq0HcwT1cvRN8QCJcofuIbDlYXtM7uX/cx4O8sG0cyOXDon9QqRW6M4vwwYj7rzt8vWu8wQ+byIX8wUHtdaQRqoVCpEM1pxHiwq/5pEV7osdcoiF6eQScjTlaXN2iywPryw8izI+vxTOUXp05pc/85NR81Ng8VE3izRErzg8Cwpq8NqDnUThlmmmcx/s5w386oWliYiBChRP9N2bU0WwUR290nQhtUmY7EBvzy8Z03wRJMWl3Q14XZxmoMFzjM+5wvr/YKujOoanVCN0IBGhIiXEZxZ0TzV3c0cn81zNJJbbrPHSdN75UA9I0dD3lcqJiUv+04nzTGqP6vM3to4JqOJROQz26uzA8KrI5ghd1eI3tUz426isr+5B3hLz/5M4jPc/x3CWwYhvT/c9tXVwXlYAdwixCICqS0Epu4xrX/No5QpyqxIHjsEU+41PFQzALgykPWH0i40N2E1Q26jo6ecohfaVVusw5fgX7NtsxfqP1olqnYoZn1XVPJC04QohdFyrPCCwNPo7d44cnaLehNNx1Z7pvbYd5CA9/A91nfpRZ2eiPHumTXumXfi1LFCnX/aJmPtlf1VrFGBf5UFLmBo73ilK8qV0h6OAl6Mw8o6kYXuetMJYg6IwVBa8tPjxy3bGEWcSFvcfp3snrXAm1i9f/cR3ZlfxBILN+LD2ZGb249fzuzVzeUWKBXr3S6drvJa7dff3FVzLG537Go7zIr/zxpzXy4w7Kq3zIN565Q1/GqXzz77XzQ/HzRR+9Sd/yTb/0x/r0JTb15bPyYXz1Y3/0NR/3Q3z26bP2VfP2KT/3X1/2Cd/1e//30zn4dXP4N3Tyof/5HTT6qX/5/7n5NTHzkZ/3id/3vf/yrz9As9+8Md/KuR/9zT/5wV/8Y5n8O5j9j1/9u1/6i1/5ayQLFE+aRsLEAQKAwIEEC17AAOBCh4IMGyZE6DCixIkUK1q8iDGjQAMaO3okyPFjxZAiJ5IsGfEkyoYqVxZs6XIgzJgA/2bGtEkTZZYSDjR6WAgAg4GhIyYeFIjhQsSjDJkKzIAzp9SpIqNS1Wi1ZNaqVzd2rfl160exHsl2NPs14s6eGTWQQMoBwIYPb5dCJKFBo1MAUNP6/WsSMFfBUtESpmj4sMTEih0yFrw24wYDIOACCGEgRMKhGjRfGGoAIojMBJNi0HA0gwbQCTWs7gBitYG8A1UP9QCAA2jcpmk3/p0S+MXHwr0WH3y8bPKxyyVGxqh6oFADH5SG+KBZxAjMGR4O1NBdeocN3j+I4MvxgoYNID546FvQPQASHwhyWIhhfPPjxP/2F/4fcAH+NmBjBV713EXRwQVCB+d5ANpsHtDmFP94pSn10GTk9cWUBu+pNFmEG1zwAWdBYbgfgCmytCJGBx72ImExCjZjTglaNFllQcU1lwfXaSYQZpqNIBpp0mF4VHWbeQeAh1DpOJB8Ak32lgh5JdWigFmCtOVIXSL2ZWBhBvfljRa5ZRl6GXw2VFy6GdDBXb4hhSRCEM6WHkQeNjgbQbb1OZ1rJ45JY5g1+keoY4myuOhLYZpZ0U8iYWmReo0ueuhNl3K5qXGdZpoWqCtBWlEHcXWkUEVsfhBep1+KihKsV8lKFa1T2VrYozy5yutyuJ7F6680Caupq8RitFMJJZjRa7MRdYAiACJAxFeJnSn3aljadpVpt9vO+q3/SCScNFer053aJXyItVoQpVixy5C7TAIHlQEoDkWtkiIAhZWh4d76b67cBpyTtyVNNxCb4akHwlx1bamuSexSKq+L8LYb7V7AycsUZpVF7KK/A48MLsm1EjwsyhmBbEB4I5w3aLpbtXwhnWVdXHPC1ArHMUTwQUVev9maDDDRApeM9MlGd8RyeBSjmxZUq30wwlAPghaXByXa21cIqG3QQZtyhT1Uq3ca4EF+Yh/02QZVwwlCCGQXBedt1VLHm1JshiYtaEAe1nOQlKHHUISGH4544oovznjjjj8OeeSST0555ZZfjnnmmm/OOeITNS3Qyzb/BVV3Gth5EoQgYAAz/3pedzcCj9gRudHEGGKAENDqdadQZdCmKpPeeSmp9eoXcOedAQ83FrhA+vKb0bHDqeySwUkXff3RSpcEemsN0wUYfFj29RNoG2QQNgYhQGWeQLLd5mHtOWOpIVNvtuk2nLjRPKGGG22QlAkJ5CjqMQAHoBQ+0NBGRHe7FrCGlr2CUW8l1tueBbH3kemgbTNiC0oHSReS8XFEA+cZV9AAELvSKSl2BBlBUZAnHZjRzwAjgkjvmpIX/g1Pbx8wnpBQuDMpOYtTXaogBo+oPSRKcGkpG2JBxKcUDnGGhoFaH0euwwGwmc9rdWPXndKmlPpR621o29v+uiPADJRIPlh6U/+c2jMU2DiRiFsyYhLvuMQINlGPxZqjH/+IrSJOMFaD1EohkXNBPAJykYwsnMj4WL1DMoeJfUxkHhuJyUyCBYKbkh4hjRUsTYqykZ70EihP+alQjnKVfiwlmFDZSVWmkpW0dJYrxTTLXMYSlrXs5aVuuRhZ7lKXv/SlMYvJSWQSs1HAfOAxn/nIOgpTmcOsJjSvuaJmKoqXzJxmN7EZEZDVC2cxG+DOwGkRbTJqmZjyZju7BEB8RYsiIsAaAjUCMmjNK2fmRGf0oqnEPVpSoAGtZEEj2aWwaYYE55QIfcgjtxMyTSWskkjz/JlOgCrSoBtFKCQpKMlAZqlEHJgnRej/wy4tGuBqAuFAXOq2wT+d5E2oyZ1s8sZBvmE0o8nsKEgp6dGBcvSSB03O2XRaqbCt8IWsglBLXyo8ACgJdEnCDX1OhDyN7ZRMggTqTz/6SbAa0qth7VIIrESzjFwHL7gJigecmpuXonE9NCQcSHiHgRCZL4AUauhW1ylNso5VrIgsalkNO9gWra6tYZOoRC5wwMuwyoWXaRnQwCZXAAhQSZ95CV6l2lY6/ZB2f8VlYAk7SdSKFLGF9elhVzStOC7vc2Sz19ishhTqmKomc9VsHFVCs9TI5kpKcaNfS0vHLNmRqK5NLGtTK9SgIvev+rwM2U6lxtn87Z89Za53Cdrc/9Z+d6jg7ci4BlJP7ebWgNO9VL0w5IHz/PB5q23RcsuLX/LqV7rhha5HEBa6IRWFYQ5r76UqNpoQeMyuQuuqap0Z3a9G+LXj5e9EGaIdFMrQpAb+UsVYZ1egQVi5IR1xf+tbYQk/F8X4VIkayfO0Di/KXQ061YJBVpPO6XjHPO6xj38M5CALeciQ+1zqHCi6cso4TJRSY2ilqpR9sXg/6gwZN9/JzhaLB0oEBt+Sv1SvPt2Pvdl1YINPa81vZplQ/dGgB/Q6FBh/8MvHrLKjrpwoO/N0zXTu8ysdnGYsBzrPfi40dwFNzUSredCGbvSdEb1oRQta0o6utKfQTGk2u/+T0JbudHLtu2lN41nUnva0nmUS6jGd+s+MLrWfV71JPmt00pF29VfGKZTj9grWsA7mqFWdaluLBM550Sd97tkQinF4JY1NGGhG4Ng9Y7rWtK42p4WdE/9F6bMUqZhU1FhdK2kGgOTEtrnPbWlt5+ZwHmDTtfZmxgDWJyELeZscNcKBEQhQqrNFt7//XWli89Y7P5LWdtIas6S0BzfuuWF1MdIeErSnO3UFuMUv7md1D/woR/XQnJT9ELysG2s+iVBchIjxlKu8tBoPLkIKLjhzbVgus9HbvTsCYvSAwErdIXdEXFoRDRaFMEDv9rObU/SJCB3pUIvI0peTdIseHer/TXfI01feEIG7fIAk31sIvkgpDvQwdLuRjJGaVFysRXsgUXe67Pr9lbZb/e1UDzrdkyP3ZN/9OHmP196L0/d2/R3rogx8aeLyQ8EYXjqIPzvgq673ym5XOIu3TOL5Dnm/S77u3W785AmfyaS/L0JXGoqSiI6u0SvQg9RZdmNEj7jSt57p34k960+P99Tbfjq4x3ztDyf73oOezY2TSOV31KDWmeRxFTk+Bg7ooLMwPyPOh77yhzN9jFQ/+dJ3HL4zL3juYyX7F9l+9Ic/yurLBeV+UX+POK902T2Z8uA//PrnDxz3sz//9Wf8/dFfeBFSbs/3FAjXfgLodgVYbkSH/4Bzp4B414CRpyYQCBoDiF0GmH8RqHkTCIAeoVUdCIIh6GhQcYH9t0/eFhN7YyE5BW0i6IIv6F5DURm6YYIfSBWWEhRFIW5ygQELCIM/CITFARUK9wG7dT+4kV6ZwXHggSUwhRsqhYEXgYP65GVBaIVX2BxQMSGQRYBstxDKozM/AWNKYVuWMgJAEYWVokBkuHZY6IZvCEIbsBohQIAkYiIFdEB2WBdN2FvxM3CoQhuYQR/4B4eFaIjfRkNH8XxUIi1z0nAdACHdwYealReUBUN6EYgtw3M86IPbBGnWRmqtNmsuKGKWESgaAEdww3FoM4kCxEWr0YkOsTe2NXIG1P+GpkVivzaKoZhphygSmHGLBrKLwKaL3XVtvogSYeZ6BDKMzWiMvEhtyNhKzviJx9iL1CiNwZYcvcZVoviMxBiEUjODutYQRzUUEoFjY0aIDyaMxViN0AiKISg1bkKOTreMBcgQx7dizOiO0xaP2Dh8WtgyHJA7a8Qb15VsYYSQWjMUBdQnbAc1ZxMXbFNx++Ur2viO4OiNAAg0p0GQUKZZPYQ76LEBd0IbWMJCc0GHrZOOERJaqrM7+9iOsvaNAAlqVgg0mBEa2kZFYVSRR9IkLok+oWFF+RiRtVVDKUFkS8mUTemUTwmVUSmVnGNoIqYbCMFZIumT0YaSkJdCg2P/H1BDQvORiPWYjWeJlhQhYpNRkHgzKBpnM1AYT9rFJ3Oiju5Wlmmpl3uZSVPpl38JmIEpmINJmKzBl4eJmImpmIvJmI3pmI8JmZEpmZNJmZXZLIWJmZhjmZsJSNyIkZwJmvBoaqFJmrt2bp5Zmqn5aaWGmqqpmq25ka4pm/zxWEdXIR/CGT1HegNhjumxNSNQGULhkxkgcAVRT1Y1djTHReazN/oBAKMxJ3aoP0G5RWQDid04m9mZIjhhKXJ4AbcpYlIGlzkzLk/YAUVxGjQ0GcT5kwTRHiMJWgO0EH44QLRxfgpRUa0RHiIQF/QJAPcJfrCpnZvJnbQRO+BZV5Q1/55AqWED4THPhzvruaAh6T/T4j5K4Z+WEhsYghpFt3/+GSemNKAjuo2PlRfX0W7U4iSgkVc0t3oYc6EDoSHPBxWfwZ4vGkOD4jFqVBmjNyIkp3M8up4c1J8iEgJvoj7YSaJLqhjc2XX5QgJAozXkMaExk2SVtTpx8TbsuXbFCS1Fl6F5cR8t5ZLx+VRNso5j6olMyqYyYqIEMS5oREPhCRtVSikQYp7oySNls6DAE3GtkZ9hKhCm8qf0Ji1SwkIg2lYfuaZt6qih8qYEkV7yUYoRupswOkC/GZynohs3aiLfgSL59pwPSZ1xhoPeOW/KmRBbc50+moTOCViPKqsT1v9oAjqri2mr/3iru2pirMmrv2phowmswzoWmWmsk0OsyXpmhdKkM6msz4qLgCEs0wqt1eprMOKszGqt27qafkGtzcqt4Rprbgqu2Cqu3NoSR3Uqx8l1cRSMSmp8EdIQ5yWiDgFnJmWhBSE3c9at50qs6Tonz/kB8DmF1ydtFBF4AMZqWdeeMoFUvClfjodq/mqtAFsQU1pXGooavfpzudkQONaoDKFXQ2cQupZgsUqxyZquJhcU54Ele2OCIdt89XFT+FivEnEdJmWDLSuzKVscq2N6enN06ipwIEBG57FBvsUQ44IuaSVA99MB3VEvtHE/GPKQ7ZEXR6VBFRghSnH/n6hojZRIEAJnKWq6rBYBsiCLsvbYFH5VY/Dqs8IhZZqFEN2JGvs2JT/ZAXKEPjXRVnBVGhiQnE4rppxKGvCxg2pEhmAIIVkbsPOyQeMSN5lRYGGLt4YqsCQwhTHrSBMBVx2gGYz6RDPjEBt7AfJVURvbTzHqZNcat8mxLxKFg7Fzueq2YCDxtyCSGX5IuHE1EKIDH1WYKqGBEHHiuG0rE7hBIvJJWbSmrqqbGyNwqtA7PZ4bEvb2eW62sKDKF7IBM6rLQBs7ZpCXq8MKAmI3nZaCokRLegsCEoZjEAvBFL2bdKnBEUMqEAJkL3SBGlnLspAbR62iAckZtohSruT6/7opApMkV7sVCYwvkbsF4aN/mCpJB7whIbxf6AG68Z3HW7LJu1Y6c43sGKyQmsDJIb3520M4mL9zonF7uyEanL8n8SRIcR4h+rZFpxsbEhIccC2K67fXAQKWcrmr67fzgR1GXMDemq3SesLJ4ZAWwsK+pXa7OZftk7SAG728WR/7GhozCBqgix4PWbUbEVpE/L9OkbTqQR47649MfMDa+sS8eqx1XGRz/Kvfaq57jMe3qscIDMh9LKt/LMeFLMiOSshOHMeH3KaJbMB8zMiN3MSPHMiRnEH3uB9sEiyxCMcEcbk+urWqZ5aXZsiUbMkGEcZjmJB+chJsAnkoiLywDP+RETEakshh5sMQals4GaDL0lFxQvGuf8hgkCy23/FkXXhXVkbMpnzKCWOfBstPw7xP0dxt9xh4mDE6u/yxZNHLuXUeIRLMabjIn3zMVSfOPWvCy9zMGqsUL8uiQYGQwyXCNUE2b7Ubf4KEfnMQZ1M8mHumvxtHscFu2qweryHQfWJvcTM3vDVcG1uoSCG4OwfMegUbXkw3GdAgI8AhrgE3OTXKJvbJIqJB1HLOa9vJldzMOXUqSSGI3jGSQAMy8xtVlCIfVwWG/UQp8eOf9StH0AJFjsE767Fw8OFw3wk9lhUSAlTEEKo1EHJCVAI8G0EC+rTR7OEeLe3GrUXO9uf/WcqM0ied0vWZG0DBVzi9lTENETr0loYzIquRhwhBKQchcmHJdib30yzBbStKpmpXNdeJ1AIxcdd5eBCi0TREh7uRP35dhPjYIW/VV4m01f7X1dWrzumsaobDybzSbKxnAEWhepjsRJuLVaRBOzN0PmC5umqdc/sHWooIM+3xcP9Mb1AiPtC8cXryIZVxQwaRQ7wMlvipeawCNGM6GmecQz+RO3niPj5C2h99tkflkHGGzDKR2eNaymA9JlntROB2O3fXzYA0vWwzcqez1uwRNhQiNmr9RX+Ciqw6xKizQSJAwHtdNmT0ITOctA6bl2halyi0G2bEW/09GiaFzDBt/y1lVHYt0yAdcF6NPd7OfWhfbdnX3SUcN3YKITXU8TbnoR4lUqdhDAJQoVSakV2U+j4P8RkS2RpxRDZw13z6dpKeZ7PoxEIbA9rJwaONUeMnll8lZpEt4uArajqo4z0bKqPKUzo7ApLF0z4b7UWUwcaTUVwQPhARN3G3hyLfvUrTAauKIbmEcn6CweXBPGU+XsJmXhxMIdd58dMcAhHPd9i3AR8uxZP+4+b5i5Tzy20Zoa7IF+ZaHtY9LlgyeeZZwhSwHUUhlOje0SPEjTZzfnI81B5CyyRjaUJ6Ps0WkXNPQoDvJ82BjuYUht3MHCZOId8fo+iEszdFUWaP3sNxUf/iuGGSys1Bq5GUt60Rk/E3NXWBUlu+yurIoy7siSLL84wSU5xydqzsgVkry+7sh8MrX24UVN4UplfdtjYgQlYwQOZfHCvqE67IlR3J2R5k2/5j3X62hU7CKhbugU7u3D4s8O7tlJ1i6/7toe6zYlHs2n4RxZ5j517mB/vjtEro7B6uXuzXoHEBcFY21m1Ri0sU7yvvQQfxnf0SE+/Jj/to8TJ16Oxc7U7h+E7sHV8R/pkWqz6XFh8RExLARbwlAHrE0r4X+k6GuAEVf8Pvml7zriPxPuYQLr/xgrd+Lu7w6k7wPD7wzdLpVUgRJt8VO0huS+/i5dlSFwD0LRKiuLv/qsZe9AVBRjuPF1CS8xLx9TEPtvrt8+Wo8f1KgJfXuXfUnHK2QeVTc0pOczLVkEEP8nsPSG0vsRLh9FfB9Eru9i10fVe/IkeKL5oRxq0y80axHoMSIduB9mlvoqo8+dtV7mofrb48e3D7WgVrMzWK06eCv2ob7ODe90GLEYFfK47Fe66HAfOH+FsypmgTwkocFUXXhG11hpXfYwi70juPQkeN8by59hOrd+Ln8a3Fzjaz45J9+jOR+iJPKM/H/CW/jlPBftgf5gwR/cUcJoL9kZGbxPsUFQxj5ElLWv8O8CYKAuvv+zuz+QxR+12v5J5u0qEPpAABAMMFABoIZjBg/0CDwIQNMwAAgBDixIkGKF7EmFHjxosWOX4EydFjSJIlTZ7ciIEDgA0fPJTU8BLlTAAiNDzcgCGDSpYuNZIwQBAAhwseFtJEilREww4bABiQeUGD0wsYKI7UCKKDgQ8GnzINUbHhWLJlzZ5tCFIrV69jO4QVi1bu3LEaPYwV2jHlyogGHmbEmhRjYABSh3aYOBDACL4AjArku8EvRImABSMlfJlkZs2dPUOmPDmkhrqfNXJoyCEnX4R/MV74kFDn3YZ5Td9GyXkmXd50TfcGbhbzZd2CCRsG0IGvYqAiIBrmyVJ05cG4Qxa3DhF7du7dvX8HD357yeDlS3s2b364cf/rx49uMIgh4UsPWxUSjC75L3W94a/6/w9AAQcksEAD00MwQQUXZLDBBdsjcDzcJLyNQgMvxDBDDS3rzMLdfuPOwwCTEnGzCE8csMQNV2SxxexU5PBFEGWkCcaKIEwRRQFtdLFHH380scOSFDuJx+pC4i/ID9mbUEcAjawRSCk1czA4/yRryDmGoKopNRAcI82ADjK4gMvCzJQQtQ/CygCx/kJSbKwRQKJQTTbdfPMjicpM6KaPOHtMpJQamnMjKGN80kn/Dp3SxxJVZDQkyZxqs1DmPnAqhKaAkomoMt0kTabxQDAABBFW0ulIOAniEiG4DCWJVFNRdW1EPS1CDoP/QmHNKFBeM+KpJRJ+nXFHRcOL9DaENPiSA6vkc4qhDSbFEMuELqAWIdu0WzK3Kw2INoRSBSKIhA9qHUHLiaS6iQT5RJW01FM9sErVjUao7amXSGD2T5Ikm5VejbDLIExcj+pgW3sp8nXgvQAQ99WF0auyYosvTvDHZVdyliHnsJwW3GpFhmhScWXKk7wow6NWu4eIvGCrD/BD+TmDOBjhLnhDsvOmrTr4kluOpHIqTkIlRvSjntsUM2ihN5q5rzP7VDjliRpOmiL5uKr6xka/Bts7hO7KoGMMMPjAVGhbNtDaOSUzt2ZbVe72u5bF/ZLIiUL4gATGLiKaK32fJskD/w7qSw5l7DhYjlWZRsDT4ZMMR7yDmovL9mCIxB2WWIaP8lxrDrRSN+uwT0c9KYRy0sBsZz1wCVy2MeQb24Qit/q6lcHLVjmIFLtgdIjPBUooTxcawXHC1cK08s6f+kgqEEBo6/F6Q/8IhOYR6+B56DmKuszCjhK31okhwvr831dqSe65U4c/fpJWF9eAZw83YITVZ8dwIMnqa0zu6LQ7u+Hld/Nh2rWeExv7kQl0g/seSS7gnLUAzWsbWUtXWAUWf5lkggCooNMiaJfb4cqAgurVCQUImr6Y74Lyg2EMM7K6odgPNOfaH8kG5JUP8i0Dk6Je6V5IN2/JcIRMohF6Qv+0HhIZ0YlGpKFk7jeRHDbkeuHxSsES8jGRwSeAy1NSkZzIqGSpj4lNImAan7hGNsbwUWqMH8bkOEc61tE3bcRjHi9ygt6cgCJ85I0fhVREQrpRiUv8TBnfR8Qz6tGRj+zRG+sGQzJ2J1mKHKJJjIRJSHbSk5MMoybHeMhVFZJK8xMRjDb5SVa20limZCQlSWKniODuiBwxWkJ2hb3TcOVOppuhCfvkQgGmb4Vbyx8KXblMZqJRjKCMY0hkdSqBuJBCcXqJqzqoFnnRCpgY2dNRdLXNixhzkevrifdW2Ex2tjOWoXxnNEECsHldMZMYwZcCucQvEX7zIvQ8nD3vSRH/LSZkfBBJGDk/p1DRQcwASDunaWhTF9joMm9Bkc4Px/JAaxlAS6hpyEs0RTWILOUlInBTxKg4loEwxSkTNcBKEvgWqUGEcQUZS04wqh+I2ccgHdCS9Nx5IGjqzohp8qXPmjbQdU2FXF/RJUTXeZGl/UyE2InanhriFWWW84Hf3FrUeGkdInGKJR2YEwZIEzKNRuufIqvUUALYEr5cYE7aOxsIvQJUguoQOXxtGF1/xyzq3DQmWlurfgRbmBFETFhDJSos4SnPklCOe4pTWuMgCDmGgsSyiYuodCilOYeqs5hfNaNKSNdV7xApXXsrlUrOplgdUuRupbrpumwJu2x9/8AmIqShzfRKkIbFbCLaI0FhV3LYxDgLA/oxLuDQukvI7siOZBllSbS3Aecx1WbTqx5ERiDQqWJku931LgDCR9rysfZqqD0m+3wiOfAQiauiVYm2/NJRjurQLyCdT/AwggHnEAk15kOIQ/gUU/SNhShXjIlycdqQ1eiXTF+EiAbSVt0CSVKy8LPQB0OY3gy2hYPujR4FrRpax5RwagpEcYvzlVrWiMaMuHGtuvDGk3y2NSO3BUFuhWvbjYYGnH5dCAfcVFw8IZc6r2UuOnuMHMCRd0ULDoqQS8olg8EYQECZyGHhY2UwGvXDqaskIknpzDPHMztE0tlZ08q+hPgYI/+949hcP1Aou0YXuTXtq1v/upLAfmA5CyEVQfj2kiiDBks/3PNz+ExmDVFZrhTB6/WS5J+thdkD1MNwef0ZYzSvmc2nTGKbJ/vmvFQ0f3njy4H5S+QZA7hV9knYfXEG6JUK+j0GgalMcR0t2G0xwzmNzoFreTuhVAVIltYyb0m2af9Q56ehFvWNSY2663bb299+EIc78zdXYvnSiSmwUKgdHmtzxa1j3Xa8w5bmVKMaR0UVpbg1wzcGsxLajZk1rwVk7VNZUN6jhvfp6H3vQTL8mU3Ud8Ql+EAh+7lvAgeQtV/C2YNrO+HzNjUuu9ZxNx9Z1ST/uMQlDu2N5mXX6/7/DjIZLRMMGBzhN8d5o5C6plp6PDEb1OUAZ+nLnvtcagv2U4zNyVRkUjfbKoe6Hj38cENyc1bVNPpTW/XQzmZkmt40ejh/5/TTdt3RF6fvb8C9drb3xomApIsgIQL3ucidOPg2O7fjFTDybiefGN1nvzoOUIGNuqCkTajS4RtRnqg07Yms0Hc4yeJGRt3e+T452HYeAqXaHDtE0/rR8k7VpDLN5re8SFaFeZ+uL73MB+QayjEf8lM7nPaWhzjVZy9Lk3zWcunNLTbFa8unX+1wlw1t5g5aWsWbXbV8TfmSAg6UGg8z+khEJLQOGC2TQgQEYSVI8JuCetxX3sy6l5+F/87Lved9nlnUU95iKE1+DG4vOd7DKkHEh5z28tL19A+W+cq5Z+Kfs9kwGkKp68u97PMo6RCZTCupJbOKm4KcoJm8iJu63Us/D1KxpXq945IZE7sdqaI8wOnA08MO2tiKF8MopVMhxqsxYqI/JpkdyeC8bBKZESC7D4Q87/AIA1QbkZE2p0Cpd2McJXOaC9S3DCw5vWs428O+yIMj9BukWTMuZ0sw+3m34jM/KZQt2LmLokk3EOKA2Pg9kMK/8qOYb8uuy6u9KCyWzBu99ZidLtuA1eEtBezCGVGJu9Af2SkyhsEty+E5HlRDDTw/RASxtmPERgQ3HGEbhAgaAkPA0/8rwbvzQXTCIXCxOL8RCtgJspWAjWhRQnFjwlVjpwu8JDXLLv7aNfQ5F5LJqwHcwx6Mjr6AD5dLnjDxk9ySirAoRQ47xUQcqmsaOT0UOpCAOWSckjIqxWeEwkOUQy5ML/hBiBqrK0LZAC0zRK0BumQip2sMjWzUpW0MNQnRKuuTPZ2TQkuSvGgskGVplgkcC/rwqWO0ju+7nS8RMw2gtGFMxidKsGZhMJsIi5woGwwzxsHRpq4ayBpaCYNkCZ3gxm40slzZwWrkNkfkSEZkkY0ZigkMIG15jvnDjZwAL4KICVCbQ1rUSNRBiIHQHt9Bu4moSL/Ll8DrJ3uJyQuYyZX/qEmbOkc9MZjlSzxmlBJnfMdMfEMDGZv/EkmKILcMSahrC8gmXMdGGZub4YnaOjcWA71cyh8SfKGtDJ6u3MKKnEH1OojVu6/HkyEJgY8WzMppXMAe3JDVUauOsTWjaEuFKJDoIg1MuUpUbEmYBBfSCAGeEECh1Lbgiz+OI5bVUUzGlBu1xBy4Yi8DMK1LBDnR2ggRsIplXMsnrLfbi0dwqZ+onIip/L/sQMIMK7idpMbShEsZWh1n4wmbwAmKVMjoeb/wkr9w5MQp4s2JTMhRW6/l67/b5D3+kcq2PEw4bEpMzEuRQQ3WhIjmGLIr8R1PWwzi88zxJM+vCS4WAjDV/7A1EgvBb6Qph9ShZEuNbTyPtVTB1aNL59xA0KSMMPEAmOoTpKTCdozDDIkiG+pLx7hHAYGphWCumqNNi8y62nwkVSzQC606tvEJc3kq0oRGpiRQaZzC6aRQR7outaMjNvKIlukocFEMD11Kd6xO1KE7ubC7GkULu6POwjRMZrJQvJxRECsZHWrMFx0XAVVEDHVDEbXLl5xQT/pR1FzSDGWpgloIxViLxbNN62RFIGXSJpXQJ+2khRzQWuwrMG3GEIVHL5XSL/2TR8yj2VmwETDHrBPLjLwnOdVGzESlF0s6JHUUNQ1S02xTN2VGSNEjtpFIhLzJIVGehsQeRdWAg//0TZwTO4HA0y2dt47kVDg11DKty2AsEA1Vp0b9iL9THn7qLFKlqqHkiMMzSnwU1UUR1FpVUi791B7VTxJFHbbxSlPdiLD8xsZaVf9KS1eFGulEOllVUVtl00Ed0VzdVaSc1QHR0Mv8TY6AzM0SzzwlUmz1J+XjP86sSyAREWcDVF2d0nWV1ml113eNH0ntzeScKumBv82av8yQV+TkU/DRv82UwTDVvNCwPnStso5wjQ+VUWdt19pE1DhlqRpKCPU8D+woMfckyzLrKHqcWPpMi/S6TxZk1jXyiEocGnuyMYXt0kIVENG8mg9YNjE5SK8UEPnIsJcYs6x8WGFcWEL/fVbeoyEdLIzRLEp2aRoAcwqVPU2fvRBxiRYCWyy1AgHo9A+QulmW1Nlo9dGeZdeuFdK+kA2qsArfOrqp0J6XSNkYXVmmvZCEssHogoi+oVrwQCnxKYiYwbby1NQSlTo7QtE5alZczMOqENd6Oay0BdG19VoCucIJhDAPmFvvIJq7ODbC5FWB1duG1Vy6qUQQcLblRNfDbT+1XdrFHRBSucHCiBy5pVnw6DKL0IDZvNy9zdzNtV0UCq6zcTbaII2hvVmJTVrSXdO73BDI2TDJOLSpbV3/oNyC2Lhuxdzold7bpd6cs7R0JUZoxTsDoT4qwrWZtSICad4HtUS93dnq/0Xf7Z2ac8lehmXbHa1egJzd9E1fpUzc0sVV+cHRs7jRPmJZMZ1e+o3fTiXgExXguPC2A1ZgHkXfal3gB4ZgeG1YB47gCo5gCk5FC9bgDVbc6wjYM4UsDObgEb7dku03cRyMv7CxVxXhSCLhF4bhJXlI1DhHFf7glaquFo7hHWZSE5bJD/AdPplUpBWT+YiI2PAJWBUIk6xQHnbiJw4Qs3QWDuCbsBCBORENjDKMqAFF1fsdJjZRKBZjHjbhuVxM/Nmqp7BhMGkZcNHMHB7jOH7hMtZNKi5E7eicyXiM8Emb5VzidtJhORZkdyrj5noxjkkInnqMDEBi+nCxP87gQf+WZAgO5Faq5EnGZCh94EvO5E6Wuk325FAu4QImZcAV5VNG5VRW5VVm5VZ25VeG5ViW5Vmm5Vq25VvG5VzW5V2OYfmQjxvm5WBeJtKEpCz8U4owly9ZYZAwGDrtDmMG5pmI3GZaion1XEKRsYmdsER+MTrNjxUeKTHB2a1hLtF4DPkgCNrKksHAC222QyHrKCHazn67YoQqlIQiFdBpumOjsDIpFK+ww3D+vWKzn4x1p3RUiGgWSJFJwNeol2X+CDGTWu4w2duY5mUyl0xpCsPIRaxptEXViW+uFegTsA6woDIBxr8458TaL7hCq46omdCtGXh2aacDQgDgUO2BWdT/VV32PbthaTTY8AmArhmSHh1yBYGcgbpLHadPCtq3sQ/VCKnJyCegGcX2oYgou7iq/pJ8glleDIGOEQjnsNsjcwqhPRPPmJ38xGifHjLG8OiaCUoW4qmJ6IArwpvWdA5zvlLnoq1wOVLtiGnDnWmAI5m8nggbPCzU9Zu34NC7Db6VUKmgNoi0IWqKuGtMY2t9g9W/wkc2ysLnWgz5CgF09YuY+ZKEQqmj/N3fuQDUTo7XdqqLiN1JoZayvojQjhbcFoy1/mxIipnYM4xFC7ZtduMtRKY6o4iwlo0QaF7H5GvIsDBfrRUDCt2comm3WuHGFa8J8u56lkRGvqjYM+4N/5AeQwPonGLugnaMrREeffPiZWUlPCTMLvMA0y4bB8swW9JqErC1Izyu9CQXaroV7rJc07hoduIbElgwQvuqRmtMuoZom3qLwH4t0TAuHqszILuKwW5txxxSwBYhO2Qsx4acYUnQ59MSyp4alXQfCsc06OMwcSUfcvWkzp1K31Vj2J4I0XxL553IheDx8SG2cfGdgilE3u61mjhpRvHtdgqeL/EhS4trijhOhBRpzO4Uq9CAJg+LzNYKVKGzlqaU76wIDwdymzTsMh/JIyWw4dnp2JgetMtw+Zo5ikAO0nBxLbepkA4LrfhtVwLdGldoKJLF57KP4nSZxQgp6TmZrMUmlKD5u5cIqw3wKb7I7OfgjNy1CiVHio19ikDXowTS4gcqbhJPz9UY0lqpZjFxCp1SCJkIZwyANZtq6Rnr8HVxZ+yuxxccil2Bnbi9Z8QI9iE949A4PE48irtQyZxq9abYgL/L1GYKWSwTdQHWnkIX5m3ndiuH3iLJGDoJ9253lFJ2RHJH93RX93Vn93Z393eH93iX93mn93q393vH93zX933n9373938H+IAX+IEn+II3+INH+IRX+IVn+IZ3+IeH+JAICAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Three typical audiograms of an individual with normal hearing, an individual age 60-years-old, and an individual age 80-years-old.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11188=[""].join("\n");
var outline_f10_59_11188=null;
var title_f10_59_11189="Capreomycin: Drug information";
var content_f10_59_11189=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Capreomycin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/56/7044?source=see_link\">",
"    see \"Capreomycin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F145236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Capastat&reg; Sulfate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F145257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Miscellaneous;",
"     </li>",
"     <li>",
"      Antitubercular Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F145238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tuberculosis: I.M., I.V.: 1 g/day (maximum: 20 mg/kg/day) for 60-120 days, followed by 1 g 2-3 times/week",
"     <b>",
"      or",
"     </b>",
"     15 mg/kg/day (maximum: 1 g/dose) for 2-4 months, followed by 15 mg/kg (maximum: 1 g/dose) 2-3 times/week (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F145250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tuberculosis: I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children &lt;15 years and &le;40 kg (unlabeled use): 15-30 mg/kg/day (maximum: 1 g/day) for 2-4 months, followed by 15-30 mg/kg (maximum: 1 g/day) twice weekly (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;15 years or &gt;40 kg (unlabeled use): 15 mg/kg/day (maximum: 1 g/dose) for 2-4 months followed by 15 mg/kg (maximum: 1 g/dose) 2-3 times/week (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F145239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution due to the increased potential for pre-existing renal dysfunction or impaired hearing. The manufacturer recommends initiating at lower end of dosing range. Adults &gt;59 years of age: 10 mg/kg (maximum: 750 mg/dose) for 5-7 days per week for 2-4 months, followed by 10 mg/kg (maximum: 750 mg/dose) 2-3 times/week (",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003).",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F145240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      The FDA-approved labeling contains the following renal dosing adjustment guidelines (maximum: 1 g/dose):",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     110 mL/minute: Administer 13.9 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     100 mL/minute: Administer 12.7 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     80 mL/minute: Administer 10.4 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     60 mL/minute: Administer 8.2 mg/kg every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50 mL/minute: Administer 7 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     14 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40 mL/minute: Administer 5.9 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     11.7 mg/kg every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30 mL/minute: Administer 4.7 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     9.5 mg/kg every 48 hours",
"     <b>",
"      or",
"     </b>",
"     14.2 mg/kg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20 mL/minute: Administer 3.6 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     7.2 mg/kg every 48 hours",
"     <b>",
"      or",
"     </b>",
"     10.7 mg/kg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10 mL/minute: Administer 2.4 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     4.9 mg/kg every 48 hours",
"     <b>",
"      or",
"     </b>",
"     7.3 mg/kg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     0 mL/minute: Administer 1.3 mg/kg every 24 hours",
"     <b>",
"      or",
"     </b>",
"     2.6 mg/kg every 48 hours",
"     <b>",
"      or",
"     </b>",
"     3.9 mg/kg every 72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <i>",
"      The following (unlabeled) guidelines may also be used:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      MMWR",
"     </i>",
"     , 2003:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No adjustment required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute and hemodialysis: 12-15 mg/kg (maximum: 1 g/dose) 2-3 days per week (",
"     <b>",
"      NOT",
"     </b>",
"     daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      Aronoff",
"     </i>",
"     , 2007:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: 1 g every 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: 1 g every 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Administer dose after hemodialysis only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): 5 mg/kg every 24 hours",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F145219\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sulfate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capastat&reg; Sulfate: 1 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F145204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F145223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer by deep I.M. injection into a large muscle mass.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Administer over 60 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F145222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of tuberculosis in conjunction with at least one other antituberculosis agent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F145264\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Capastat&reg; may be confused with Cepastat&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F145255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ototoxicity (subclinical hearing loss: 11%; clinical loss: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Nephrotoxicity (36%, increased BUN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Hematologic: Eosinophilia (dose related, mild)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute tubular necrosis, Bartter's syndrome, creatinine increased, hypersensitivity (maculopapular rash, urticaria and/or fever), hypocalcemia, hypokalemia, hypomagnesemia, injection site reactions (abscess, bleeding, induration and pain), leukocytosis, leukopenia, liver function decreased (BSP excretion decreased), renal injury, thrombocytopenia (rare), tinnitus, toxic nephritis, urinary sediment abnormal, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F145226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to capreomycin or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F145208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte imbalance: Hypocalcemia, hypokalemia, and hypomagnesemia have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Auditory impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use in patients with pre-existing auditory impairment must be undertaken with great caution, and the risk of additional eighth nerve impairment should be weighed against the benefits to be derived from therapy.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Use in patients with renal impairment must be undertaken with great caution, and the risk of additional renal injury should be weighed against the benefits to be derived from therapy.",
"     </b>",
"     Dosage reductions are recommended for known or suspected renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with ototoxic or nephrotoxic potential:",
"     <b>",
"      [U.S. Boxed Warning]: Use with nonantituberculous drugs (ie, aminoglycoside antibiotics) having ototoxic or nephrotoxic potential should be undertaken only with great caution.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral antituberculous agents:",
"     <b>",
"      [U.S. Boxed Warning]: Since other parenteral antituberculous agents (eg, streptomycin) also have similar and sometimes irreversible toxic effects, particularly on eighth cranial nerve and renal function, simultaneous administration of these agents with capreomycin is not recommended.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations;",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Safety has not been established in children.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Safety has not been established in pregnant women.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F145213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: Capreomycin may enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Capreomycin may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Capreomycin may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Polymyxin B: Capreomycin may enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F145215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F145228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capreomycin has been shown to be teratogenic in animal studies.",
"     <b>",
"      [U.S. Boxed Warning]: Safety has not been established in pregnant women",
"     </b>",
"     ; use during pregnancy only if the potential benefit to the mother outweighs the possible risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F145243\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Capastat Sulfate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 g (1): $179.90",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F145217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Audiometric measurements and vestibular function at baseline and during therapy; renal function at baseline and weekly during therapy; frequent assessment of serum electrolytes (including calcium, magnesium, and potassium), liver function tests",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F145220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommended concentration for susceptibility testing: 10 mcg/mL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F145229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Capacin (KP);",
"     </li>",
"     <li>",
"      Capastat (AT, AU, CZ, ES, GB, GR, IE, NZ, PL, RU);",
"     </li>",
"     <li>",
"      Kapocin (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F145207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Capreomycin is a cyclic polypeptide antimicrobial. It is administered as a mixture of capreomycin IA and capreomycin IB. The mechanism of action of capreomycin is not well understood. Mycobacterial species that have become resistant to other agents are usually still sensitive to the action of capreomycin. However, significant cross-resistance with viomycin, kanamycin, and neomycin occurs.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F145225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Normal renal function: 4-6 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     100-110 mL/minute: 5-6 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: 7-10 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-40 mL/minute: 12-20 hours; Cl",
"     <sub>",
"      cr",
"     </sub>",
"     10 mL/minute: 29 hours;  Cl",
"     <sub>",
"      cr",
"     </sub>",
"     0 mL/minute: 55 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: I.M.: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (52% within 12 hours)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1992, 43(5):651-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/59/11189/abstract-text/1379145/pubmed\" id=\"1379145\" target=\"_blank\">",
"        1379145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Tuberculosis,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1993, 35(908):99-101.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/59/11189/abstract-text/8412982/pubmed\" id=\"8412982\" target=\"_blank\">",
"        8412982",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 329(11):784-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/59/11189/abstract-text/8350889/pubmed\" id=\"8350889\" target=\"_blank\">",
"        8350889",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lehmann CR, Garrett LE, Winn RE, et al, &ldquo;Capreomycin Kinetics in Renal Impairment and Clearance by Hemodialysis,&rdquo;",
"      <i>",
"       Am Rev Respir Dis",
"      </i>",
"      , 1988, 138(5):1312-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?10/59/11189/abstract-text/2462388/pubmed\" id=\"2462388\" target=\"_blank\">",
"        2462388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Treatment of Tuberculosis. Joint Statement of the American Thoracic Society, CDC, and the Infectious Diseases Society of America.&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5211a1.htm",
"      </a>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9194 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-60.18.131.125-10F4DE3033-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11189=[""].join("\n");
var outline_f10_59_11189=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708654\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145236\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145257\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145238\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145250\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145239\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145240\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682458\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145219\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145204\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145223\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145222\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145264\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145255\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145226\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145208\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298954\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145213\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145215\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145228\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145243\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323040\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145217\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145220\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145229\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145207\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145225\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9194\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9194|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/56/7044?source=related_link\">",
"      Capreomycin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_59_11190="Complement pathways";
var content_f10_59_11190=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Complement pathways",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11190/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11190/contributors\">",
"     M Kathryn Liszewski, BA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11190/contributors\">",
"     John P Atkinson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11190/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11190/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11190/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11190/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11190/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/59/11190/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complement system is an ancient host defense system that is part of innate and adaptive immunity. It guards the host&rsquo;s intravascular space by opsonizing and lysing bacteria. In addition, it promotes the local acute inflammatory response, which in turn, instructs and influences the adaptive immune response. The complement system consists of plasma proteins of the activating cascades and membrane regulators and receptors. The plasma proteins interact via three major cascades: the classical, alternative, and lectin pathways [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/1-5\">",
"     1-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A review of the complement pathways is presented here. Other discussions of the complement system and associated diseases, as well as an overview of the innate immune system, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=see_link\">",
"     \"Overview and clinical assessment of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=see_link\">",
"     \"Inherited disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=see_link\">",
"     \"Acquired disorders of the complement system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1665915\">",
"    <span class=\"h1\">",
"     PROTEINS OF THE COMPLEMENT SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proteins of the complement activation pathways circulate in the plasma and are present at a lower concentration in other body fluids as well as in the intracellular space. The components in plasma are synthesized in the liver while the components at other sites represent a combination of local synthesis (many cell types) and filtration from plasma (",
"    <a class=\"graphic graphic_table graphicRef68272 \" href=\"UTD.htm?11/28/11725\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10652019\">",
"    <span class=\"h1\">",
"     BIOLOGIC FUNCTIONS OF COMPLEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goal of the complement system is the destruction of microbes. This is accomplished through the deposition of large quantities of C3b and its subsequent limited cleavage products on a target. This process, known as opsonization, refers to the coating of targets with complement ligands to promote their elimination through immune adherence and phagocytosis by cells bearing complement receptors. Opsonization also facilitates the adaptive immune response, including antigen presentation and retention, as well as immunologic memory and costimulation of B lymphocytes through the antigen receptor.",
"   </p>",
"   <p>",
"    A second goal of the complement system is promotion of the inflammatory response, primarily through the liberation of peptides C3a and C5a, known as anaphylatoxins. These approximately 10 kDa peptides bind to their receptors to promote vasodilation, chemotaxis and other cell activation phenomena.",
"   </p>",
"   <p>",
"    Through these functional activities, complement participates in an array of processes including tissue regeneration, clearance of immune complexes, detection and removal of apoptotic cells, angiogenesis, and mobilization of hematopoietic progenitor cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17876989\">",
"    <span class=\"h1\">",
"     COMPLEMENT PATHWAYS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the complement pathways is triggered in a distinct manner, yet all have the common goal of modifying the target membrane by depositing C3 activation products and then engaging a common terminal sequence called the \"membrane attack complex\" (",
"    <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"     figure 1",
"    </a>",
"    ). Three concepts facilitate the understanding of the different complement pathways: attachment (the trigger), activation and amplification, and membrane attack.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Classical pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical pathway was discovered first (in 1892), hence it was named the classical pathway to distinguish it from the alternative pathway (discovered in 1954).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classical pathway is most commonly triggered by antibodies binding to antigens. The C1 complex is composed of three subunits, C1q, C1r, and C1s. The C1q subcomponent has a hydra-like conformation in which two C1r and two C1s molecules (both serine proteases) are entwined (",
"    <a class=\"graphic graphic_figure graphicRef63027 \" href=\"UTD.htm?6/15/6399\">",
"     figure 2",
"    </a>",
"    ). The C1q subcomponent attaches to the Fc portion of antibody (",
"    <a class=\"graphic graphic_figure graphicRef63027 \" href=\"UTD.htm?6/15/6399\">",
"     figure 2",
"    </a>",
"    ). IgM and IgG subclasses 1 and 3 activate complement in this manner; IgA, IgD, and IgE do not. Attachment of C1 to antibody of the classical pathway by the C1 complex requires two IgG molecules in close proximity or a single IgM. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=see_link\">",
"     \"Function and clinical applications of immunoglobulins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Activation and amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;After C1q of the C1 complex binds to antibody, C1r undergoes an autoactivation cleavage process. Activated C1r then cleaves and thereby activates the C1s. C1s, in turn, cleaves C4 and C2. The large fragments derived from C4 (C4b) and C2 (C2a) assemble on the target, forming the complex called the C3 convertase, C4b2a. C4b is bound to the target (see below) and binds the C2a fragment that is a serine protease (catalytic domain).",
"   </p>",
"   <p>",
"    The function of a C3 convertase is to activate, again by limited proteolytic cleavage, many molecules of the key next component, C3. These activated fragments bind covalently to the target and form clusters at the site where antibody is bound (a complement-fixing site). C4b and C3b become attached to the antigen and to the antibody. A complex of IgG-C3b is a particularly potent opsonic fragment, being able to engage both complement and immunoglobulin receptors.",
"   </p>",
"   <p>",
"    C4 and C3 possess an internal thioester bond. Upon cleavage of C4 to C4a and C4b or C3 to C3a and C3b, the highly reactive thioester bond is broken. The nascent C4b or C3b has a few microseconds to covalently bind to the target by forming an ester or amide linkage. Thus, through this mechanism, C4 and C3 are able to transfer from the fluid phase onto a target.",
"   </p>",
"   <p>",
"    Amplification occurs since the activated proteins are enzymes that cleave the next component(s) in the cascade. Each activated C1 generates many C4b and C2a fragments. Most C4b fragments serve as opsonins, while some bind C2a and form C3 convertases. In turn, each C3 convertase rapidly generates many activated C3bs. These C3bs serve as opsonins and also form C5 convertases that cleave C5 to initiate the terminal, lytic sequence. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Attack (the membrane attack complex)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One study of classical pathway activation determined that following a saturating amount of antibody affixing to a mammalian cell: 2.5 million C4b molecules became bound, and about 0.5 million C2 molecules subsequently attached to form C3 convertases [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/7\">",
"     7",
"    </a>",
"    ]. Within five minutes, 20 million molecules of C3b were deposited and one million membrane attack complexes were formed. The number of anaphylatoxin fragments (C3a and C5a) would be several-fold more than the number of C3b and C5b fragments bound, because only 10 to 20 percent of the latter group of fragments actually attach to the target (",
"    <a class=\"graphic graphic_table graphicRef65948 \" href=\"UTD.htm?28/18/28971\">",
"     table 2",
"    </a>",
"    ). Studies employing other types of targets, including bacteria, have given similar results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Attack (the membrane attack complex)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most C3b molecules deposited on foreign surfaces serve as ligands for receptors, although some generate the C5 convertase (C4b2a3b). The C5 convertase cleaves C5 to C5a and C5b:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C5a is a potent anaphylatoxin.",
"     </li>",
"     <li>",
"      C5b begins the formation of the \"membrane attack complex\" (MAC), a multimolecular unit composed of C5b, C6, C7, C8, and C9.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    After C5b is generated by the C5 convertase, it binds C6 and then C7. The C7 protein confers lipophilicity and thereby membrane attachment capability to the trimeric complex. Upon insertion into the lipid bilayer, this complex acts as a high-affinity membrane receptor for C8. While some lytic activity is expressed by the C5b-8 complex, efficient lysis is dependent upon an interaction with multiple molecules of C9.",
"   </p>",
"   <p>",
"    The fully functional MAC forms transmembrane channels or pores that displace lipid molecules and other constituents, resulting in membrane perturbation and osmotic lysis. The concept of membrane damage by pore-forming proteins, such as C9, is a mechanism that is also used by bacterial cytolysins, fungal toxins, parasitic metabolites, and perforins of cytotoxic T lymphocytes and natural killer cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During complement activation, host cells are protected from being damaged as innocent bystanders by plasma and membrane regulatory proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=see_link\">",
"     \"Regulators and receptors of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lectin pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, the lectin pathway (also called the mannan- or mannose-binding pathway) is similar to the classical pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/11\">",
"     11",
"    </a>",
"    ]. Lectins are proteins that bind to sugars. Mannose-binding lectin (MBL) is part of the acute phase response. MBL is a ficolin (ie,",
"    <span class=\"nowrap\">",
"     collagen/fibrinogen",
"    </span>",
"    domain containing lectins), consisting of four to six C-lectin domains connected to a central region by triple-helical collagen stems (resembles the structure of C1q). In serum, MBL and other ficolins (ficolin-1, ficolin-2, and ficolin-3) are found in complex with the MBL-associated serine proteases (MASPs): MASP-1, MASP-2, MASP-3, and a non-enzymatic protein MAp19 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/5,12\">",
"     5,12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Attachment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall scheme for the lectin pathway is similar to the classical pathway. Lectins (or ficolins) substitute for antibodies, sugars on pathogens are the &ldquo;antigens,&rdquo; and MASPs replace",
"    <span class=\"nowrap\">",
"     C1r/C1s",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thus, the lectin pathway begins with the binding of MBL or related ficolins to repeating sugar residues on the surface of pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/12\">",
"     12",
"    </a>",
"    ]. These sugar residues include mannose, N-acetyl-d-glucosamine (GlcNAc), N-acetyl-mannosamine, fucose, and glucose. However, neither MBL nor ficolins bind D-galactose or sialic acid, sugars found on mammalian cell surface glycoproteins. This selectivity promotes pattern recognition of surface carbohydrates to distinguish pathogens from host cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/13\">",
"     13",
"    </a>",
"    ]. Other mechanisms used in the innate immune system to distinguish between self and foreign tissues are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=see_link\">",
"     \"An overview of the innate immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Activation and amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following formation of lectin-sugar complexes, MASP-2 cleaves C4 and C2. The C4b binds to the surface of the antigen and C4bC2a functions as a C3-convertase, just as in the classical pathway. The C3 and C5 convertases and MAC are identical in the classical and lectin pathways. Thus, the key differences are that MBL and a sugar substitute for an antibody and an antigen and MASP replaces the C1 complex.",
"   </p>",
"   <p>",
"    Deficiency of MBL is relatively common in human populations and is discussed in detail separately. An inherited deficiency of MASP-2 has also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=see_link\">",
"     \"Mannose-binding lectin deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Alternative pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alternative pathway is an ancient pathway of innate immunity that formed more than 600 million years ago. It preceded adaptive immunity. Thus, the alternative pathway does not require antibody or prior contact with a microbe to function, and serves as an independent immune system, capable of recognizing and destroying infecting elements [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Another arm of the innate immune system is provided by toll-like receptors, which mediate defense against bacteria, fungi, and viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=see_link\">",
"     \"Toll-like receptors: Roles in disease and therapy\"",
"    </a>",
"    .) Interactions between these two systems have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Activation and amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small amount of autoactivated C3 is always present (so-called \"C3 tick over\" termed C3i or C3(H",
"    <sub>",
"     2",
"    </sub>",
"    O)) due to the presence of a labile thioester bond. C3 tick over is a mechanism by which the complement system monitors and probes the environment. The process is rapidly stopped on healthy human cells, but amplification may occur on foreign or damaged cells. The alternative pathway is engaged when this activated C3 binds factor B (",
"    <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"     figure 1",
"    </a>",
"    ). Bound factor B undergoes proteolytic cleavage mediated by another serine protease, factor D, to produce the fragments Bb and Ba (",
"    <a class=\"graphic graphic_figure graphicRef61780 \" href=\"UTD.htm?33/54/34669\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/20\">",
"     20",
"    </a>",
"    ]. Ba is released into the surrounding milieu. The alternative pathway C3 convertase, C3bBb, is then stabilized by properdin (P), creating the complex C3bBbP. As the convertase cleaves more C3 to C3b, an amplification loop is set in motion, resulting in the deposition of large amounts of C3b on the target.",
"   </p>",
"   <p>",
"    C3b, deposited by the classical or lectin pathway, can serve as a nidus for amplification by the alternative pathway. In many clinical situations, the initial deposition of C3b by the classical or lectin pathways is then amplified many-fold by the feedback loop of the alternative pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Attack",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alternative pathway also engages the membrane attack complex. Another C3b binds to the C3 convertase to form C3bBbC3bP, the C5 convertase. The assembly of the MAC is then the same as for the classical pathway.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Additional pathways",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other means to activate complement have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. These additional pathways may be important at extravascular sites as a means of initiating an inflammatory process.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta amyloid and certain viruses interact directly with the C1q subcomponent of C1 to activate the classical pathway, without a requirement for antibody [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/22-24\">",
"       22-24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      C-reactive protein (CRP), which is structurally and functionally related to lectins, can activate the classical pathway by binding C1 [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trypsin-like proteases can directly cleave C3 to release C3a (to trigger a local inflammatory process) and C3b (to attach to a nearby target to initiate the alternative pathway). These types of proteases may also directly cleave C5 to produce C5a and C5b. C5a could then initiate an inflammatory response while the C5b could begin the formation of the membrane attack complex [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/21\">",
"       21",
"      </a>",
"      ]. Examples of such proteases are thrombin and kallikrein.",
"     </li>",
"     <li>",
"      If a component such as C4 or C2 is completely lacking in blood, \"bypass\" pathways are available to allow for complement activation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/26\">",
"       26",
"      </a>",
"      ]. However, these mechanisms of activation are much less efficient.",
"     </li>",
"     <li>",
"      Properdin, released from granules upon neutrophil activation, can bind activated C3 to form a C3 convertase. Properdin likely serves as a platform for efficient C3 activation by the alternative pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11190/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10652131\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The complement system is an ancient proinflammatory and membrane-altering host defense system that is part of both innate and adaptive immunity. There is also growing recognition of the complement system playing a role in tissue regeneration, instructing the adaptive immune response, removal of damaged cells, and angiogenesis. (See",
"      <a class=\"local\" href=\"#H10652019\">",
"       'Biologic functions of complement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complement system may be divided into three major cascades: the classical, lectin, and alternative pathways (",
"      <a class=\"graphic graphic_figure graphicRef60513 \" href=\"UTD.htm?34/45/35550\">",
"       figure 1",
"      </a>",
"      ). Each pathway is activated by a distinct set of conditions, but all three pathways result in the creation of a proinflammatory environment, deposition of large amounts of C3 on the target cell (opsonization) and in membrane perturbation including lysis by the membrane attack complex (MAC). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Attack (the membrane attack complex)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The classical pathway is activated by the binding of C1q in the C1 complex to the Fc portion of immunoglobulin G or M in immune complexes. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classical pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ficolin-attaching lectin pathway is activated by MBL binding to sugar moieties on the surface of pathogens leading to the engagement of proteases, analogous to C1r and C1s of the classical pathway. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Lectin pathway'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The alternative pathway does not require antibody or contact with a microbe to become activated. Instead, C3 is constantly autoactivated (C3 tick over) at a low level, a process that is rapidly amplified in the presence of a microbe, a damaged host cell, or lack of a complement regulatory protein. Deposition of C3b on a target can be efficiently amplified by the alternative pathway&rsquo;s feedback loop. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Alternative pathway'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional pathways to trigger complement activation exist, such as C5 activation by thrombin. These mechanisms may contribute to inflammatory responses within specific tissues, and may be important in patients with an inherited deficiency of a component. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Additional pathways'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/1\">",
"      Walport MJ. Complement. First of two parts. N Engl J Med 2001; 344:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/2\">",
"      Walport MJ. Complement. Second of two parts. N Engl J Med 2001; 344:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/3\">",
"      Wen L, Atkinson JP, Giclas PC. Clinical and laboratory evaluation of complement deficiency. J Allergy Clin Immunol 2004; 113:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/4\">",
"      Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol 2007; 25:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/5\">",
"      Wallis R, Mitchell DA, Schmid R, et al. Paths reunited: Initiation of the classical and lectin pathways of complement activation. Immunobiology 2010; 215:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/6\">",
"      Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/7\">",
"      Ollert MW, Kadlec JV, David K, et al. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps. J Immunol 1994; 153:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/8\">",
"      Pipkin ME, Lieberman J. Delivering the kiss of death: progress on understanding how perforin works. Curr Opin Immunol 2007; 19:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/9\">",
"      Liszewski MK, Farries TC, Lublin DM, et al. Control of the complement system. Adv Immunol 1996; 61:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/10\">",
"      Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009; 9:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/11\">",
"      Degn SE, Thiel S, Jensenius JC. New perspectives on mannan-binding lectin-mediated complement activation. Immunobiology 2007; 212:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/12\">",
"      Runza VL, Schwaeble W, M&auml;nnel DN. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008; 213:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/13\">",
"      Holmskov U, Thiel S, Jensenius JC. Collections and ficolins: humoral lectins of the innate immune defense. Annu Rev Immunol 2003; 21:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/14\">",
"      Stengaard-Pedersen K, Thiel S, Gadjeva M, et al. Inherited deficiency of mannan-binding lectin-associated serine protease 2. N Engl J Med 2003; 349:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/15\">",
"      Thurman JM, Holers VM. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/16\">",
"      Lachmann PJ. The amplification loop of the complement pathways. Adv Immunol 2009; 104:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/17\">",
"      Wagner E, Frank MM. Therapeutic potential of complement modulation. Nat Rev Drug Discov 2010; 9:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/18\">",
"      Seitz M. Toll-like receptors: sensors of the innate immune system. Allergy 2003; 58:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/19\">",
"      Hajishengallis G, Lambris JD. Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol 2010; 31:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/20\">",
"      Forneris F, Ricklin D, Wu J, et al. Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science 2010; 330:1816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/21\">",
"      Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006; 12:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/22\">",
"      Fonseca MI, Zhou J, Botto M, Tenner AJ. Absence of C1q leads to less neuropathology in transgenic mouse models of Alzheimer's disease. J Neurosci 2004; 24:6457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/23\">",
"      Thielens NM, Tacnet-Delorme P, Arlaud GJ. Interaction of C1q and mannan-binding lectin with viruses. Immunobiology 2002; 205:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/24\">",
"      Alexander JJ, Anderson AJ, Barnum SR, et al. The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration. J Neurochem 2008; 107:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/25\">",
"      McGrath FD, Brouwer MC, Arlaud GJ, et al. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol 2006; 176:2950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/26\">",
"      Farries TC, Steuer KL, Atkinson JP. Evolutionary implications of a new bypass activation pathway of the complement system. Immunol Today 1990; 11:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11190/abstract/27\">",
"      Kemper C, Atkinson JP, Hourcade DE. Properdin: emerging roles of a pattern-recognition molecule. Annu Rev Immunol 2010; 28:131.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3968 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-ADE281C057-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11190=[""].join("\n");
var outline_f10_59_11190=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10652131\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1665915\">",
"      PROTEINS OF THE COMPLEMENT SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10652019\">",
"      BIOLOGIC FUNCTIONS OF COMPLEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17876989\">",
"      COMPLEMENT PATHWAYS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Classical pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Attachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Activation and amplification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Attack (the membrane attack complex)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lectin pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Attachment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Activation and amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Alternative pathway",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Activation and amplification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Attack",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Additional pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10652131\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3968\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3968|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/45/35550\" title=\"figure 1\">",
"      Pathways of complement activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/15/6399\" title=\"figure 2\">",
"      C1 complement complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/54/34669\" title=\"figure 3\">",
"      Alternative complement pathway",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3968|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/28/11725\" title=\"table 1\">",
"      Components of complement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/18/28971\" title=\"table 2\">",
"      Complement fragment functions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=related_link\">",
"      Acquired disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/37/16986?source=related_link\">",
"      An overview of the innate immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/53/40792?source=related_link\">",
"      Function and clinical applications of immunoglobulins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/58/42920?source=related_link\">",
"      Inherited disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/14/19690?source=related_link\">",
"      Mannose-binding lectin deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/25/10647?source=related_link\">",
"      Overview and clinical assessment of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/38/10854?source=related_link\">",
"      Regulators and receptors of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/54/23401?source=related_link\">",
"      Toll-like receptors: Roles in disease and therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_59_11191="Normal MLO view";
var content_f10_59_11191=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75940&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Normal MLO (mediolateral oblique) view of both breasts",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 433px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    By convention, the mammograms of both breasts are viewed as mirror images. The pectoralis muscle is seen at least till the level of the nipple. The top portion of the image represents the upper half of the breast and the bottom portion of the image represents the lower half of the breast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11191=[""].join("\n");
var outline_f10_59_11191=null;
var title_f10_59_11192="Nodular BCC 20x";
var content_f10_59_11192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F79258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F79258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nodular basal cell carcinoma (20x)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gary Goldenberg, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11192=[""].join("\n");
var outline_f10_59_11192=null;
var title_f10_59_11193="Strongyloidiasis";
var content_f10_59_11193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Strongyloidiasis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Karin Leder, MBBS, FRACP, PhD, MPH, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Edward T Ryan, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11193/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/59/11193/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strongyloidiasis is caused by infection with Strongyloides stercoralis. Manifestations of infection can range from asymptomatic eosinophilia in the immunocompetent host to disseminated disease with septic shock in the immunocompromised host.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strongyloidiasis is endemic in tropical and subtropical regions and occurs sporadically in temperate areas. In tropical and subtropical regions the overall regional prevalence may exceed 25 percent. The highest rates of infection in the United States are among residents of the southeastern states and among individuals who have been in endemic areas (including immigrants, refugees, travelers and military personnel) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A Canadian study of newly arrived Southeast Asian refugees identified strongyloidiasis seroprevalence among Kampucheans, Laotians, and Vietnamese (76, 56, and 12 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/2\">",
"     2",
"    </a>",
"    ]. In another study, over 40 percent of Cambodian immigrants to Australia had positive or equivocal strongyloides serology indicating possible infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIFE CYCLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The infection begins when human skin contacts filariform larvae (the infective larval stage) of S. stercoralis, which are found in soil or other materials contaminated with human feces (",
"    <a class=\"graphic graphic_figure graphicRef87284 \" href=\"UTD.htm?27/45/28377\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The filariform larvae penetrate the skin and migrate hematogenously to the lungs where they penetrate into the alveolar air sacs. The larvae then ascend the tracheobronchial tree and are swallowed.",
"   </p>",
"   <p>",
"    The larvae mature into adult worms that burrow into the mucosa of the duodenum and jejunum. Adult worms may live for up to five years. The adult female produces eggs, from which noninfectious larvae (rhabditiform larvae) develop within the lumen of the gastrointestinal tract. The rhabditiform larvae are generally passed in the feces. The cycle from dermal penetration to appearance of larvae in the stool requires approximately three to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Autoinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to other helminthic parasites, S. stercoralis can complete its life cycle entirely within the human host [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/6\">",
"     6",
"    </a>",
"    ]. As a result, the burden of adult worms in infected humans can increase substantially through a cycle of autoinfection. During autoinfection, the rhabditiform larvae mature into filariform larvae within the gastrointestinal tract. The filariform larvae can then penetrate the perianal skin or colonic mucosa to complete the cycle of autoinfection. Larval transformation within the gastrointestinal tract may also be accelerated by constipation, diverticula, other conditions that reduce bowel motility, and steroid use.",
"   </p>",
"   <p>",
"    Although autoinfection is limited by an intact immune response, a low level of autoinfection may permit the organism to persist for decades and cause clinical manifestations long after the initial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/7\">",
"     7",
"    </a>",
"    ]. This has been observed in prisoners of war who were found to be infected more than 40 years after exposure in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in patients with depressed cell-mediated immunity, autoinfection may give rise to potentially fatal hyperinfection with disseminated disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Hyperinfection syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most infected patients do not experience prominent symptoms. The most common manifestations are mild waxing and waning gastrointestinal, cutaneous, or pulmonary symptoms that persist for years; others simply have eosinophilia in the absence of symptoms.",
"   </p>",
"   <p>",
"    Eosinophilia is not universally present in strongyloidiasis, but may be the only clue that the patient harbors a parasitic infection. One report, for example, evaluated 128 Indochinese patients with eosinophilia, the cause of which was not apparent by routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/11\">",
"     11",
"    </a>",
"    ]. Intestinal parasitism with one or more organisms was responsible for the eosinophilia in 122; hookworm (55 percent) and S. stercoralis (38 percent) were the most common organisms.",
"   </p>",
"   <p>",
"    However, eosinophilia may be suppressed or absent in disseminated disease because of concomitant pyogenic infection or steroid administration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/12\">",
"     12",
"    </a>",
"    ]. The serum IgE concentration is often elevated in these settings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Skin reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strongyloides stercoralis may produce cutaneous reactions when larvae penetrate the skin, sometimes termed ground itch [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. These reactions include inflammation, edema, petechiae, serpiginous or urticarial tracts, and severe pruritus. The feet are the most commonly affected site with initial infection, but dermal manifestations of primary infection rarely lead patients to seek medical attention.",
"   </p>",
"   <p>",
"    With chronic infection, urticaria or pruritis can develop. In addition, the dermal migration of larvae may produce a distinctive eruption at other sites, most commonly on the buttocks. As larvae migrate, at a rate detectable by observers, a serpiginous, raised, erythematous track develops, and these lesions are pathognomonic of strongyloidiasis. This is known as larva currens (\"running\" larva). Other skin lesions in chronic strongyloidiasis may include periumbilical purpura in disseminated infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/16\">",
"     16",
"    </a>",
"    ]; nonpalpable purpura [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/17\">",
"     17",
"    </a>",
"    ], angioedema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/18,19\">",
"     18,19",
"    </a>",
"    ], and erythroderma that mimics drug reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adult worms in the small bowel induce duodenitis, which can lead to upper abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Patients may also experience diarrhea, anorexia, nausea, and vomiting. Epigastric pain may mimic a duodenal ulcer, except that food ingestion may aggravate the pain of strongyloidiasis. Chronic enterocolitis and malabsorption can result from a high intestinal worm burden.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transpulmonary migration of larvae can produce dry cough, throat irritation, dyspnea, wheezing, and hemoptysis. A Loeffler's-like syndrome with eosinophilia is rarely observed.",
"   </p>",
"   <p>",
"    Some patients with chronic strongyloidiasis experience repeated episodes of fever and mild pneumonitis, producing a picture that resembles recurrent bacterial pneumonia. Eosinophilia is often absent initially, but may develop later in the infection. Treatment of the strongyloidiasis terminates the episodes of pneumonia.",
"   </p>",
"   <p>",
"    Patients with chronic strongyloidiasis may also develop asthma that paradoxically worsens with corticosteroid use [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/23,24\">",
"     23,24",
"    </a>",
"    ], or dyspnea due to restrictive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/25\">",
"     25",
"    </a>",
"    ]. Strongyloidiasis can present as acute respiratory failure or pulmonary embolism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hyperinfection syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cycle of autoinfection can lead to the hyperinfection syndrome by greatly increasing the parasite burden. Autoinfection within the gastrointestinal tract begins when rhabditiform larvae transform into filariform larvae, which penetrate the intestinal wall to enter the bloodstream. The massive dissemination of filariform larvae to the lungs, liver, heart, central nervous system, and endocrine glands induces inflammation that may result in symptomatic dysfunction of these organs and even septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/9,27-29\">",
"     9,27-29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Life cycle'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most common manifestations of the hyperinfection syndrome include [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/21,27,30\">",
"     21,27,30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"     </li>",
"     <li>",
"      Nausea and vomiting",
"     </li>",
"     <li>",
"      Anorexia",
"     </li>",
"     <li>",
"      Diarrhea",
"     </li>",
"     <li>",
"      Abdominal pain",
"     </li>",
"     <li>",
"      Dyspnea",
"     </li>",
"     <li>",
"      Wheezing",
"     </li>",
"     <li>",
"      Hemoptysis",
"     </li>",
"     <li>",
"      Cough",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The chest radiograph reveals pulmonary infiltrates which consist of foci of hemorrhage, pneumonitis, and edema [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/31\">",
"     31",
"    </a>",
"    ]. Rarely, adult parasites localize in the bronchial tree and lay eggs that develop into larvae in the airway. Bronchospasm frequently accompanies this manifestation of hyperinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical findings in the hyperinfection syndrome may be attributable to the direct consequences of organ invasion by the filariform larvae or to secondary Gram negative bacteremia, pneumonia, or even meningitis due to bloodstream seeding originating from the gastrointestinal tract or lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Eosinophilia may be absent when complications such as Gram negative bacteremia ensue [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/31\">",
"     31",
"    </a>",
"    ]. Mortality rates of 10 to &gt;80 percent have been reported in the hyperinfection syndrome. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Whom to test'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Role of immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of developing the hyperinfection syndrome is increased if cell-mediated immunity is impaired by congenital immunodeficiency, underlying malignancy, malnutrition, alcoholism, hematopoietic stem cell transplantation (HSCT), or the administration of corticosteroids or cytotoxic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/9,35-46\">",
"     9,35-46",
"    </a>",
"    ]. Even short courses of corticosteroids of 6 to 17 days have led to overwhelming hyperinfection and death [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/47\">",
"     47",
"    </a>",
"    ]. The pathophysiology underlying these risk factors, whether disease-related or iatrogenically induced, is a compromised immune system leading to dysfunction of TH-2 helper cells [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/48\">",
"     48",
"    </a>",
"    ]. It is therefore important to detect and eradicate Strongyloides infection prior to initiation of immunosuppressive therapy. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Whom to test'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In comparison with steroids and cytotoxic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has activity against Strongyloides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/49\">",
"     49",
"    </a>",
"    ]. It is unknown, however, whether this effect is sufficient to reduce the risk of hyperinfection in patients receiving cyclosporine.",
"   </p>",
"   <p>",
"    Underlying HTLV-1 infection is also a significant risk factor for disseminated disease with strongyloidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. Patients with HTLV-1 infection have high levels of interferon-gamma production, which decreases the production of IL-4, IL-5, IL-13, and IgE, important molecules in host defense against strongyloides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/13,53,54\">",
"     13,53,54",
"    </a>",
"    ]. Regulatory T cells may play a role in susceptibility to strongyloides hyperinfection; among patients with HTLV-1 and strongyloides co-infection, regulatory T cell counts are increased and correlate with both low circulating eosinophil counts and reduced antigen-driven IL-5 production [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disseminated strongyloidiasis can occur in patients with AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/56,57\">",
"     56,57",
"    </a>",
"    ], but it occurs less frequently than in patients with HTLV-1 and is much less common than might be predicted given the coendemicity of the two infections. However, immune reconstitution may be a risk factor for disseminated strongyloidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/58-60\">",
"     58-60",
"    </a>",
"    ] and HIV positive patients may be at risk for strongyloides treatment failure [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other conditions or medications may be associated with an increased risk of strongyloidiasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypogammaglobulinemia [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-TNF receptor therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunosuppression associated with organ transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/66-68\">",
"       66-68",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     WHOM TO TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testing for strongyloidiasis is appropriate for individuals in the following categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with clinical manifestations and epidemiologic exposure as described above (including unexplained eosinophilia, urticarial or serpiginous skin lesions, or pulmonary or gastrointestinal symptoms)",
"     </li>",
"     <li>",
"      Immunosuppressed patients (steroid and other immunosuppressive treatments, HTLV-1 infection, hematologic malignancy, malnutrition, AIDS) with unexplained eosinophilia, history of characteristic skin lesions, or epidemiologic exposure [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/12\">",
"       12",
"      </a>",
"      ]. Transplant candidates should also be tested prior to immunosuppression if they have a potential exposure history [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Asymptomatic individuals such as immigrants, refugees, long term travelers, or military personnel who have been in areas known to be endemic for strongyloidiasis, even if their last exposure was decades prior [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/1,70-73\">",
"       1,70-73",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In endemic regions, patients with invasive infections caused by enteric organisms (especially systemic Gram negative bacterial infections) without an obvious cause [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of uncomplicated strongyloidiasis is usually made by detecting rhabditiform larvae in concentrated stool or via serologic methods. As noted above, larvae first appear in the stool three to four weeks after initial dermal penetration (",
"    <a class=\"graphic graphic_picture graphicRef63898 \" href=\"UTD.htm?26/22/26977\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Detection of larvae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard stool examination is notoriously insensitive for detecting strongyloides (&lt;50 percent sensitivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/77\">",
"     77",
"    </a>",
"    ]. This is because larvae are excreted only intermittently, and many patients have a low burden of infectious organisms. Specialized tests on stool specimens, including the Baerman concentration technique, the Harada-Mori filter paper technique, and a modified agar plate method, can increase the yield, but even three or more stool examinations can fail to detect Strongyloides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. Of the specialized techniques, the agar plate method is used most commonly and is most sensitive [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/80\">",
"     80",
"    </a>",
"    ]. It involves inoculating agar plates with stool and incubating for two days at room temperature. Larvae crawl on the agar and spread bacteria in their paths, creating bacterial growth patterns on the agar surface. Larvae can be seen by macroscopic examination of the plates and their presence confirmed with formalin washing of the plate surface and examination of the sediment from the washing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aspiration of duodenojejunal fluid or the use of a string test (Enterotest) is sometimes used to detect Strongyloides larvae in patients with negative stool samples [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/76\">",
"     76",
"    </a>",
"    ]. Alternatively, serologic testing may be helpful (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Serology'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In disseminated strongyloidiasis, filariform larvae can be found in stool, sputum, bronchoalveolar lavage fluid, pleural fluid, peritoneal fluid, and surgical drainage fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/40,82-86\">",
"     40,82-86",
"    </a>",
"    ]. Sputum should also be examined for larvae if disseminated strongyloidiasis is suspected [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/84,86,87\">",
"     84,86,87",
"    </a>",
"    ]. For patients with rash, larvae may be visualized by skin biopsy.",
"   </p>",
"   <p>",
"    PCR tests have also been developed for detection of strongyloides in stool samples, but are not widely available. In one study, stool samples analyzed by microscopic examination were positive for strongyloides in 0.1 percent, compared with 0.8 percent positivity when the same samples were tested via PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnosis of strongyloidiasis by ELISA has proven useful in immunocompetent individuals, both in symptomatic and asymptomatic strongyloidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. The ELISA may be positive even if repeated examinations of stool samples are unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/91\">",
"     91",
"    </a>",
"    ]. The ELISA for detecting Strongyloides stercoralis infection detects immunoglobulin G (IgG) to filariform larvae. Negative test results in immunocompetent individuals decrease the likelihood that infection is present; however, some ELISA serologies run by commercial laboratories are of variable reliability. In addition, ELISA results can be falsely negative in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/87\">",
"     87",
"    </a>",
"    ]. False positive results may occur in the presence of other helminth infections [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The ELISA may be positive even when repeated examinations of stool samples have been unrevealing [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/91\">",
"     91",
"    </a>",
"    ]. However, ELISA can be falsely negative in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, some ELISA serologies run by commercial laboratories are of variable reliability.",
"   </p>",
"   <p>",
"    In one study, two commercially available ELISAs (IVD-ELISA and Bordier-ELISA) were found to have sensitivity of 89 and 83 percent, respectively, and specificity of 97.2 percent for both in the diagnosis of intestinal strongyloidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indirect immunofluorescence assays have also been developed, as has a gelatin particle agglutination test [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/93\">",
"     93",
"    </a>",
"    ]. A newer technique, luciferase immunoprecipitation system (LIPS), is another attractive alternative to ELISA-based methods [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upper endoscopy is not usually needed to establish a diagnosis of strongyloidiasis. However, it may be performed in patients with gastrointestinal symptoms with unsuspected disease. Strongyloidiasis has a broad range of endoscopic features [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/95\">",
"     95",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the duodenum, the findings included edema, brown discoloration of the mucosa, erythematous spots, subepithelial hemorrhages, and megaduodenum.",
"     </li>",
"     <li>",
"      In the colon, the findings include loss of vascular pattern, edema, aphthous ulcers, erosions, serpiginous ulcerations, and xanthoma-like lesions.",
"     </li>",
"     <li>",
"      In the stomach, thickened folds and mucosal erosions are seen [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/96\">",
"       96",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Larvae may be demonstrated on biopsies of the affected mucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/12,97\">",
"     12,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strongyloides colitis can sometimes mimic ulcerative colitis, but distinctive features of the strongyloidiasis include: skip pattern of the inflammation, distal attenuation of the disease, eosinophil-rich infiltrates, relatively intact crypt architecture, and frequent involvement of submucosa (",
"    <a class=\"graphic graphic_picture graphicRef51753 \" href=\"UTD.htm?28/18/28960\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for manifestations of strongyloidiasis (nonspecific gastrointestinal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulmonary symptoms, or chronic urticaria",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pruritus) is broad. In patients with larva currens the most important alternative diagnosis is cutaneous larva migrans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Uncomplicated infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, thiabendazole was administered for uncomplicated infection. However, thiabendazole is now rarely used due to the availability of more efficacious and better tolerated medications. The treatment of choice for strongyloidiasis at present is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    as an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Ivermectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     Ivermectin",
"    </a>",
"    is usually administered as two single 200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    doses of ivermectin administered either on two consecutive days or two weeks apart [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/99,101\">",
"     99,101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 88 patients with strongyloidiasis, 31 patients received thiabendazole 25",
"    <span class=\"nowrap\">",
"     mg/kg/12",
"    </span>",
"    hours for three consecutive days; 22 patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    200",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    as a single dose, and 35 patients received ivermectin for two consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/100\">",
"     100",
"    </a>",
"    ]. The efficacy rates were 78, 77, and 100 percent in the thiabendazole, ivermectin single-dose, and ivermectin two-dose regimens, respectively. Sixteen percent of patients taking thiabendazole experienced side effects in contrast to three percent in the combined ivermectin groups.",
"   </p>",
"   <p>",
"    In immigrants from areas of Africa endemic for loiasis, patients should be screened to exclude high levels of L. loa microfilaremia, because administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    to highly microfilaremic subjects can precipitate life-threatening encephalopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Albendazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    (400 mg PO twice daily for three to seven days) also has activity against Strongyloides [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. In varied studies, the efficacy of albendazole has been lower than that of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    , with a mean of 60 percent effectiveness for three days of albendazole versus 92 percent for ivermectin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/104\">",
"     104",
"    </a>",
"    ]. One study of 42 Thai patients with chronic strongyloidiasis noted a cure rate of 90 percent following a single dose of ivermectin compared with 50 percent for seven days of albendazole 800",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Disseminated disease/hyperinfection syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of disseminated disease and hyperinfection is uncertain, as data are limited. In immunocompromised patients with disseminated disease, reduction of immunosuppressive therapy, if possible, is an important adjunct to any anthelminthic therapy. In such cases it is also usually necessary to prolong or repeat",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    therapy, although there is no generally agreed upon regimen. Some experts give five to seven days of ivermectin in disseminated disease, or combine ivermectin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    until the patient responds. Often the duration of treatment is determined by the patient's response; daily ivermectin should be administered until symptoms resolve and stool tests have been negative for at least two weeks (one autoinfection cycle), or longer if patient remains immunosuppressed [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The optimal treatment of critically ill patients with the hyperinfection syndrome is uncertain; data regarding the ideal dose, duration, and route of therapy is limited. In patients with hyperinfection strongyloidiasis who were not able to receive oral therapy due to ileus or obtundation, alternative (not FDA-approved) regimens including subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mcg/kg)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/107-109\">",
"     107-109",
"    </a>",
"    ], per rectal ivermectin administration [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/110\">",
"     110",
"    </a>",
"    ], and a parenteral veterinary formulation of ivermectin [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/111-113\">",
"     111-113",
"    </a>",
"    ] have been used with variable success. Combined longer term ivermectin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    has been successful in a case of refractory strongyloidiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/114\">",
"     114",
"    </a>",
"    ]. Ongoing monthly doses of ivermectin for at least six months is may be given in the setting of ongoing immunosuppression among survivors of the hyperinfection syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are being treated for strongyloidiasis should have follow-up stool examinations, complete blood counts with eosinophilia and serologies.",
"   </p>",
"   <p>",
"    Treatment failures may occur even with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    in nonimmunocompromised hosts. If stool exams were positive for larvae prior to treatment, repeat stool exams should be performed about two to four weeks after treatment. However, a negative stool exam is not definitive proof of parasitologic cure since stool exams are insensitive for detecting larvae. Persistent symptoms following treatment for strongyloidiasis should raise the possibility that initial ivermectin treatment was not fully curative.",
"   </p>",
"   <p>",
"    Decreasing titers of antistrongyloides antibodies may also be useful to assess treatment adequacy of treatment; we recommend repeat serologies at three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/115\">",
"     115",
"    </a>",
"    ]. One retrospective study of 31 patients treated for strongyloidiasis noted a significant reduction in blood eosinophilia and serologic antibody titer after an average of 96 and 270 days, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/70\">",
"     70",
"    </a>",
"    ]. In another study among Cambodian refugees, 65 percent of patients followed with serial serology reached levels consistent with cure 6 to 12 months after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/116\">",
"     116",
"    </a>",
"    ]. Eosinophilia persisting for several months after treatment suggests either failure to eradicate strongyloides",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other etiologies for eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"     \"Approach to the patient with eosinophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of strongyloidiasis is good except in the hyperinfection syndrome. The latter patients have high case-fatality rates that are increased by concomitant immunosuppression, bacteremia, and delayed diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/117\">",
"     117",
"    </a>",
"    ]. Failure to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"     ivermectin",
"    </a>",
"    raises the possibility that the patient has underlying HTLV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11193/abstract/118,119\">",
"     118,119",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of disease is mainly achieved by wearing shoes in endemic areas to avoid contact with infected soil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strongyloidiasis is endemic in tropical and subtropical regions and occurs sporadically in temperate areas. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The burden of adult worms in infected humans can increase substantially via autoinfection. Among immunocompromised hosts, autoinfection can lead to the hyperinfection syndrome where there is massive dissemination of filariform larvae to the lungs, liver, heart, central nervous system, and endocrine glands. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Life cycle'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Hyperinfection syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most infected patients do not experience prominent symptoms. The most common manifestations are mild waxing and waning gastrointestinal, cutaneous, or pulmonary symptoms that persist for years; others simply have eosinophilia in the absence of symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For diagnosis, we recommend that at least two concentrated stool specimens be examined for the presence of rhabditiform larvae as well as serologic testing. If these diagnostic tests are negative and clinical suspicion of strongyloidiasis remains, we recommend either examination of duodenal fluid for larvae or empiric",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      for uncomplicated strongyloidiasis (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). The typical dose of ivermectin is 200",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      administered in two single doses, usually given two weeks apart. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Ivermectin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with disseminated disease (hyperinfection syndrome), we suggest extended dosing of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32976?source=see_link\">",
"       ivermectin",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The typical dose schedule is 200",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      daily for five to seven days minimum. Ivermectin can also be combined with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      . Daily stool examinations should be performed during treatment to determine the effect on larval burden, and ongoing daily treatment until symptoms resolve and stool tests have been negative for at least two weeks is often recommended. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Disseminated disease/hyperinfection syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with eosinophilia that persists for more than three months despite therapy, we recommend evaluation for treatment failure or other causes of eosinophilia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=see_link\">",
"       \"Approach to the patient with eosinophilia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/1\">",
"      Posey DL, Blackburn BG, Weinberg M, et al. High prevalence and presumptive treatment of schistosomiasis and strongyloidiasis among African refugees. Clin Infect Dis 2007; 45:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/2\">",
"      Gyorkos TW, Genta RM, Viens P, MacLean JD. Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol 1990; 132:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/3\">",
"      Caruana SR, Kelly HA, Ngeow JY, et al. Undiagnosed and potentially lethal parasite infections among immigrants and refugees in Australia. J Travel Med 2006; 13:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/4\">",
"      Schupf N, Ortiz M, Kapell D, et al. Prevalence of intestinal parasite infections among individuals with mental retardation in New York State. Ment Retard 1995; 33:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/5\">",
"      Lindo JF, Robinson RD, Terry SI, et al. Age-prevalence and household clustering of Strongyloides stercoralis infection in Jamaica. Parasitology 1995; 110 ( Pt 1):97.",
"     </a>",
"    </li>",
"    <li>",
"     Siddiqui AA, Genta RM, Berk SL. Chapter 111. In: Infectious Diseases - Principles, Practices and Pathogens, Guerrant RL, Walker DH, Weller PF (Eds), Churchhill-Livingstone Elsevier, Philadelphia 2006. p.1274.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/7\">",
"      Chu E, Whitlock WL, Dietrich RA. Pulmonary hyperinfection syndrome with Strongyloides stercoralis. Chest 1990; 97:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/8\">",
"      Pelletier LL Jr, Baker CB, Gam AA, et al. Diagnosis and evaluation of treatment of chronic strongyloidiasis in ex-prisoners of war. J Infect Dis 1988; 157:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/9\">",
"      Keiser PB, Nutman TB. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004; 17:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/10\">",
"      Haque AK, Schnadig V, Rubin SA, Smith JH. Pathogenesis of human strongyloidiasis: autopsy and quantitative parasitological analysis. Mod Pathol 1994; 7:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/11\">",
"      Nutman TB, Ottesen EA, Ieng S, et al. Eosinophilia in Southeast Asian refugees: evaluation at a referral center. J Infect Dis 1987; 155:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/12\">",
"      Arsi��-Arsenijevi�� V, Dzami�� A, Dzami�� Z, et al. Fatal Strongyloides stercoralis infection in a young woman with lupus glomerulonephritis. J Nephrol 2005; 18:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/13\">",
"      Robinson RD, Lindo JF, Neva FA, et al. Immunoepidemiologic studies of Strongyloides stercoralis and human T lymphotropic virus type I infections in Jamaica. J Infect Dis 1994; 169:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/14\">",
"      Mackey SL, Wagner KF. Dermatologic manifestations of parasitic diseases. Infect Dis Clin North Am 1994; 8:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/15\">",
"      Meinking TL, Burkhart CN, Burkhart CG. Changing paradigms in parasitic infections: common dermatological helminthic infections and cutaneous myiasis. Clin Dermatol 2003; 21:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/16\">",
"      Salluh JI, Bozza FA, Pinto TS, et al. Cutaneous periumbilical purpura in disseminated strongyloidiasis in cancer patients: a pathognomonic feature of potentially lethal disease? Braz J Infect Dis 2005; 9:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/17\">",
"      Reddy TS, Myers JW. Syndrome of inappropriate secretion of antidiuretic hormone and nonpalpable purpura in a woman with Strongyloides stercoralis hyperinfection. Am J Med Sci 2003; 325:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/18\">",
"      Van Dellen RG, Maddox DE, Dutta EJ. Masqueraders of angioedema and urticaria. Ann Allergy Asthma Immunol 2002; 88:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/19\">",
"      Mehta RK, Shah N, Scott DG, et al. Case 4. Chronic urticaria due to strongyloidiasis. Clin Exp Dermatol 2002; 27:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/20\">",
"      Ly MN, Bethel SL, Usmani AS, Lambert DR. Cutaneous Strongyloides stercoralis infection: an unusual presentation. J Am Acad Dermatol 2003; 49:S157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/21\">",
"      Scowden EB, Schaffner W, Stone WJ. Overwhelming strongyloidiasis: an unappreciated opportunistic infection. Medicine (Baltimore) 1978; 57:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/22\">",
"      Berkmen YM, Rabinowitz J. Gastrointestinal manifestations of the stongyloidiasis. Am J Roentgenol Radium Ther Nucl Med 1972; 115:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/23\">",
"      Sen P, Gil C, Estrellas B, Middleton JR. Corticosteroid-induced asthma: a manifestation of limited hyperinfection syndrome due to Strongyloides stercoralis. South Med J 1995; 88:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/24\">",
"      Wehner JH, Kirsch CM, Kagawa FT, et al. The prevalence and response to therapy of Strongyloides stercoralis in patients with asthma from endemic areas. Chest 1994; 106:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/25\">",
"      Lin AL, Kessimian N, Benditt JO. Restrictive pulmonary disease due to interlobular septal fibrosis associated with disseminated infection by Strongyloides stercoralis. Am J Respir Crit Care Med 1995; 151:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/26\">",
"      Newberry AM, Williams DN, Stauffer WM, et al. Strongyloides hyperinfection presenting as acute respiratory failure and gram-negative sepsis. Chest 2005; 128:3681.",
"     </a>",
"    </li>",
"    <li>",
"     Longworth DL, Weller PF. Hyperinfection syndrome with strongyloidiasis. In: Current Clinical Topics in Infectious Diseases, Remington JS, Swartz MN (Eds), McGraw-Hill, New York 1986. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/28\">",
"      Woodring JH, Halfhill H 2nd, Reed JC. Pulmonary strongyloidiasis: clinical and imaging features. AJR Am J Roentgenol 1994; 162:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/29\">",
"      Cebular S, Lee S, Tolaney P, Lutwick L. Community-acquired pneumonia in immunocompromised patients. Opportunistic infections to consider in differential diagnosis. Postgrad Med 2003; 113:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/30\">",
"      Strazzella WD, Safirstein BH. Asthma due to parasitic infestation. N J Med 1989; 86:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/31\">",
"      Lam CS, Tong MK, Chan KM, Siu YP. Disseminated strongyloidiasis: a retrospective study of clinical course and outcome. Eur J Clin Microbiol Infect Dis 2006; 25:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/32\">",
"      Nwokolo C, Imohiosen EA. Strongyloidiasis of respiratory tract presenting as \"asthma\". Br Med J 1973; 2:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/33\">",
"      Ghoshal UC, Ghoshal U, Jain M, et al. Strongyloides stercoralis infestation associated with septicemia due to intestinal transmural migration of bacteria. J Gastroenterol Hepatol 2002; 17:1331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/34\">",
"      Walker M, Zunt JR. Parasitic central nervous system infections in immunocompromised hosts. Clin Infect Dis 2005; 40:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/35\">",
"      Schaeffer MW, Buell JF, Gupta M, et al. Strongyloides hyperinfection syndrome after heart transplantation: case report and review of the literature. J Heart Lung Transplant 2004; 23:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/36\">",
"      Adam M, Morgan O, Persaud C, Gibbs WN. Hyperinfection syndrome with Strongyloides stercoralis in malignant lymphoma. Br Med J 1973; 1:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/37\">",
"      Cruz T, Reboucas G, Rocha H. Fatal strongyloidiasis in patients receiving corticosteroids. N Engl J Med 1966; 275:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/38\">",
"      Higenbottam TW, Heard BE. Opportunistic pulmonary strongyloidiasis complicating asthma treated with steroids. Thorax 1976; 31:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/39\">",
"      Purtilo DT, Meyers WM, Connor DH. Fatal strongyloidiasis in immunosuppressed patients. Am J Med 1974; 56:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/40\">",
"      Smith SB, Schwartzman M, Mencia LF, et al. Fatal disseminated strongyloidiasis presenting as acute abdominal distress in an urban child. J Pediatr 1977; 91:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/41\">",
"      Stemmermann GN. Strongyloidiasis in migrants. Pathological and clinical considerations. Gastroenterology 1967; 53:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/42\">",
"      Davidson RA. Infection due to Strongyloides stercoralis in patients with pulmonary disease. South Med J 1992; 85:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/43\">",
"      Safdar A, Malathum K, Rodriguez SJ, et al. Strongyloidiasis in patients at a comprehensive cancer center in the United States. Cancer 2004; 100:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/44\">",
"      Lemos LB, Qu Z, Laucirica R, Fred HL. Hyperinfection syndrome in strongyloidiasis: report of two cases. Ann Diagn Pathol 2003; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/45\">",
"      Hira PR, Al-Ali F, Shweiki HM, et al. Strongyloidiasis: challenges in diagnosis and management in non-endemic Kuwait. Ann Trop Med Parasitol 2004; 98:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/46\">",
"      Orlent H, Crawley C, Cwynarski K, et al. Strongyloidiasis pre and post autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/47\">",
"      Ghosh K, Ghosh K. Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases. Trans R Soc Trop Med Hyg 2007; 101:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/48\">",
"      Concha R, Harrington W Jr, Rogers AI. Intestinal strongyloidiasis: recognition, management, and determinants of outcome. J Clin Gastroenterol 2005; 39:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/49\">",
"      Schad GA. Cyclosporine may eliminate the threat of overwhelming strongyloidiasis in immunosuppressed patients. J Infect Dis 1986; 153:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/50\">",
"      Porto MA, Alc&acirc;ntara LM, Leal M, et al. Atypical clinical presentation of strongyloidiasis in a patient co-infected with human T cell lymphotrophic virus type I. Am J Trop Med Hyg 2005; 72:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/51\">",
"      Satoh M, Kiyuna S, Shiroma Y, et al. Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1. Clin Exp Immunol 2003; 133:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/52\">",
"      Rahim S, Drabu Y, Jarvis K, Melville D. Strongyloidiasis: a mistaken diagnosis and a fatal outcome in a patient with diarrhoea. Trans R Soc Trop Med Hyg 2005; 99:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/53\">",
"      Carvalho EM, Da Fonseca Porto A. Epidemiological and clinical interaction between HTLV-1 and Strongyloides stercoralis. Parasite Immunol 2004; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/54\">",
"      Plumelle Y, Pascaline N, Nguyen D, et al. Adult T-cell leukemia-lymphoma: a clinico-pathologic study of twenty-six patients from Martinique. Hematol Pathol 1993; 7:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/55\">",
"      Montes M, Sanchez C, Verdonck K, et al. Regulatory T cell expansion in HTLV-1 and strongyloidiasis co-infection is associated with reduced IL-5 responses to Strongyloides stercoralis antigen. PLoS Negl Trop Dis 2009; 3:e456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/56\">",
"      Celedon JC, Mathur-Wagh U, Fox J, et al. Systemic strongyloidiasis in patients infected with the human immunodeficiency virus. A report of 3 cases and review of the literature. Medicine (Baltimore) 1994; 73:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/57\">",
"      Lessnau KD, Can S, Talavera W. Disseminated Strongyloides stercoralis in human immunodeficiency virus-infected patients. Treatment failure and a review of the literature. Chest 1993; 104:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/58\">",
"      Kim AC, Lupatkin HC. Strongyloides stercoralis infection as a manifestation of immune restoration syndrome. Clin Infect Dis 2004; 39:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/59\">",
"      Taylor CL, Subbarao V, Gayed S, Ustianowski AP. Immune reconstitution syndrome to Strongyloides stercoralis infection. AIDS 2007; 21:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/60\">",
"      Brown M, Cartledge JD, Miller RF. Dissemination of Strongyloides stercoralis as an immune restoration phenomenon in an HIV-1-infected man on antiretroviral therapy. Int J STD AIDS 2006; 17:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/61\">",
"      Viney ME, Brown M, Omoding NE, et al. Why does HIV infection not lead to disseminated strongyloidiasis? J Infect Dis 2004; 190:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/62\">",
"      Seet RC, Lau LG, Tambyah PA. Strongyloides hyperinfection and hypogammaglobulinemia. Clin Diagn Lab Immunol 2005; 12:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/63\">",
"      Sathiyasekaran M, Shibalan S. Intestinal strongyloidiasis and common variable immunodeficiency syndrome. Indian Pediatr 2005; 42:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/64\">",
"      Boatright MD, Wang BW. Clinical infection with Strongyloides sterocoralis following etanercept use for rheumatoid arthritis. Arthritis Rheum 2005; 52:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/65\">",
"      Krishnamurthy R, Dincer HE, Whittemore D. Strongyloides stercoralis hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. J Clin Rheumatol 2007; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/66\">",
"      Marty FM. Strongyloides hyperinfection syndrome and transplantation: a preventable, frequently fatal infection. Transpl Infect Dis 2009; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/67\">",
"      Vilela EG, Clemente WT, Mira RR, et al. Strongyloides stercoralis hyperinfection syndrome after liver transplantation: case report and literature review. Transpl Infect Dis 2009; 11:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/68\">",
"      Valar C, Keitel E, Dal Pr&aacute; RL, et al. Parasitic infection in renal transplant recipients. Transplant Proc 2007; 39:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/69\">",
"      Roxby AC, Gottlieb GS, Limaye AP. Strongyloidiasis in transplant patients. Clin Infect Dis 2009; 49:1411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/70\">",
"      Nuesch R, Zimmerli L, Stockli R, et al. Imported strongyloidosis: a longitudinal analysis of 31 cases. J Travel Med 2005; 12:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/71\">",
"      Gill GV, Welch E, Bailey JW, et al. Chronic Strongyloides stercoralis infection in former British Far East prisoners of war. QJM 2004; 97:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/72\">",
"      Johnston FH, Morris PS, Speare R, et al. Strongyloidiasis: a review of the evidence for Australian practitioners. Aust J Rural Health 2005; 13:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/73\">",
"      Lim S, Katz K, Krajden S, et al. Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management. CMAJ 2004; 171:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/74\">",
"      Agrawal V, Agarwal T, Ghoshal UC. Intestinal strongyloidiasis: a diagnosis frequently missed in the tropics. Trans R Soc Trop Med Hyg 2009; 103:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/75\">",
"      Al-Hasan MN, McCormick M, Ribes JA. Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. Am J Clin Pathol 2007; 128:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/76\">",
"      Beal CB, Viens P, Grant RG, Hughes JM. A new technique for sampling duodenal contents: demonstration of upper small-bowel pathogens. Am J Trop Med Hyg 1970; 19:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/77\">",
"      Boulware DR, Stauffer WM 3rd, Walker PF. Hypereosinophilic syndrome and mepolizumab. N Engl J Med 2008; 358:2839; author reply 2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/78\">",
"      Rosenblatt JE. Clinical importance of adequately performed stool ova and parasite examinations. Clin Infect Dis 2006; 42:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/79\">",
"      Hirata T, Nakamura H, Kinjo N, et al. Increased detection rate of Strongyloides stercoralis by repeated stool examinations using the agar plate culture method. Am J Trop Med Hyg 2007; 77:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/80\">",
"      Ramanathan R, Nutman T. Strongyloides stercoralis infection in the immunocompromised host. Curr Infect Dis Rep 2008; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/81\">",
"      Greiner K, Bettencourt J, Semolic C. Strongyloidiasis: a review and update by case example. Clin Lab Sci 2008; 21:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/82\">",
"      Eveland LK, Kenney M, Yermakov V. Laboratory diagnosis of autoinfection in strongyloidiasis. Am J Clin Pathol 1975; 63:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/83\">",
"      Schainberg L, Scheinberg MA. Recovery of Strongyloides stercoralis by bronchoalveolar lavage in a patient with acquired immunodeficiency syndrome. Am J Med 1989; 87:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/84\">",
"      Smith B, Verghese A, Guiterrez C, et al. Pulmonary strongyloidiasis. Diagnosis by sputum gram stain. Am J Med 1985; 79:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/85\">",
"      Williams J, Nunley D, Dralle W, et al. Diagnosis of pulmonary strongyloidiasis by bronchoalveolar lavage. Chest 1988; 94:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/86\">",
"      Harris RA Jr, Musher DM, Fainstein V, et al. Disseminated strongyloidiasis. Diagnosis made by sputum examination. JAMA 1980; 244:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/87\">",
"      Abdalla J, Saad M, Myers JW, Moorman JP. An elderly man with immunosuppression, shortness of breath, and eosinophilia. Clin Infect Dis 2005; 40:1464, 1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/88\">",
"      ten Hove RJ, van Esbroeck M, Vervoort T, et al. Molecular diagnostics of intestinal parasites in returning travellers. Eur J Clin Microbiol Infect Dis 2009; 28:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/89\">",
"      Carroll SM, Karthigasu KT, Grove DI. Serodiagnosis of human strongyloidiasis by an enzyme-linked immunosorbent assay. Trans R Soc Trop Med Hyg 1981; 75:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/90\">",
"      Neva FA, Gam AA, Burke J. Comparison of larval antigens in an enzyme-linked immunosorbent assay for strongyloidiasis in humans. J Infect Dis 1981; 144:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/91\">",
"      Savage D, Foadi M, Haworth C, Grant A. Marked eosinophilia in an immunosuppressed patient with strongyloidiasis. J Intern Med 1994; 236:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/92\">",
"      van Doorn HR, Koelewijn R, Hofwegen H, et al. Use of enzyme-linked immunosorbent assay and dipstick assay for detection of Strongyloides stercoralis infection in humans. J Clin Microbiol 2007; 45:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/93\">",
"      Boscolo M, Gobbo M, Mantovani W, et al. Evaluation of an indirect immunofluorescence assay for strongyloidiasis as a tool for diagnosis and follow-up. Clin Vaccine Immunol 2007; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/94\">",
"      Ramanathan R, Burbelo PD, Groot S, et al. A luciferase immunoprecipitation systems assay enhances the sensitivity and specificity of diagnosis of Strongyloides stercoralis infection. J Infect Dis 2008; 198:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/95\">",
"      Sreenivas DV, Kumar A, Kumar YR, et al. Intestinal strongyloidiasis--a rare opportunistic infection. Indian J Gastroenterol 1997; 16:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/96\">",
"      Thompson BF, Fry LC, Wells CD, et al. The spectrum of GI strongyloidiasis: an endoscopic-pathologic study. Gastrointest Endosc 2004; 59:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/97\">",
"      Overstreet K, Chen J, Rodriguez JW, Wiener G. Endoscopic and histopathologic findings of Strongyloides stercoralis infection in a patient with AIDS. Gastrointest Endosc 2003; 58:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/98\">",
"      Qu Z, Kundu UR, Abadeer RA, Wanger A. Strongyloides colitis is a lethal mimic of ulcerative colitis: the key morphologic differential diagnosis. Hum Pathol 2009; 40:572.",
"     </a>",
"    </li>",
"    <li>",
"     Drugs for Parasitic Infections, The Medical Letter file://medlet-best.securesites.com/html/parasitic_desc.htm (Accessed on August 17, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/100\">",
"      Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, et al. Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis. Expert Opin Pharmacother 2004; 5:2615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/101\">",
"      Zaha O, Hirata T, Kinjo F, et al. Efficacy of ivermectin for chronic strongyloidiasis: two single doses given 2 weeks apart. J Infect Chemother 2002; 8:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/102\">",
"      Marti H, Haji HJ, Savioli L, et al. A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children. Am J Trop Med Hyg 1996; 55:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/103\">",
"      Archibald LK, Beeching NJ, Gill GV, et al. Albendazole is effective treatment for chronic strongyloidiasis. Q J Med 1993; 86:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/104\">",
"      Muennig P, Pallin D, Challah C, Khan K. The cost-effectiveness of ivermectin vs. albendazole in the presumptive treatment of strongyloidiasis in immigrants to the United States. Epidemiol Infect 2004; 132:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/105\">",
"      Suputtamongkol Y, Kungpanichkul N, Silpasakorn S, Beeching NJ. Efficacy and safety of a single-dose veterinary preparation of ivermectin versus 7-day high-dose albendazole for chronic strongyloidiasis. Int J Antimicrob Agents 2008; 31:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/106\">",
"      Segarra-Newnham M. Manifestations, diagnosis, and treatment of Strongyloides stercoralis infection. Ann Pharmacother 2007; 41:1992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/107\">",
"      Pacanowski J, Santos MD, Roux A, et al. Subcutaneous ivermectin as a safe salvage therapy in Strongyloides stercoralis hyperinfection syndrome: a case report. Am J Trop Med Hyg 2005; 73:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/108\">",
"      Leung V, Al-Rawahi GN, Grant J, et al. Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection. Am J Trop Med Hyg 2008; 79:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/109\">",
"      Turner SA, Maclean JD, Fleckenstein L, Greenaway C. Parenteral administration of ivermectin in a patient with disseminated strongyloidiasis. Am J Trop Med Hyg 2005; 73:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/110\">",
"      Tarr PE, Miele PS, Peregoy KS, et al. Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome. Am J Trop Med Hyg 2003; 68:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/111\">",
"      Marty FM, Lowry CM, Rodriguez M, et al. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin. Clin Infect Dis 2005; 41:e5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/112\">",
"      Salluh JI, Feres GA, Velasco E, et al. Successful use of parenteral ivermectin in an immunosuppressed patient with disseminated strongyloidiasis and septic shock. Intensive Care Med 2005; 31:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/113\">",
"      Miller MA, Church LW, Salgado CD. Strongyloides hyperinfection: a treatment dilemma. Am J Med Sci 2008; 336:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/114\">",
"      Pornsuriyasak P, Niticharoenpong K, Sakapibunnan A. Disseminated strongyloidiasis successfully treated with extended duration ivermectin combined with albendazole: a case report of intractable strongyloidiasis. Southeast Asian J Trop Med Public Health 2004; 35:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/115\">",
"      Kobayashi J, Sato Y, Toma H, et al. Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasis. Diagn Microbiol Infect Dis 1994; 18:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/116\">",
"      Biggs BA, Caruana S, Mihrshahi S, et al. Management of chronic strongyloidiasis in immigrants and refugees: is serologic testing useful? Am J Trop Med Hyg 2009; 80:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/117\">",
"      El Masry HZ, O'Donnell J. Fatal stongyloides hyperinfection in heart transplantation. J Heart Lung Transplant 2005; 24:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/118\">",
"      Terashima A, Alvarez H, Tello R, et al. Treatment failure in intestinal strongyloidiasis: an indicator of HTLV-I infection. Int J Infect Dis 2002; 6:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11193/abstract/119\">",
"      Jeyamani R, Joseph AJ, Chacko A. Severe and treatment resistant strongyloidiasis--indicator of HTLV-I infection. Trop Gastroenterol 2007; 28:176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5714 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D487AFE9F4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11193=[""].join("\n");
var outline_f10_59_11193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIFE CYCLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Autoinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Skin reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hyperinfection syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Role of immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      WHOM TO TEST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Detection of larvae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Uncomplicated infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Ivermectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Albendazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Disseminated disease/hyperinfection syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5714\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5714|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/45/28377\" title=\"figure 1\">",
"      Strongyloides life cycle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5714|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/22/26977\" title=\"picture 1\">",
"      Strongyloides in stool",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/18/28960\" title=\"picture 2\">",
"      Endoscopy - strongyloidiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/10/24745?source=related_link\">",
"      Approach to the patient with eosinophilia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_59_11194="The pediatric physical examination: HEENT";
var content_f10_59_11194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The pediatric physical examination: HEENT",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?10/59/11194/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?10/59/11194/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the head, eyes, ears, nose, and throat (HEENT) in children will be reviewed here. Other aspects of the pediatric physical examination are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link\">",
"     \"The pediatric physical examination: General principles and standard measurements\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link\">",
"     \"The pediatric physical examination: Chest and abdomen\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=see_link\">",
"     \"The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=see_link\">",
"     \"The pediatric physical examination: The perineum\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HEAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial part of the HEENT examination includes visualization of the head for shape and for the presence of hair, scalp defects, abnormal lesions or protuberances, lacerations, and abrasions or contusions.",
"   </p>",
"   <p>",
"    Lumps and bumps on the head may arise from soft tissue or bone. Firm or hard masses include exostoses and calcified hematomas. Soft tissue masses include hemangiomas, dermoid cysts, encephaloceles, and infected scalp lesions. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Intradiploic epidermoid cysts are rare, congenital bone masses most frequently located in the skull. They are derived from ectodermal cell rests in bone during embryogenesis. The characteristic finding on plain radiographs, a well-defined lesion with sclerotic borders, is highly suggestive of the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/1\">",
"     1",
"    </a>",
"    ]. Although these lesions are benign and grow slowly, prophylactic removal is generally recommended because they can increase in size and may be complicated by abscess formation, bleeding, intracranial extension with neurologic manifestations, and malignant change [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Head circumference",
"    </span>",
"    &nbsp;&mdash;&nbsp;Head circumference should be measured at each regularly scheduled well-child visit throughout the first 24 to 36 months of life. Measurement should be attempted only at the conclusion of the physical examination, as infants dislike this part of this examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=see_link&amp;anchor=H8#H8\">",
"     \"The pediatric physical examination: General principles and standard measurements\", section on 'Weight, height, head, and chest circumference'",
"    </a>",
"    .) Measurements are plotted on a standard head circumference growth chart to determine percentile for age and rate of growth. A number of standardized head circumference charts are available for infants and children. They are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=see_link&amp;anchor=H18523310#H18523310\">",
"     \"Etiology and evaluation of microcephaly in infants and children\", section on 'Head circumference charts'",
"    </a>",
"    .) Approximately 75 percent of adult head size is reached by two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Fontanelles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the anterior and posterior fontanelles is fairly easy during the first several weeks of life. Palpation is performed with the patient in the upright position.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The anterior fontanelle is located at the juncture of the metopic, sagittal, and coronal sutures. Generally, it is 3 to 6 cm in diameter through the first six months of life.",
"     </li>",
"     <li>",
"      The posterior fontanelle is located at the juncture of the sagittal and lambdoid sutures. Usually, it is no larger than 1 to 1.5 cm in diameter.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both fontanelles normally are soft and relatively flat. Visible or palpable pulsations of the anterior fontanelle are common, especially in the crying or agitated infant. Pounding pulsations or persistent tenseness of the fontanelle may indicate increased intracranial pressure. A depressed or sunken anterior fontanelle is compatible with dehydration or malnutrition.",
"   </p>",
"   <p>",
"    Palpation of the parietal area of the skull, particularly in a premature infant, may elicit an unusual, spring-like, bony compressibility (craniotabes), similar to the sensation of pushing in the side of a ping-pong ball. Persistent craniotabes found in children older than six to nine months are indications of several disorders, including syphilis and rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Normal closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal time of fontanelle closure depends somewhat upon the patient's gestational age at birth. The posterior fontanelle usually cannot be palpated after two months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The anterior fontanelle generally closes between 10 and 24 months of age. The fontanelles of premature infants tend to close at a later time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Early closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early closure of the fontanelles may actually represent the growth of fibrous tissue, which precedes bony closure by several months. Early closure of either fontanelle is not uncommon in an otherwise normal child. However, it should alert the examiner to the possibility of developing microcephaly. Other causes of early closure of the anterior fontanelle include craniosynostosis, hyperthyroidism, hypophosphatasia, rickets, and hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Delayed closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common causes of delayed closure of the anterior fontanelle include normal variation, congenital hypothyroidism, primary megalencephaly, increased intracranial pressure, Down syndrome, and rickets [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/8\">",
"     8",
"    </a>",
"    ]. Other causes of delayed closure of the anterior fontanelle are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef76080 \" href=\"UTD.htm?21/3/21565\">",
"     table 1",
"    </a>",
"    ). Many of these disorders are associated with an enlarged anterior fontanelle and have dysmorphic features that help to make the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Auscultation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Occasionally, auscultation of the skull for a bruit is helpful in detecting an arteriovenous malformation. A transmitted cardiac murmur may give rise to an audible cranial bruit, eliminated readily by gentle pressure over the ipsilateral carotid artery. An audible bruit in a child during the first several years of life may not be abnormal. Systolic bruits assume more significance as the child gets older.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Transillumination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial defects, such as hydranencephaly and hydrocephaly, can be transilluminated with a Chun gun or flashlight fitted circumferentially with a rubber or sponge cup. Unlike the skull of the normal child, that of the patient with either of these defects or anencephaly permits light to be transmitted far beyond the circumferential rim of the instrument being used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Scalp and hair",
"    </span>",
"    &nbsp;&mdash;&nbsp;The texture, pattern, and abundance or absence of scalp hair may suggest an underlying problem.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dry, scaling areas of the scalp can be caused by psoriasis or seborrheic dermatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of psoriasis\", section on 'Plaque psoriasis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=see_link&amp;anchor=H608072814#H608072814\">",
"       \"Cradle cap and seborrheic dermatitis in infants\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A bald spot over the occipital area frequently is found in infants placed in the supine position for sleeping and in developmentally delayed children who fail to change head position.",
"     </li>",
"     <li>",
"      A white forelock, associated with congenital deafness, may be found in patients with Waardenburg syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/9\">",
"       9",
"      </a>",
"      ]. The major features of Waardenburg syndrome are lateral displacement of medial canthi, partial albinism, and deafness [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/10\">",
"       10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H24#H24\">",
"       \"The genodermatoses\", section on 'Waardenburg syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Twisted, short, fragile hair can be associated with Menkes syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/11\">",
"       11",
"      </a>",
"      ]. The other major features of Menkes syndrome are progressive cerebral deterioration, seizures, twisted and fractured hair, and metaphyseal widening of bones (particularly ribs and femur) [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coarse, dry hair is found in patients with hypothyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"       \"Acquired hypothyroidism in childhood and adolescence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patches of alopecia may occur in patients with tinea capitis, trichotillomania, ectodermal dysplasia, or alopecia areata, and at the site of a scalp probe or intravenous insertion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=see_link&amp;anchor=H3#H3\">",
"       \"Dermatophyte (tinea) infections\", section on 'Tinea capitis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=see_link&amp;anchor=H13#H13\">",
"       \"Nonscarring hair loss\", section on 'Traumatic alopecia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=see_link&amp;anchor=H35#H35\">",
"       \"The genodermatoses\", section on 'Ectodermal dysplasias'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=see_link\">",
"       \"Clinical manifestations and diagnosis of alopecia areata\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FACE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should pay close attention to the patient's anatomical facial structures: the size of the mouth; the shape of the lips; the length of the philtrum; the size and shape of the nose; the distance between the eyes; the width of the palpebral fissures; and the size, shape, and position of the pinnae. Atypical facial features may reveal a phenotypic pattern compatible with a particular syndrome attributable to maternal drug ingestion or to a specific genetic or chromosomal abnormality.",
"   </p>",
"   <p>",
"    Periorbital or facial edema can occur as part of a systemic allergic reaction or may be the first indication of nephrotic syndrome. Unilateral orbital or facial edema can occur as a result of an insect bite or cellulitis. Unilateral or bilateral facial swelling not caused by edema may be secondary to an infectious process or, in the case of mumps, parotid gland swelling. Lymphadenopathy and salivary gland pathology cause submandibular soft tissue swelling. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Unilateral facial paralysis secondary to a peripheral or central facial nerve defect may be attributable to a traumatic injury, viral or bacterial infection, or other abnormality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=see_link\">",
"     \"Facial nerve palsy in children\"",
"    </a>",
"    .) Tense, rigid facial muscles are seen in patients with hypocalcemia, tetanus, and other infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical manifestations of hypocalcemia\", section on 'Acute manifestations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=see_link\">",
"     \"Tetanus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EYES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient cooperation and compliance are essential to a good eye examination. Infants and younger children are best examined held upright in the comforting arms of their caregivers, with their attention drawn to a toy or bright object. Infants tend to be easier to examine than the uncooperative 18-month-old to 3-year-old. By age six to eight years, children usually are able to sit alone facing the examiner and are able to follow directions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before using the ophthalmoscope or touching the child, the examiner should note the position and spacing of the eyes, width of palpebral fissures, eye color, appearance of the sclera and conjunctiva, condition of the eyelids, pupillary size, and eye movement. Asymmetry of the eyes may be the result of prominent epicanthal folds, a difference in the size of the globes, or ptosis. Widened or narrow palpebral fissures are the norm for some patients but can be part of a syndrome complex in others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Eyelids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of eyelids should include the lashes, color, presence of ptosis, and skin defects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythematous or violaceous eyelids may be the result of hemangiomas or vascular malformations, or they can appear secondary to trauma, infection, metastasis, or connective tissue disorders",
"     </li>",
"     <li>",
"      Small linear creases involving the lower eyelid (Dennie lines or Morgan folds) occur in patients with allergies [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Edematous eyelids may be the result of hypoproteinemia as part of the nephrotic syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=see_link&amp;anchor=H10#H10\">",
"       \"Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A mild degree of unilateral or bilateral congenital ptosis, often of undetermined cause, is common. Acquired causes of ptosis include myasthenia gravis, third cranial nerve palsy, and ophthalmoplegic migraine. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=see_link\">",
"       \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Flaking, erythema, and mild swelling of the eyelid margins are seen in patients with blepharitis, which often is attributable to seborrheic dermatitis of the scalp or face. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=see_link\">",
"       \"Blepharitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A stye (external hordeolum) presents as painful inflammation of the hair follicles or accessory glands along the lid margin, usually caused by Staphylococcus aureus infection (",
"      <a class=\"graphic graphic_picture graphicRef79059 \" href=\"UTD.htm?2/54/2916\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4088?source=see_link&amp;anchor=H7#H7\">",
"       \"Eyelid lesions\", section on 'Hordeolum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A chalazion is a nontender, nodular lesion located deeper in the eyelid, caused by chronic inflammation of a meibomian gland (",
"      <a class=\"graphic graphic_picture graphicRef62030 \" href=\"UTD.htm?23/30/24034\">",
"       picture 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4088?source=see_link&amp;anchor=H5#H5\">",
"       \"Eyelid lesions\", section on 'Chalazion'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Discharge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eye discharge or excessive tearing from one or both eyes may indicate a pathologic condition.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Purulent discharge can occur as a result of bacterial infection (eg, Neisseria gonorrhea) or chemical irritant (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/46/20194?source=see_link\">",
"       silver nitrate",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"       \"Conjunctivitis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=see_link&amp;anchor=H6#H6\">",
"       \"Gonococcal infection in the newborn\", section on 'Ophthalmia neonatorum'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abundant tearing may result from a blocked tear duct, presence of a foreign body, allergic reaction, infection, or glaucoma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=see_link&amp;anchor=H5#H5\">",
"       \"Approach to the child with persistent tearing\", section on 'Etiology of persistent tearing'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Conjunctivae",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammation of the conjunctivae (conjunctivitis) is caused by an infectious process, irritants, toxins, emotional problems, crying, or systemic disorders (eg, Kawasaki disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=see_link\">",
"       \"Conjunctivitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Subconjunctival hemorrhages caused by injury or inflammation generally are benign and self-limiting",
"     </li>",
"     <li>",
"      Epithelial hyperplasia that gives rise to a mildly uncomfortable yellow-white lesion involving the bulbar conjunctiva (pinguecula) (",
"      <a class=\"graphic graphic_picture graphicRef72441 \" href=\"UTD.htm?5/31/5617\">",
"       picture 3",
"      </a>",
"      ) should be differentiated from a pterygium (",
"      <a class=\"graphic graphic_picture graphicRef72309 \" href=\"UTD.htm?32/3/32831\">",
"       picture 4",
"      </a>",
"      ), a painless lesion of similar appearance that may grow over the cornea [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41879?source=see_link\">",
"       \"Pterygium\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Extraocular movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;A penlight, finger, or other object should be used to assess extraocular muscle movement. Symmetric movement of the eyes should occur as the patient's eyes follow the finger or object, tracking it superiorly, inferiorly, laterally, medially, and obliquely. Nystagmus should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Ocular alignment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The corneal light reflex is tested to determine eye alignment. When a light source is held directly in front of a patient who is staring straight ahead, normal eye alignment will reveal a symmetric reflex in the center of each pupil (",
"    <a class=\"graphic graphic_figure graphicRef63631 \" href=\"UTD.htm?28/23/29040\">",
"     figure 1",
"    </a>",
"    ). If the light reflex in one eye is inwardly displaced, that eye is exotropic; if outwardly displaced, it is esotropic; and if inferiorly displaced, it is hypertropic [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cover-uncover eye test is a more accurate test for ocular alignment in the cooperative patient. Testing is done with the patient looking first at a near object and then at a far object. As the patient fixates on the object, one eye is rapidly covered with a hand or occluder, and the other eye is observed for movement (",
"    <a class=\"graphic graphic_figure graphicRef68374 \" href=\"UTD.htm?17/61/18386\">",
"     figure 2",
"    </a>",
"    ). Normally, no movement of either eye occurs as they are alternately tested.",
"   </p>",
"   <p>",
"    Strabismic gaze, a misalignment of the eyes, may be normal during the first several months of life. Persistent strabismus should be referred to an ophthalmologist for further evaluation. Many factors, including eye muscle weakness, cranial nerve abnormalities, cataract, chorioretinitis, and retinoblastoma can interfere with the normal visual axis. In young infants and children, pseudostrabismus can be seen in the presence of unilateral or bilateral epicanthal folds. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation and management of strabismus in children\", section on 'Strabismus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vision",
"    </span>",
"    &nbsp;&mdash;&nbsp;An infant's interest and attentiveness to bright light and the accompanying pupillary response indicate his or her ability to see. Visual fixation can be assessed in infants by observing their ability to focus upon an object or, more often, their parent's face. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=see_link\">",
"     \"Visual development and vision assessment in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rotating multicolored drum also helps determine the presence of sight. The patient with an intact visual pathway will have nystagmus when the drum is turned; the eyes of a visually impaired patient will not move.",
"   </p>",
"   <p>",
"    Visual acuity in the infant and younger child can be tested by having the child look at and follow the expression and movement of the caregiver's (or other person's) face. For children older than three to four years, Allen cards (pictures of familiar objects: car, cake, horse, and bird) and the HOTV test can be used to assess acuity (",
"    <a class=\"graphic graphic_table graphicRef62277 \" href=\"UTD.htm?14/43/15037\">",
"     table 2",
"    </a>",
"    ). For the child four to six years old, the tumbling E test can be used; the standard Snellen eye chart may be considered for children who have mastered the alphabet.",
"   </p>",
"   <p>",
"    Visual field assessment can be conducted in the child old enough to cooperate by having the child sit opposite the examiner at a distance of only a few feet and telling him or her to look at a particular part of the examiner's face (eg, the nose). With both arms fully extended in opposite directions, the examiner begins wiggling a toy or the fingers of one hand and asks the patient to indicate (verbally or by pointing) when the movement comes into the child's visual field. Assuming the examiner has normal visual fields, assessment of any significant loss or deficiency in the patient can be determined. All four visual field quadrants should be tested. For the older patient, the examiner may choose to perform the test by holding up a certain number of fingers and having the patient identify them when they come into range.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ophthalmoscopic examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Red reflex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the red reflex should be performed in a darkened room. Ophthalmoscopic examination of the eyes should begin at a distance with the beam of light projected onto the upper facial area. The lens setting should be at zero [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/15\">",
"     15",
"    </a>",
"    ]. From a distance of approximately 18 inches, the fundi are visualized individually and simultaneously (Bruckner test). Viewing the retina obliquely, in addition to straight-on, may improve the detection of retinoblastoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/16\">",
"     16",
"    </a>",
"    ].&nbsp;In more darkly pigmented individuals, the reflex may be more gray than red [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, visualization of the red reflex through the ophthalmoscope is difficult, particularly in young children, who may cry, turn away from the examiner, or shut their eyes as the examiner approaches. Better visualization may be achieved with the handheld otoscope from a distance of several feet. The magnifying lens of the otoscope is moved to the side, out of the examiner's field of vision. While the examiner looks through the aperture, the beam of light can be directed onto each eye separately or onto both eyes simultaneously.",
"   </p>",
"   <p>",
"    Any opacity involving anatomic structures through which the light must pass will create a dull or abnormal color; mucus in the tear film, a transient opacity, disappears after the child blinks [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/15\">",
"     15",
"    </a>",
"    ]. Children who have an abnormal red reflex (eg, dark spots, markedly diminished reflex, white reflex, asymmetry) should be referred to an ophthalmologist experienced in the examination of children (",
"    <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H16#H16\">",
"     \"Approach to the child with leukocoria\", section on 'Referral'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cornea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the cornea should reveal a clear transparent membrane. Adequate visualization requires use of an ophthalmoscope set at +8 to +6 diopters. Any corneal opacity, including that owing to haziness or ulceration, is abnormal.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A hazy cornea is seen in a number of disorders, including metabolic disease (",
"      <a class=\"graphic graphic_picture graphicRef52924 \" href=\"UTD.htm?15/2/15392\">",
"       picture 5",
"      </a>",
"      ), glaucoma, and vitamin deficiency",
"     </li>",
"     <li>",
"      Ulcerations may appear as a result of infection, foreign body, connective tissue disease, or trauma. Traumatic lacerations and acute ulcerations are extremely painful and are accompanied by photophobia, conjunctivitis, and pupillary constriction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=see_link\">",
"       \"Corneal abrasions and corneal foreign bodies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Anterior chamber",
"    </span>",
"    &nbsp;&mdash;&nbsp;After visualization of the cornea, the anterior chamber should be examined with the ophthalmoscopic lens set at about +6 diopters. It should be completely free of opacities. Blood in the anterior chamber is a result of trauma. Turbidity and cellular debris in the chamber are caused by inflammation of the iris and ciliary muscle secondary to an autoimmune reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Iris and lens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmoscopic setting should be +4 to +2 diopters to examine the iris and lens. Cataracts, noted as a white pupillary reflex (leukocoria), can be seen without use of an ophthalmoscope. Cataracts appear white or gray in a well-lit room or in natural sunlight; through the ophthalmoscope, they are dark or almost black. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link&amp;anchor=H11#H11\">",
"     \"Cataract in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cataracts can be congenital or acquired as the result of infection, metabolic disease, drugs, toxins, traumatic injury, glaucoma, or retinoblastoma. Certain dermatologic abnormalities and several musculoskeletal, central nervous system, and craniofacial syndromes also can give rise to cataracts. Two renal syndromes, Lowe and Alport, have cataracts as a major component, as does a primary hepatic condition, Zellweger (cerebrohepatorenal) syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Visual impairment generally develops with cataracts. If the cataract remains small, however, no visual difficulty may occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Retina and optic disk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the retina and optic disk requires ophthalmoscopic lens settings of 0 to -2 diopters. When close to the patient, the examiner can clearly visualize the optic disk, blood vessels, and more laterally the macula. The fundus should be pink to red, although in anemic patients and in darkly pigmented individuals, it may be gray-white. If an almost completely white and somewhat opaque light reflex is noted, impairing the examiner's ability to identify the optic disk, blood vessels, and macula, the patient may have a cloudy cornea, lens opacity, retinoblastoma, retinopathy of prematurity, or retinal detachment [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the child with leukocoria\", section on 'Causes of leukocoria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     EARS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Appearance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examiner should note the relationship of the ears to the rest of the face, particularly the shape and position of the pinnae (auricles) (",
"    <a class=\"graphic graphic_figure graphicRef57082 \" href=\"UTD.htm?33/19/34103\">",
"     figure 4",
"    </a>",
"    ). A renal anomaly (eg, absence of kidneys in Potter syndrome) should be considered if the superior rim of the pinnae is below a line drawn posteriorly from the superior orbital rim. Malformation of the pinnae may occur in syndromes that affect mandibulofacial structures (eg, Treacher Collins or Goldenhar syndrome).",
"   </p>",
"   <p>",
"    Protruding, anteriorly placed pinnae can be a normal anatomical variant. If the external ear is displaced outward and anteriorly, consideration should be given to a diagnosis of mastoiditis (",
"    <a class=\"graphic graphic_picture graphicRef70910 \" href=\"UTD.htm?23/27/23999\">",
"     picture 6",
"    </a>",
"    ), external otitis (",
"    <a class=\"graphic graphic_picture graphicRef55712 \" href=\"UTD.htm?43/29/44511\">",
"     picture 7",
"    </a>",
"    ), or cellulitis (",
"    <a class=\"graphic graphic_picture graphicRef58541 \" href=\"UTD.htm?9/10/9376\">",
"     picture 8",
"    </a>",
"    ), among others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=see_link&amp;anchor=H7#H7\">",
"     \"Acute mastoiditis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, preauricular skin tags (",
"    <a class=\"graphic graphic_picture graphicRef66027 \" href=\"UTD.htm?36/33/37407\">",
"     picture 9",
"    </a>",
"    ) are associated with hearing loss, but generally they have no clinical significance. Ear pits (",
"    <a class=\"graphic graphic_picture graphicRef75371 \" href=\"UTD.htm?31/1/31775\">",
"     picture 10",
"    </a>",
"    ) involving the pinnae and preauricular skin pits also are unlikely to be associated with hearing loss, except in the branchiootorenal syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/19\">",
"     19",
"    </a>",
"    ]. Occasionally, a pit located just in front of the tragus may extend into a subcutaneous cyst and become infected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link&amp;anchor=H9#H9\">",
"     \"Congenital anomalies of the ear\", section on 'Preauricular pits'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital anomalies of the ear\", section on 'Accessory auricular appendage/preauricular tag'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Palpation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the tragus or pinnae may elicit significant pain in the patient with external auditory canal irritation. The canal can become swollen, erythematous, and painful as a result of a foreign body, external otitis (",
"    <a class=\"graphic graphic_picture graphicRef55712 \" href=\"UTD.htm?43/29/44511\">",
"     picture 7",
"    </a>",
"    ), insect bite, or furuncle. In these situations, discomfort and swelling may become so significant that visualization of the tympanic membrane becomes difficult. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=see_link\">",
"     \"External otitis: Pathogenesis, clinical features, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcification or ossification of the auricular cartilage (\"petrified ear\") occurs infrequently. It is characterized by the development of hardened auricular cartilage without changes in the appearance of the ear [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The earlobe is spared [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Some patients may have pain with pressure, but most are asymptomatic. Auricular calcification may be related to increased levels of calcium and phosphorous or occur after injury or inflammation of the cartilage (eg, cold injury, frostbite, mechanical trauma, radiation therapy) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Associated systemic conditions include endocrine disorders (diabetes mellitus, adrenal insufficiency, hypopituitarism, hypothyroidism, acromegaly), sarcoidosis, ochronosis, and familial cold hypersensitivity. Laboratory evaluation of patients with calcification of the auricular cartilage should be guided by other clinical findings [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/20\">",
"     20",
"    </a>",
"    ]. Extensive evaluation usually is not necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Otoscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should have an appropriate otoscope containing an excellent light source (preferably a halogen light) to complete the ear examination. The diameter of the external auditory canal varies considerably among children; a range of specula should be available.",
"   </p>",
"   <p>",
"    The examiner must clear the canal of excessive cerumen and foreign material. Cerumen removal and removal of foreign bodies in the ear are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=see_link&amp;anchor=H9#H9\">",
"     \"Cerumen\", section on 'Cerumen removal'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Otoscopic examination should proceed as painlessly as possible once the anatomical structures are clearly visible. Visualization is best achieved with the patient sitting in an upright position or lying supine with the head appropriately tilted. The examiner should insert the otoscopic speculum into the external auditory canal as gently as possible; the ulnar aspect of the hand holding the instrument is comfortably braced against the patient's face or forehead to steady the position of the instrument. At the same time, the thumb and index finger of the opposite hand are used to pull the pinna superiorly and posteriorly, allowing maximal visualization of the external auditory canal.",
"   </p>",
"   <p>",
"    The caregiver can hold firmly on his or her lap the child who is difficult to examine, holding the child's flailing legs between his or her own legs. The patient's head should be turned to the side and securely positioned to rest on the caregiver's shoulder or chest. Alternatively, the child may be placed in a supine position with extended arms and elbows firmly pinioned at the sides and extended legs gently immobilized by the weight of the accompanying adult's body lying over the thighs, knees, and lower legs. A papoose-like device to secure the patient is even more beneficial.",
"   </p>",
"   <p>",
"    The smooth pink external auditory canal normally is short and straight in the infant and younger child, and somewhat longer and more angulated in the older patient. Tympanic membranes generally are translucent, occasionally allowing for visualization of several middle ear structures (umbo, manubrium of the malleus, round window niche, pars flaccid, and chorda tympani nerve) (",
"    <a class=\"graphic graphic_picture graphicRef52626 \" href=\"UTD.htm?5/14/5345\">",
"     picture 11",
"    </a>",
"    ). The normal tympanic membrane varies slightly in color and appearance; inexperienced examiners should not misinterpret what they are seeing.",
"   </p>",
"   <p>",
"    A normal light reflex from the tympanic membrane provides little information regarding middle ear function. The degree of mobility of the tympanic membrane using pneumatic otoscopy or tympanometry is more helpful. Both techniques require a tight seal between the speculum or rubber ear piece and the external auditory canal. Movement is best visualized in the posterosuperior quadrant of the ear drum.",
"   </p>",
"   <p>",
"    The tympanic membrane normally moves inward with slight positive pressure and outward with slight negative pressure. The middle ear has significant negative pressure when positive pressure produces no movement and negative pressure produces exaggerated movement. Negative pressure in the middle ear is caused by thick, tenacious middle ear effusion. A full ear drum accompanied by fluid and air in the middle ear will move with positive pressure but will have no movement with negative pressure. A bulging ear drum caused by excessive middle ear effusion and little to no air will exhibit nearly complete or total absence of mobility [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The otoscopic findings of acute otitis media and otitis media with effusion (OME) are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=see_link&amp;anchor=H8#H8\">",
"     \"Acute otitis media in children: Diagnosis\", section on 'Otoscopy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=see_link&amp;anchor=H5#H5\">",
"     \"Otitis media with effusion (serous otitis media) in children\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The finding of a perforated ear drum alone is indicative of traumatic injury as a result of a foreign body (",
"    <a class=\"graphic graphic_picture graphicRef65160 \" href=\"UTD.htm?21/31/22015\">",
"     picture 12",
"    </a>",
"    ), increased barometric pressure, iatrogenic injury, or previous surgical incision for ventilating tubes (",
"    <a class=\"graphic graphic_picture graphicRef65036 \" href=\"UTD.htm?0/50/800\">",
"     picture 13",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several techniques are available to assess hearing in children [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link\">",
"     \"Evaluation of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gross hearing can be evaluated by observing an infant's physical response to sound; a startle response, eye blinking, and turning toward the sound are normal reactions",
"     </li>",
"     <li>",
"      In the older, more cooperative child, crude testing can be performed by standing close to the patient and mouthing relatively inaudible words into the child's ear, or whispering words at a distance of one to two feet from one ear while occluding the external auditory canal of the opposite ear. The child then can be asked to repeat what was said.",
"     </li>",
"     <li>",
"      More formal testing can be done in the relatively uncooperative child using otoacoustic emissions testing or auditory brainstem responses",
"     </li>",
"     <li>",
"      Various behavioral tests are available for the more cooperative younger patient; the older child can undergo standardized audiometric testing",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hearing deficits may be congenital or idiopathic; may result from an infectious disease, a hereditary renal disorder, or a drug exposure; or may be a component of numerous syndromes. The problem can be conductive, neurosensory, or both. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=see_link\">",
"     \"Etiology of hearing impairment in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the child is old enough to cooperate, the Rinne and Weber tests should be used to determine which type of problem is involved. These tests are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=see_link&amp;anchor=H7#H7\">",
"     \"Evaluation of hearing impairment in children\", section on 'Office hearing tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     NOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the nose is conducted with the patient's head tilted back in a sniffing position and the clinician sitting directly opposite. The shape, size, and position of the nose should be noted. Inspection of internal structures is done using a bright light source and nasal speculum or, for the smaller child, an ear speculum. To reduce patient discomfort and steady the head, the examiner should position the outer ulnar aspect of the hand not holding an instrument against the patient's forehead; the thumb of that hand is used to elevate the tip of the nose. This procedure allows for optimal visualization of each vestibule, the nasal turbinates, septum, and mucosal surfaces.",
"   </p>",
"   <p>",
"    Normally, the mucosal surfaces are pink, and the vestibules are patent and easily visible to the level of the middle turbinates. The septum should be in the midline, although a slight deviation is acceptable. Transient septal deformity secondary to in utero positioning may be noted in the newborn. The differential diagnosis of septal perforation includes infectious diseases, inhaled drugs (particularly cocaine), and traumatic injury.",
"   </p>",
"   <p>",
"    Swelling, bleeding, abnormal lesions, and types of secretions should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Nasal discharge",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thin serous or watery nasal discharge may be seen in patients with allergic rhinitis or a viral upper respiratory tract infection (URI). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"       \"An overview of rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An almost crystal clear nasal discharge can occur with leaking cerebral spinal fluid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link&amp;anchor=H13#H13\">",
"       \"An overview of rhinitis\", section on 'Differential diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A more viscous nasal discharge may occur during the latter stages of a viral URI. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=see_link&amp;anchor=H6#H6\">",
"       \"The common cold in children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thick purulent nasal discharge is typical of a viral or bacterial infection involving the nasopharynx or sinuses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=see_link&amp;anchor=H7#H7\">",
"       \"Acute bacterial rhinosinusitis in children: Clinical features and diagnosis\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An impacted foreign body should be suspected in the patient with unilateral, malodorous, purulent nasal discharge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Epistaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epistaxis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=see_link\">",
"     \"Epidemiology and etiology of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=see_link\">",
"     \"Evaluation of epistaxis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=see_link\">",
"     \"Management of epistaxis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Nasal obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a newborn has an apparent nasal obstruction, the examiner should rule out the possibility of choanal atresia by attempting to pass a small-gauge feeding tube or French catheter through each nasal passageway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=see_link&amp;anchor=H10#H10\">",
"     \"Congenital anomalies of the nose\", section on 'Choanal atresia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occluded nasal passageways caused by boggy nasal mucosa may develop as a result of allergies, vasomotor rhinitis, or overuse of nasal decongestants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=see_link\">",
"     \"An overview of rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nasal polyps caused by allergies or associated with cystic fibrosis may cause unilateral or bilateral nasal obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=see_link&amp;anchor=H9#H9\">",
"     \"Cystic fibrosis: Clinical manifestations and diagnosis\", section on 'Sinus disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Adenoidal hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adenoidal enlargement can obstruct the nasopharynx, making nasal breathing difficult and creating the typical open-mouth adenoid facies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=see_link\">",
"     \"Etiologies of nasal symptoms: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although estimates of adenoidal size on lateral skull radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58633 \" href=\"UTD.htm?25/26/26031\">",
"     image 1",
"    </a>",
"    ) have been reported to correlate with adenoidal weight at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/23\">",
"     23",
"    </a>",
"    ] and with a clinical score of adenoidal symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/24\">",
"     24",
"    </a>",
"    ], there is no evidence that such analysis is clinically useful. Evaluation of adenoidal hypertrophy is best made on clinical grounds and by direct visualization of the adenoids by the otolaryngologist. Radiographs contribute little to the care of children with suspected adenoidal hypertrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     MOUTH AND THROAT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the mouth begins with visual inspection of the lips for color, texture, and anatomical defects. The width of the vermilion border and the shape and size of the orifice should be noted. Abnormal findings may be compatible with multisystem disorders, such as Williams syndrome, or they can be caused by maternal substance abuse, as seen in the fetal alcohol syndrome.",
"   </p>",
"   <p>",
"    Mouth examination includes the gingiva, teeth, buccal mucosa, salivary ducts, tongue, palate, tonsils, and uvula.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ulcerations of the lips, gingiva,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mucosal surfaces are compatible with herpetic stomatitis, aphthous ulcers, metabolic disorders, drug reactions, or secondary complications from underlying immunosuppressive disease. Extensive inflammation and erosion of surfaces may be the result of primary infection or poor oral hygiene with secondary infection. (See appropriate topic reviews).",
"     </li>",
"     <li>",
"      Obstructed salivary ducts can be caused by concretions, leading to the development of a cyst-like structure in the floor of the mouth (ranula) (",
"      <a class=\"graphic graphic_picture graphicRef50630 \" href=\"UTD.htm?31/8/31875\">",
"       picture 14",
"      </a>",
"      ), or by inflammation leading to painful swelling in the area of the parotid gland. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=see_link&amp;anchor=H21#H21\">",
"       \"Congenital anomalies of the jaw, mouth, oral cavity, and pharynx\", section on 'Ranulas'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fissuring or cracking of the tongue may be a normal variant but also occurs with poor hydration and vitamin deficiency",
"     </li>",
"     <li>",
"      Defects in the hard",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      soft palate, particularly midline cleft palate defects, should be noted. Dimpling of the soft palate",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence of a bifid uvula may occur with a submucosal cleft [",
"      <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Teeth",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development and continued good health of dentition in childhood is extremely important. Deciduous tooth eruption generally begins at six months of age with the appearance of upper",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower central incisors, followed over the next 18 months by the eruption of lateral incisors, canines, and molars. The majority of toddlers have the full complement of 20 teeth by age two [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/26\">",
"     26",
"    </a>",
"    ]. Misshapen or absent teeth or significant delay in the development of these teeth may occur in patients with underlying metabolic disorders, infectious diseases, or various syndromes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=see_link\">",
"     \"Anatomy and development of the teeth\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=see_link\">",
"     \"Developmental defects of the teeth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Tonsils",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visualization of the palatine tonsils generally is not possible until the child is six to nine months old. Once fully developed, the tonsils remain enlarged throughout childhood. Removal is not necessary unless they become a nidus of significant recurrent infection or are enlarged enough to obstruct normal breathing.",
"   </p>",
"   <p>",
"    Enlarged tonsils with exudate may be caused by bacterial infection of the throat and tonsils with group A beta-hemolytic streptococcus and other infectious agents (eg, diphtheria, Epstein-Barr virus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to diagnosis of acute infectious pharyngitis in children and adolescents\", section on 'Etiology and clinical clues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Tonsillar asymmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tonsillar asymmetry or unilateral tonsillar enlargement may be caused by infection, chronic inflammatory process, or neoplasm (particularly lymphoma). In addition, symmetric tonsils may appear to be asymmetric because of differences in the depth of the tonsillar fossa or asymmetric effacement of the tonsils by the tonsillar pillars [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/27-31\">",
"     27-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infectious causes of tonsillar asymmetry include peritonsillar cellulitis or tonsillar abscess. Associated clinical features include severe sore throat, fever, a muffled voice, drooling, trismus,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neck pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=see_link\">",
"     \"Peritonsillar cellulitis and abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tonsillar asymmetry in the absence of acute infection is concerning for a neoplastic process, particularly lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. However, in otherwise healthy and asymptomatic children with tonsillar asymmetry, the risk of malignancy is very low [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/28-30,35-37\">",
"     28-30,35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical features suggestive of lymphoma in children with unilateral tonsil enlargement include rapid and progressive enlargement, systemic symptoms (eg, persistent fevers, weight loss, night sweats), significant cervical lymphadenopathy (&gt;3 cm), and hepatosplenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/27,29,34,35\">",
"     27,29,34,35",
"    </a>",
"    ]. Other features that increase the concern for lymphoma include immunodeficiency, previous malignancy, unilateral tonsillitis unresponsive to medical therapy, and rapid bilateral tonsillar enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=see_link\">",
"     \"Clinical assessment of the child with suspected cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tonsillectomy is indicated in children with tonsillar asymmetry and features suggestive of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/30,33,37\">",
"     30,33,37",
"    </a>",
"    ]. However, a period of watchful waiting before surgical intervention is appropriate for asymptomatic children without acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/28,35,37\">",
"     28,35,37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link\">",
"     \"Tonsillectomy and adenoidectomy in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Pharynx",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the pharynx usually requires visualization only. Pharyngitis is suggested by erythema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pharyngeal adenopathy (cobblestoning). It can be caused by viral, bacterial, or fungal disease; by a chemical irritant; or by a complication of some other condition. Soft tissue lesions and foreign body injuries should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     NECK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of the neck is best accomplished with the patient sitting or standing. The head should be in the midline position, comfortably held in extension. The size and position of anatomical neck structures should be noted.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A webbed-shape neck may be associated with Turner syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=see_link\">",
"       \"Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Redundant posterior neck folds can be seen in patients with Down syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=see_link\">",
"       \"Clinical features and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A short neck with a low hairline and limited range of motion may be the result of bony anomalies of the cervical spine associated with Klippel-Feil syndrome; these patients frequently have accompanying genitourinary abnormalities.",
"     </li>",
"     <li>",
"      A short neck also occurs with congenital hypothyroidism and in some of the mucopolysaccharidoses (eg, Hurler and Morquio syndromes). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=see_link\">",
"       \"Clinical features and detection of congenital hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Distended or pulsating neck veins may indicate obstruction to right heart return (eg, mediastinal masses) or impaired cardiac function (eg, pericarditis or poor myocardial contractility). Distended pulsating carotid arteries normally are seen in patients who are emotionally upset and after vigorous exercise; if the finding persists, however, disorders such as aortic insufficiency, patent ductus arteriosus (PDA), hypertension, and severe anemia must be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/38\">",
"     38",
"    </a>",
"    ]. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    A head tilt can result from several different conditions. In the infant, torticollis may be the result of sternocleidomastoid muscle fibrosis secondary to in utero pressure or trauma during delivery; myopathy; denervation; or venous occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/39\">",
"     39",
"    </a>",
"    ]. Head tilt also may occur in patients with a visual defect and in those with a posterior fossa tumor or neuroblastoma. Patients with severe gastroesophageal reflux may exhibit a head tilt as a compensatory maneuver to help reduce the discomfort of reflux esophagitis (Sandifer syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=see_link\">",
"     \"Congenital muscular torticollis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=see_link\">",
"     \"Acquired torticollis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A soft tissue, freely movable, cystic mass in the midline of the neck superior to the upper border of the thyroid cartilage is most compatible with a thyroglossal duct cyst. Other midline lesions of the neck include sebaceous (epidermal) cysts, small abscesses, lipomas, and dermoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=see_link\">",
"     \"Thyroglossal duct cysts and ectopic thyroid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Below the thyroid cartilage, the thyroid gland separates into two symmetric lobes and curves posteriorly around the sides of the trachea and esophagus. Palpation of the thyroid is accomplished best with the examiner positioned behind the standing or sitting patient. The fingers of the examiner's hands are gently positioned over the respective lobes, which are normally soft, smooth, and not enlarged. The thyroid gland moves upward when the patient swallows. Only repetitive palpation of the thyroid of many patients will give the examiner the feel for normal size, shape, and contour.",
"   </p>",
"   <p>",
"    Moving the hands from the midline to lateral structures of the neck, the examiner should feel for abnormal masses. Within the sternocleidomastoid muscle, a firm mass could be caused by fibrosis or a benign or malignant tumor. Branchial cleft cysts palpable in the upper portion of the neck are soft and smooth. Cystic hygromas and lymphangiomas of the neck, which generally transilluminate easily, may vary in size and shape and are not tender. Additional detectable soft tissue structures include hemangiomas, dermoid cysts, lipomas, and neurofibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few shotty, freely movable, nontender lymph nodes in the anterior and posterior cervical chain are palpable in many young children and are considered normal. Enlarged, firm, nontender, freely movable, or fixed neck nodes may be found in patients with lymphoma, Hodgkin disease, and other metastatic disease. Enlarged nodes that are tender, warm, and painful to movement are compatible with lymphadenitis. Numerous infectious and noninfectious causes for lymphadenopathy and lymphadenitis must be considered for a complete differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?10/59/11194/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=see_link&amp;anchor=H5#H5\">",
"     \"Etiology and clinical manifestations of cervical lymphadenitis in children\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Examination of the head includes assessment of head shape, distribution of hair, scalp defects, abnormal lesions or protuberances, lacerations, abrasions or contusions, head circumference, and fontanelles. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Head'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the face includes assessment of the anatomic structures (eg, the size, shape and position of the eyes, ears, nose, and mouth), periorbital or facial edema or swelling, musculature, and facial nerve function. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Face'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the eyes includes assessment of appearance, presence of discharge, extraocular movements, ocular alignment, vision (",
"      <a class=\"graphic graphic_table graphicRef62277 \" href=\"UTD.htm?14/43/15037\">",
"       table 2",
"      </a>",
"      ), corneal light reflection (",
"      <a class=\"graphic graphic_figure graphicRef68374 \" href=\"UTD.htm?17/61/18386\">",
"       figure 2",
"      </a>",
"      ), red reflex (",
"      <a class=\"graphic graphic_figure graphicRef66431 \" href=\"UTD.htm?31/47/32506\">",
"       figure 3",
"      </a>",
"      ), and ophthalmoscopic examination. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Eyes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the ears includes assessment of the shape, size, and position of the pinnae (auricles), preauricular skin tags or pits, external ear canal, tympanic membrane, and hearing. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Ears'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the nose includes assessment of the shape, size and position; inspection of the internal structures; presence and type of nasal discharge; and presence of nasal obstruction. (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Nose'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the mouth includes inspection of the lips, gingiva, teeth, buccal mucosa, salivary ducts, tongue, palate, pharynx, tonsils, and uvula. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Mouth and throat'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Examination of the neck includes assessment of the size and position of the anatomic structures, neck vessels, presence of head tilt, presence of masses or enlarged lymph nodes, and palpation of the thyroid gland. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Neck'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/1\">",
"      Arana E, Latorre FF, Revert A, et al. Intradiploic epidermoid cysts. Neuroradiology 1996; 38:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/2\">",
"      Bikmaz K, Cosar M, Bek S, et al. Intradiploic epidermoid cysts of the skull: a report of four cases. Clin Neurol Neurosurg 2005; 107:262.",
"     </a>",
"    </li>",
"    <li>",
"     Athreya, BH, Silverman, BK. Pediatric physical diagnosis, Appleton-Century-Crofts, Norwalk, CT 1985.",
"    </li>",
"    <li>",
"     Bates B. A Guide to Physical Examination and History Taking, 6th ed, Lippincott, Philadelphia 1995.",
"    </li>",
"    <li>",
"     Green, M. The head. In: Pediatric Diagnosis Interpretation os Symptoms and Signs in Children and Adolescents, 6th ed, WB Saunders Company, Philadelphia 1998. p.4.",
"    </li>",
"    <li>",
"     Haslam, RH. The nervous system. In: Nelson Textbook of Pediatrics, 18th ed. Kleigman, RM, Behrman, RE, Jenson, HB, Stanton, BF (Eds), Saunders Elsevier, Philadelphia 2007. p. 2433.",
"    </li>",
"    <li>",
"     Tunnessen, WW. Early closure of anterior fontanelle. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.196.",
"    </li>",
"    <li>",
"     Tunnessen, WW. Delayed closure of the anterior fontanelle. In: Signs and Symptoms in Pediatrics, 3rd ed, Lippincott, Williams &amp; Wilkins, Philadelphia 1999. p.192.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/9\">",
"      WAARDENBURG PJ. A new syndrome combining developmental anomalies of the eyelids, eyebrows and nose root with pigmentary defects of the iris and head hair and with congenital deafness. Am J Hum Genet 1951; 3:195.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, KL. Waardenburg syndrome, Types I and II. In: Smith's Recognizable patterns of Human Malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.278.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/11\">",
"      Hart DB. Menkes' syndrome: an updated review. J Am Acad Dermatol 1983; 9:145.",
"     </a>",
"    </li>",
"    <li>",
"     Jones, KL. Menkes syndrome (Menkes kinky hair syndrome). In: Smith's Recognizable patterns of Human Malformation, 6th ed, Elsevier Saunders, Philadelphia 2006. p.216.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/13\">",
"      MORGAN DB. A suggestive sign of allergy. Arch Derm Syphilol 1948; 57:1050.",
"     </a>",
"    </li>",
"    <li>",
"     Trobe, JD. The physician's guide to eye care, American Academy of Ophthalmology, San Francisco 1993.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/15\">",
"      American Academy of Pediatrics, Section on Ophthalmology, American Association for Pediatric Ophthalmology And Strabismus, et al. Red reflex examination in neonates, infants, and children. Pediatrics 2008; 122:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/16\">",
"      Li J, Coats DK, Fung D, et al. The detection of simulated retinoblastoma by using red-reflex testing. Pediatrics 2010; 126:e202.",
"     </a>",
"    </li>",
"    <li>",
"     Walton, DS. Eye evaluation in the newborn. In: Principles and Practice of Pediatrics, Oski, FA, DeAngelis, CD, Feigin, RD, Warshaw, JB (Eds), Lippincott, Philadelphia 1990. p.468.",
"    </li>",
"    <li>",
"     Pediatric ophthalmology, 3rd ed, Nelson, LB, Calhoun, JH, Harley, RD (Eds), Saunders, Philadelphia 1991.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/19\">",
"      Eavey RD. Management strategies for congenital ear malformations. Pediatr Clin North Am 1989; 36:1521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/20\">",
"      Clarke JT, Clarke LE, Miller JJ. Petrified ears: calcification of the auricular cartilage. J Am Acad Dermatol 2004; 51:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/21\">",
"      Stites PC, Boyd AS, Zic J. Auricular ossificans (ectopic ossification of the auricle). J Am Acad Dermatol 2003; 49:142.",
"     </a>",
"    </li>",
"    <li>",
"     Bluestone, CD, Klein, JO. Otitis media in infants and children, Saunders, Philadelphia 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/23\">",
"      Hibbert J, Whitehouse GH. The assessment of adenoidal size by radiological means. Clin Otolaryngol Allied Sci 1978; 3:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/24\">",
"      Crepeau J, Patriquin HB, Poliquin JF, Tetreault L. Radiographic evaluation of the symptom-producing adenoid. Otolaryngol Head Neck Surg 1982; 90:548.",
"     </a>",
"    </li>",
"    <li>",
"     Gray, SD, Parkin, JL. Congenital malformations of the mouth and pharynx. In: Pediatric Otolaryngology, 3rd ed, Bluestone, CD, Stool, SE, Kenna, MA (Eds), Saunders, Philadelphia 1996. p.985.",
"    </li>",
"    <li>",
"     Athreya, BH, Silverman, BK. Pediatric physical diagnosis, Appleton-Century-Crofts, Norwalk, CT, 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/27\">",
"      Harley EH. Asymmetric tonsil size in children. Arch Otolaryngol Head Neck Surg 2002; 128:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/28\">",
"      Spinou E, Kubba H, Konstantinidis I, Johnston A. Tonsillectomy for biopsy in children with unilateral tonsillar enlargement. Int J Pediatr Otorhinolaryngol 2002; 63:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/29\">",
"      Cinar F. Significance of asymptomatic tonsil asymmetry. Otolaryngol Head Neck Surg 2004; 131:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/30\">",
"      van Lierop AC, Prescott CA, Fagan JJ, Sinclair-Smith CC. Is diagnostic tonsillectomy indicated in all children with asymmetrically enlarged tonsils? S Afr Med J 2007; 97:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/31\">",
"      Darrow DH, Siemens C. Indications for tonsillectomy and adenoidectomy. Laryngoscope 2002; 112:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/32\">",
"      Cortez EA, Mattox DE, Holt GR, Gates GA. Unilateral tonsillar enlargement. Otolaryngol Head Neck Surg (1979) 1979; 87:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/33\">",
"      Dolev Y, Daniel SJ. The presence of unilateral tonsillar enlargement in patients diagnosed with palatine tonsil lymphoma: experience at a tertiary care pediatric hospital. Int J Pediatr Otorhinolaryngol 2008; 72:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/34\">",
"      Ridgway D, Wolff LJ, Neerhout RC, Tilford DL. Unsuspected non-Hodgkin's lymphoma of the tonsils and adenoids in children. Pediatrics 1987; 79:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/35\">",
"      Berkowitz RG, Mahadevan M. Unilateral tonsillar enlargement and tonsillar lymphoma in children. Ann Otol Rhinol Laryngol 1999; 108:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/36\">",
"      Puttasiddaiah P, Kumar M, Gopalan P, Browning ST. Tonsillectomy and biopsy for asymptomatic asymmetric tonsillar enlargement: are we right? J Otolaryngol 2007; 36:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/37\">",
"      Sunkaraneni VS, Jones SE, Prasai A, Fish BM. Is unilateral tonsillar enlargement alone an indication for tonsillectomy? J Laryngol Otol 2006; 120:E21.",
"     </a>",
"    </li>",
"    <li>",
"     Barness LA. Manual of pediatric physical diagnosis, 6th ed, Mosby Year Book, St. Louis 1991.",
"    </li>",
"    <li>",
"     Renshaw TS.. Pediatric Orthopedics, Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/40\">",
"      Murphy WJ, Gellis SS. Torticollis with hiatus hernia in infancy. Sandifer syndrome. Am J Dis Child 1977; 131:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/41\">",
"      Zitelli, BJ. Evaluating the child with a neck mass. Contemp Pediatr 1990; 7:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?10/59/11194/abstract/42\">",
"      Carpentieri U, Smith LR Jr, Daeschner CW 3rd. Approach to a child with enlarged lymph nodes. Tex Med 1983; 79:58.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2869 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11194=[""].join("\n");
var outline_f10_59_11194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H42\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HEAD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Head circumference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Fontanelles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Normal closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Early closure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Delayed closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Auscultation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Transillumination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Scalp and hair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FACE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EYES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Appearance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Eyelids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Discharge",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Conjunctivae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Extraocular movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Ocular alignment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ophthalmoscopic examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Red reflex",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cornea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Anterior chamber",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Iris and lens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Retina and optic disk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      EARS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Appearance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Palpation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Otoscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hearing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      NOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Nasal discharge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Epistaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Nasal obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Adenoidal hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      MOUTH AND THROAT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Teeth",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Tonsils",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Tonsillar asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      NECK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/2869\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2869|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/26/26031\" title=\"diagnostic image 1\">",
"      Adenoid hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2869|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/23/29040\" title=\"figure 1\">",
"      Corneal light reflex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/61/18386\" title=\"figure 2\">",
"      Cover uncover test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/47/32506\" title=\"figure 3\">",
"      Red reflex interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/19/34103\" title=\"figure 4\">",
"      External ear anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2869|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/54/2916\" title=\"picture 1\">",
"      Hordeolum stye",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/30/24034\" title=\"picture 2\">",
"      Chalazion 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/31/5617\" title=\"picture 3\">",
"      Inflamed pinguecula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/3/32831\" title=\"picture 4\">",
"      Pterygium 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/2/15392\" title=\"picture 5\">",
"      Corneal clouding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/27/23999\" title=\"picture 6\">",
"      Mastoiditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/29/44511\" title=\"picture 7\">",
"      Severe otitis externa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/10/9376\" title=\"picture 8\">",
"      Auricular cellulitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/33/37407\" title=\"picture 9\">",
"      Accessory auricle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/1/31775\" title=\"picture 10\">",
"      Preauricular pit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/14/5345\" title=\"picture 11\">",
"      Normal tympanic membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/31/22015\" title=\"picture 12\">",
"      Perforation of TM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/50/800\" title=\"picture 13\">",
"      Persistent perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/8/31875\" title=\"picture 14\">",
"      Ranula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/2869|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/3/21565\" title=\"table 1\">",
"      Delayed closure ant fontanelle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/43/15037\" title=\"table 2\">",
"      Vision screen infants children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8616?source=related_link\">",
"      Acquired torticollis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/0/11273?source=related_link\">",
"      Acute bacterial rhinosinusitis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/16/5385?source=related_link\">",
"      Acute mastoiditis in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/35/8760?source=related_link\">",
"      Acute otitis media in children: Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30999?source=related_link\">",
"      An overview of rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39590?source=related_link\">",
"      Anatomy and development of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41417?source=related_link\">",
"      Approach to diagnosis of acute infectious pharyngitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/23/5496?source=related_link\">",
"      Approach to the child with leukocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=related_link\">",
"      Approach to the child with persistent tearing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12823?source=related_link\">",
"      Cerumen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/47/5882?source=related_link\">",
"      Clinical assessment of the child with suspected cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2682?source=related_link\">",
"      Clinical features and detection of congenital hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/42/33449?source=related_link\">",
"      Clinical manifestations and diagnosis of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/46/1768?source=related_link\">",
"      Clinical manifestations and diagnosis of alopecia areata",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/34/35370?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/49/12055?source=related_link\">",
"      Congenital anomalies of the ear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/59/1977?source=related_link\">",
"      Congenital anomalies of the jaw, mouth, oral cavity, and pharynx",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35575?source=related_link\">",
"      Congenital anomalies of the nose",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/49/43798?source=related_link\">",
"      Congenital muscular torticollis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/50/34600?source=related_link\">",
"      Corneal abrasions and corneal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/14/2278?source=related_link\">",
"      Cradle cap and seborrheic dermatitis in infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/49/28442?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7082?source=related_link\">",
"      Dermatophyte (tinea) infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/27/440?source=related_link\">",
"      Developmental defects of the teeth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/16/27912?source=related_link\">",
"      Epidemiology and etiology of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27625?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/44/16072?source=related_link\">",
"      Etiologies of nasal symptoms: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8632?source=related_link\">",
"      Etiology and clinical manifestations of cervical lymphadenitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/51/36665?source=related_link\">",
"      Etiology and evaluation of microcephaly in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/38/19050?source=related_link\">",
"      Etiology of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/35/37432?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34951?source=related_link\">",
"      Evaluation and management of strabismus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/42/18086?source=related_link\">",
"      Evaluation of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44344?source=related_link\">",
"      Evaluation of hearing impairment in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/62/32743?source=related_link\">",
"      External otitis: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/63/4088?source=related_link\">",
"      Eyelid lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/34/39462?source=related_link\">",
"      Gonococcal infection in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/58/26536?source=related_link\">",
"      Management of epistaxis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13846?source=related_link\">",
"      Nonscarring hair loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22153?source=related_link\">",
"      Otitis media with effusion (serous otitis media) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31705?source=related_link\">",
"      Peritonsillar cellulitis and abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41879?source=related_link\">",
"      Pterygium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7353?source=related_link\">",
"      Tetanus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/48/22281?source=related_link\">",
"      The common cold in children: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24586?source=related_link\">",
"      The genodermatoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/30/34280?source=related_link\">",
"      The pediatric physical examination: Back, extremities, nervous system, skin, and lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19943?source=related_link\">",
"      The pediatric physical examination: General principles and standard measurements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/3/10295?source=related_link\">",
"      The pediatric physical examination: The perineum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/16/25864?source=related_link\">",
"      Thyroglossal duct cysts and ectopic thyroid",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/59/24505?source=related_link\">",
"      Visual development and vision assessment in infants and children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f10_59_11195="GVHD prophylaxis in beta thal";
var content_f10_59_11195=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F68788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F68788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preparative regimen and graft-versus-host disease prophylaxis for class 1 and class 2 patients with beta thalassemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Preparative regimen",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Busulfan - 14 mg/kg PO over four days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cyclophosphamide - 200 mg/kg IV over four days",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Graft versus host disease prophylaxis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       Cyclosporine",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       5 mg/kg IV from day -2 to day +5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3 mg/kg IV from day +6 to day +21",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       12.5 mg/kg PO from day +21 to day +60 with gradual tapering up to + 1 year",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <p>",
"        Methotrexate",
"       </p>",
"       <p>",
"        10 mg/m2 IV day +1",
"       </p>",
"       <p>",
"        10 mg/m2 IV on days +3 and +6",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11195=[""].join("\n");
var outline_f10_59_11195=null;
var title_f10_59_11196="SSRI kinetics";
var content_f10_59_11196=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67511&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    SSRI kinetics",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Peak serum concentration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Elimination half-life",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism",
"       </td>",
"       <td class=\"subtitle1\">",
"        Active metabolites",
"       </td>",
"       <td class=\"subtitle1\">",
"        Protein binding, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fluoxetine",
"       </td>",
"       <td rowspan=\"2\">",
"        6-8 hours",
"       </td>",
"       <td>",
"        Parent: 2-6 days",
"       </td>",
"       <td rowspan=\"2\">",
"        Liver (2D6, 2C9, 3A4)",
"       </td>",
"       <td rowspan=\"2\">",
"        Norfluoxetine",
"       </td>",
"       <td rowspan=\"2\">",
"        94.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metabolite: 7-10 days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sertraline",
"       </td>",
"       <td>",
"        4.5-8.4 hours",
"       </td>",
"       <td>",
"        26 hours",
"       </td>",
"       <td>",
"        Liver (2C9, 2D6, 3A4)",
"       </td>",
"       <td>",
"        Desmethylsertraline (weakly active)",
"       </td>",
"       <td>",
"        98",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paroxetine",
"       </td>",
"       <td>",
"        5.2 hours",
"       </td>",
"       <td>",
"        21 hours",
"       </td>",
"       <td>",
"        Liver (2D6)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluvoxamine",
"       </td>",
"       <td>",
"        3-8 hours",
"       </td>",
"       <td>",
"        15.6 hours",
"       </td>",
"       <td>",
"        Liver (1A2, 2D6)",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citalopram",
"       </td>",
"       <td>",
"        4 hours",
"       </td>",
"       <td>",
"        35 hours",
"       </td>",
"       <td>",
"        Liver (3A4, 2D6, 2C19)",
"       </td>",
"       <td>",
"        Desmethylcitalopram, didesmethylcitalopram (weakly active)",
"       </td>",
"       <td>",
"        80",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Escitalopram",
"       </td>",
"       <td>",
"        5 hours",
"       </td>",
"       <td>",
"        27-32 hours",
"       </td>",
"       <td>",
"        Liver (3A4, 2D6, 2C19)",
"       </td>",
"       <td>",
"        S-desmethylcitalopram, S-didesmethylcitalopram (weakly active)",
"       </td>",
"       <td>",
"        56",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11196=[""].join("\n");
var outline_f10_59_11196=null;
var title_f10_59_11197="Birth weight by gestational age";
var content_f10_59_11197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F81379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F81379&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Smoothed percentiles of birth weight (g) by gestational age: United States 1991 single live births",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Gestational age, weeks",
"       </td>",
"       <td class=\"subtitle1\">",
"        5th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        10th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        50th percentile",
"       </td>",
"       <td class=\"subtitle1\">",
"        90th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        435",
"       </td>",
"       <td>",
"        498",
"       </td>",
"       <td>",
"        674",
"       </td>",
"       <td>",
"        977",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        480",
"       </td>",
"       <td>",
"        558",
"       </td>",
"       <td>",
"        779",
"       </td>",
"       <td>",
"        1138",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        26",
"       </td>",
"       <td>",
"        529",
"       </td>",
"       <td>",
"        625",
"       </td>",
"       <td>",
"        899",
"       </td>",
"       <td>",
"        1362",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        27",
"       </td>",
"       <td>",
"        591",
"       </td>",
"       <td>",
"        702",
"       </td>",
"       <td>",
"        1035",
"       </td>",
"       <td>",
"        1635",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        670",
"       </td>",
"       <td>",
"        798",
"       </td>",
"       <td>",
"        1196",
"       </td>",
"       <td>",
"        1977",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        29",
"       </td>",
"       <td>",
"        772",
"       </td>",
"       <td>",
"        925",
"       </td>",
"       <td>",
"        1394",
"       </td>",
"       <td>",
"        2361",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        910",
"       </td>",
"       <td>",
"        1085",
"       </td>",
"       <td>",
"        1637",
"       </td>",
"       <td>",
"        2710",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        1088",
"       </td>",
"       <td>",
"        1278",
"       </td>",
"       <td>",
"        1918",
"       </td>",
"       <td>",
"        2986",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        32",
"       </td>",
"       <td>",
"        1294",
"       </td>",
"       <td>",
"        1495",
"       </td>",
"       <td>",
"        2203",
"       </td>",
"       <td>",
"        3200",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        1513",
"       </td>",
"       <td>",
"        1725",
"       </td>",
"       <td>",
"        2458",
"       </td>",
"       <td>",
"        3370",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        1735",
"       </td>",
"       <td>",
"        1950",
"       </td>",
"       <td>",
"        2667",
"       </td>",
"       <td>",
"        3502",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        1950",
"       </td>",
"       <td>",
"        2159",
"       </td>",
"       <td>",
"        2831",
"       </td>",
"       <td>",
"        3596",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        2156",
"       </td>",
"       <td>",
"        2354",
"       </td>",
"       <td>",
"        2974",
"       </td>",
"       <td>",
"        3668",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        2357",
"       </td>",
"       <td>",
"        2541",
"       </td>",
"       <td>",
"        3117",
"       </td>",
"       <td>",
"        3755",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        2543",
"       </td>",
"       <td>",
"        2714",
"       </td>",
"       <td>",
"        3263",
"       </td>",
"       <td>",
"        3867",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        39",
"       </td>",
"       <td>",
"        2685",
"       </td>",
"       <td>",
"        2852",
"       </td>",
"       <td>",
"        3400",
"       </td>",
"       <td>",
"        3980",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        2761",
"       </td>",
"       <td>",
"        2929",
"       </td>",
"       <td>",
"        3495",
"       </td>",
"       <td>",
"        4060",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41",
"       </td>",
"       <td>",
"        2777",
"       </td>",
"       <td>",
"        2948",
"       </td>",
"       <td>",
"        3527",
"       </td>",
"       <td>",
"        4094",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        2764",
"       </td>",
"       <td>",
"        2935",
"       </td>",
"       <td>",
"        3522",
"       </td>",
"       <td>",
"        4098",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol 1996; 87:163.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11197=[""].join("\n");
var outline_f10_59_11197=null;
var title_f10_59_11198="Characteristics of SCA types";
var content_f10_59_11198=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74269&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the autosomal dominant spinocerebellar ataxias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Disorder",
"       </td>",
"       <td class=\"subtitle1\">",
"        Distinguishing features",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Gene locus and protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA1",
"       </td>",
"       <td>",
"        Pyramidal signs, peripheral neuropathy",
"       </td>",
"       <td>",
"        ATXN1",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA2",
"       </td>",
"       <td>",
"        Slow saccades; less often myoclonus, areflexia",
"       </td>",
"       <td>",
"        ATXN2",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA3 (MJD)",
"       </td>",
"       <td>",
"        Slow saccades, persistent stare, extrapyramidal signs, peripheral neuropathy",
"       </td>",
"       <td>",
"        ATXN3",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-3 (MJD1)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA4",
"       </td>",
"       <td>",
"        Sensory neuropathy",
"       </td>",
"       <td>",
"        16q22.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA5",
"       </td>",
"       <td>",
"        Early onset but slow progression",
"       </td>",
"       <td>",
"        SPTBN2",
"       </td>",
"       <td>",
"        Beta III spectrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA6",
"       </td>",
"       <td>",
"        May have very late onset, mild, may lack family history, nystagmus",
"       </td>",
"       <td>",
"        CACNA1A",
"       </td>",
"       <td>",
"        CAG repeat, alpha 1A P/Q calcium channel subunit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA7",
"       </td>",
"       <td>",
"        Macular degeneration",
"       </td>",
"       <td>",
"        ATXN7",
"       </td>",
"       <td>",
"        CAG repeat, ataxin-7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA8",
"       </td>",
"       <td>",
"        Mild disease",
"       </td>",
"       <td>",
"        <p>",
"         ATXN8",
"        </p>",
"        <p>",
"         ATXN8OS",
"        </p>",
"       </td>",
"       <td>",
"        CTG*CAG repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA9",
"       </td>",
"       <td>",
"        Not assigned",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA10",
"       </td>",
"       <td>",
"        Generalized or complex partial seizures",
"       </td>",
"       <td>",
"        ATXN10",
"       </td>",
"       <td>",
"        ATTCT repeat, ataxin-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA11",
"       </td>",
"       <td>",
"        Mild disease",
"       </td>",
"       <td>",
"        TTBK2",
"       </td>",
"       <td>",
"        Tau tubulin kinase-2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA12",
"       </td>",
"       <td>",
"        Tremor, dementia",
"       </td>",
"       <td>",
"        PPP2R2B",
"       </td>",
"       <td>",
"        CAG repeat in 5' region, protein phosphatase 2A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA13",
"       </td>",
"       <td>",
"        Mental retardation",
"       </td>",
"       <td>",
"        KCNC3",
"       </td>",
"       <td>",
"        Voltage gated potassium channel KCNC3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA14",
"       </td>",
"       <td>",
"        Intermittent myoclonus with early onset disease",
"       </td>",
"       <td>",
"        PRKCG",
"       </td>",
"       <td>",
"        Protein kinase C gamma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA15/16",
"       </td>",
"       <td>",
"        Slowly progressive",
"       </td>",
"       <td>",
"        ITPR1",
"       </td>",
"       <td>",
"        Inositol 1,4,5-triphosphate receptor 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA17",
"       </td>",
"       <td>",
"        Gait ataxia, dementia",
"       </td>",
"       <td>",
"        TBP",
"       </td>",
"       <td>",
"        CAG repeats, TATA binding protein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA18",
"       </td>",
"       <td>",
"        Pyramidal signs, weakness, sensory axonal neuropathy",
"       </td>",
"       <td>",
"        7q22-q32",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA19/22",
"       </td>",
"       <td>",
"        Predominantly cerebellar syndrome, sometimes with cognitive impairment or myoclonus",
"       </td>",
"       <td>",
"        KCND3 gene",
"       </td>",
"       <td>",
"        Voltage-gated potassium channel Kv4.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA20",
"       </td>",
"       <td>",
"        Palatal tremor and dysphonia",
"       </td>",
"       <td>",
"        11q12",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA21",
"       </td>",
"       <td>",
"        Extrapyramidal signs",
"       </td>",
"       <td>",
"        7p21.3-p15.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA23",
"       </td>",
"       <td>",
"        Distal sensory deficits",
"       </td>",
"       <td>",
"        PDYN",
"       </td>",
"       <td>",
"        Prodynorphin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA24",
"       </td>",
"       <td>",
"        Recessive inheritance; redesignated as SCAR4",
"       </td>",
"       <td>",
"        1p36",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA25",
"       </td>",
"       <td>",
"        Sensory neuropathy, facial tics, gastrointestinal symptoms",
"       </td>",
"       <td>",
"        2p21-p13",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA26",
"       </td>",
"       <td>",
"        Pure cerebellar ataxia",
"       </td>",
"       <td>",
"        19p13.3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA27",
"       </td>",
"       <td>",
"        Cognitive impairment",
"       </td>",
"       <td>",
"        FGF14",
"       </td>",
"       <td>",
"        Fibroblast growth factor 14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA28",
"       </td>",
"       <td>",
"        Ophthalmoparesis and ptosis",
"       </td>",
"       <td>",
"        AFG3L2",
"       </td>",
"       <td>",
"        Catalytic subunit of the mitochondrial AAA protease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA29",
"       </td>",
"       <td>",
"        Early onset, nonprogressive ataxia; may be an allelic variant of SCA15",
"       </td>",
"       <td>",
"        3p26",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA30",
"       </td>",
"       <td>",
"        Slowly progressive, relatively pure ataxia",
"       </td>",
"       <td>",
"        4q34.3-q35.1",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA31",
"       </td>",
"       <td>",
"        Decreased muscle tone",
"       </td>",
"       <td>",
"        BEAN",
"       </td>",
"       <td>",
"        (TGGAA)n repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA32",
"       </td>",
"       <td>",
"        Cognitive impairment, affected males with azoospermia and testicular atrophy",
"       </td>",
"       <td>",
"        7q32-q33",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA33",
"       </td>",
"       <td>",
"        Not assigned",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA34",
"       </td>",
"       <td>",
"        Skin lesions consisting of papulosquamous erythematous ichthyosiform plaques",
"       </td>",
"       <td>",
"        6p12.3-q16.2",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA35",
"       </td>",
"       <td>",
"        Late onset, slowly progressive gait and limb ataxia",
"       </td>",
"       <td>",
"        TGM6",
"       </td>",
"       <td>",
"        Transglutaminase 6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SCA36",
"       </td>",
"       <td>",
"        Late onset, truncal ataxia, dysarthria, variable motor neuron disease and&nbsp;sensorineural hearing loss",
"       </td>",
"       <td>",
"        NOP56",
"       </td>",
"       <td>",
"        GGCCTG repeat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DRPLA",
"       </td>",
"       <td>",
"        Chorea, seizures, myoclonus, dementia",
"       </td>",
"       <td>",
"        ATN1",
"       </td>",
"       <td>",
"        CAG repeat, atrophin-1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DRPLA: dentatorubral pallidoluysian atrophy; MJD: Machado-Joseph disease; SCA: spinocerebellar ataxia.",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <a href=\"file://www.ncbi.nlm.nih.gov/sites/entrez?db=omim\" target=\"_blank\">",
"      Online Mendelian Inheritance in Man",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11198=[""].join("\n");
var outline_f10_59_11198=null;
var title_f10_59_11199="Approach to pancreatic necrosis in SAP";
var content_f10_59_11199=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Approach to pancreatic necrosis in severe acute pancreatitis (SAP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 505px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Navaneethan U, Vege SS, Chari ST, Baron TH. Minimally invasive techniques in pancreatic necrosis. Pancreas 2009; 38:867. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f10_59_11199=[""].join("\n");
var outline_f10_59_11199=null;
